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Promoting and measuring remyelination and 
neuroprotection in clinical trials of people with 
multiple sclerosis 
Nicholas Gerard Cunniffe 
 
Abstract 
The most tractable strategy to delay or prevent the progressive phase of MS is to 
promote endogenous remyelination; doing so restores nerve conduction and 
prevents demyelinated axons from degenerating. The rate-limiting stage in this 
process is differentiation of oligodendrocyte progenitor cells (OPCs) into mature, 
myelinating, oligodendrocytes. In animals, agonism of the retinoid X receptor (RXR)-
γ enhances remyelination in this way. Metformin also promotes remyelination, this 
time by overcoming an age-associated block to the responsiveness of OPCs to pro-
differentiation factors.  
 
In this PhD I show that bexarotene, a non-selective agonist of the RXR receptor, 
promotes remyelination in people with relapsing remitting multiple sclerosis. 
Converging evidence from electrophysiology and neuroimaging in a phase II clinical 
trial (CCMR One) demonstrate that this occurs in demyelinated lesions and is 
greatest in lesions located in grey matter regions of the brain. I additionally 
conducted analyses which suggest an age-dependency of bexarotene’s 
remyelinating effect and led a follow-up sub study of the trial participants which 
showed the treatment effect afforded by bexarotene is sustained, years after 
treatment. Unfortunately, bexarotene was poorly tolerated, and so the legacy of this 
trial will likely be one of shaping the framework for future assessments of 
remyelinating therapies. As such, I designed, obtained funding and secured 
approvals for a clinical trial to test the remyelinating effect of the combination of 
metformin with clemastine (CCMR Two), implementing lessons from CCMR One in 
the trial design; this is due to commence participant recruitment in 2021. 
 - 6 - 
In exploring treatments for progressive forms of MS, not limited to the process of 
remyelination, I worked with the MS Society to develop and implement a rigorous, 
expert-led, evidence-based approach to the selection of licensed drugs for 
repurposing and testing in clinical trials of people with progressive MS. I reviewed 
the preclinical and clinical literature for a list of compounds and condensed these into 
a database of summary documents. These were presented to a panel of experts and 
people affected by MS, ultimately leading to four treatments being recommended for 
immediate testing in progressive MS trials: R-α-lipoic acid, metformin, the 
combination treatment of R-α-lipoic acid and metformin, and niacin. 
 
Regrettably, much of my research has been halted by the COVID-19 pandemic. In 
this PhD I had additionally sought to evaluate electrophysiological techniques for 
quantifying remyelination and neuroprotection – multifocal VEP and saccadometry – 
in cohorts of people with MS and in the setting of the CCMR Two trial. Instead, when 
these studies were delayed, I embraced an opportunity to help the Cambridge 
COVID-19 research effort, working on the RECOVERY trial in the first wave, and 
leading my own project to analyse enrolment to treatment trials, ultimately describing 
the barriers to, and implications of, low recruitment rates in advance of the 
subsequent waves. Consequently, further exploratory research with 
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Foreword 
 
I am interested in finding treatments for people with multiple sclerosis. There have 
been three overarching aims of my PhD. First, to advance knowledge in 
remyelination research by translating preclinical results into clinical trials of people 
with MS. Second to understand and develop the electrophysiological and imaging 
outcome measures required to demonstrate their effects in phase II trials. And third, 
to evaluate other treatments for progressive MS, not limited to the strategy of 
enhancing endogenous remyelination.  
 
In my first chapter, I provide an introduction to the bulk of the thesis, starting with a 
brief examination of the aetiology, pathology, diagnosis, phenotype and current 
management of MS, before describing the biology of remyelination, why this fails in 
MS and how this might be therapeutically targeted. I then summarise the 
remyelinating therapies that have been, and are being, evaluated and discuss the 
best approach to measure remyelination in people. This will lead into the key 
research questions for the PhD. 
 
In organising this thesis, I have apportioned each research project a chapter, with 
the methods, results and discussions contained within each. I start by presenting the 
Cambridge Centre for Myelin Repair trials: the results of CCMR One, related work I 
have undertaken to investigate the age-dependency and durability of remyelination 
in response to bexarotene, and the development of CCMR Two. I then describe the 
processes by which we selected licensed drugs for repurposing in a clinical trial of 
people with progressive MS. My final chapter details the key conclusions from the 
thesis alongside a presentation of my future research plans. 
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Impact of the COVID-19 pandemic 
 
Unfortunately, my PhD has been significantly impacted by the coronavirus disease 
2019 (COVID-19) pandemic. A primary objective of my PhD was to translate the 
recent discovery of the remyelinating effect of metformin in rats, into a clinical trial of 
people with MS. Despite securing funding for this trial in October 2019, CCMR Two 
has still not been able to start. Additionally, over the course of the first year of the 
PhD I rekindled an affinity for electrophysiology, in particular the use of visual evoked 
potentials (VEPs) and saccadometry, having recognised the importance of the 
former as a sensitive marker of remyelination across a range of trials. Indeed, as part 
of this PhD I spent 3 weeks at Sydney University with Prof Sasha Klistorner and built 
a collaboration with his research group to bring multifocal VEP to our trials in 
Cambridge. Regrettably, my natural history electrophysiology projects were halted in 
March 2020, not long after their ethical approvals, and I have not been able to recruit 
any patients since that time as they – as observational studies – were deemed level 
3 research in the NIHR recovery strategy. Helpfully, we were able to demonstrate 
that our follow-up sub study of the Cambridge CCMR One participants qualified as 
level 2 (a non-COVID trial that might benefit patients), and I present these results in 
Chapter 4. 
 
I have embraced opportunities to help the research response to the pandemic. I am 
particularly proud to have contributed to getting the RECOVERY trial up and running 
in Cambridge within just 10 days, and to have worked to successfully recruit patients 
during the first wave. I also led a research study, under the supervision of Dr Mark 
Toshner, to better understand the recruitment barriers we had been observing in the 
first wave and the potential effects this might have on the national response – these 
data are presented in the penultimate chapter.  
 
I therefore leave my PhD with more research questions than when I first started, but I 
hope to have opportunities to answer these over the next few years of my research 
career. 
 - 20 - 
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Multiple Sclerosis (MS) is a chronic, primarily inflammatory, disorder of the central 
nervous system (CNS) characterised by focal lymphocytic infiltration causing 
damage to myelin and axons.1-3 It is estimated to effect over 130,000 people in the 
United Kingdom4 and is the leading cause of non-traumatic disability in young adults 
in the developed world.5,6 Typical clinical features include weakness, sensory loss, 
diplopia, reduced visual acuity, dysarthria, dysphagia, ataxia, and bladder 
dysfunction; largely a reflection of the distribution of demyelinating foci throughout 
the CNS.7 In 85% of patients, there is an initial period of episodic neurological 
dysfunction followed by partial or complete recovery (relapsing remitting MS, 
RRMS).8 Over time, the clinical picture often develops to one of progressive disability 
(secondary progressive MS, SPMS),9 while in 15% the illness is progressive from the 
outset (primary progressive MS, PPMS).10  
 
There now exists an extensive therapeutic armamentarium against the inflammation 
of MS.11 These disease modifying treatments (DMTs) reduce the incidence and 
severity of new lesions by limiting the activity and availability of immune cells, 
manifesting clinically through reductions in relapse rates and disability accrual.12-21 
However, the “therapeutic window” for treatment with these immunotherapies is 
limited;22 best long-term results on disability are seen if an anti-inflammatory 
treatment is started within five years of the first clinical episode of demyelination in 
relapsing remitting disease.23 Furthermore, while 16 DMTs are currently licensed for 
RRMS, only one – ocrelizumab – is approved for primary progressive disease,24 and 
even then its effects are so modest that several reimbursement agencies, notably 
NICE in the UK, declared it only cost-effective in a subset of people with new or 
contrast-enhancing lesions on MRI and a disease duration of less than 15 years. 
Similarly, while siponimod confers a small reduction in disability progression to those 
with active SPMS,25 it is approved by NICE only if the patient is still having relapses 
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or has imaging evidence of inflammatory activity. Evidently, the degenerative 
mechanisms that characterise progressive MS are not sufficiently targeted by 
immunomodulatory compounds26 and the greatest unmet need for people with 
progressive forms of MS are effective neuroprotective and neurorestorative 
treatments.27 
 
The promotion of regeneration of the myelin sheath, through enhancing the process 
of endogenous remyelination, has emerged as one of the most tractable prospects to 
delay, prevent or reverse progression.28 This is grounded in experimental evidence 
that demonstrates that the myelin sheath (and its associated oligodendrocytes) does 
not just facilitate nerve conduction but is also directly protective against 
degeneration.29-34 In this introduction, I describe the aetiology, pathology, diagnosis, 
and current management of MS, before describing the biology of remyelination, why 
this fails in MS and how this might be therapeutically targeted. I then summarise the 
remyelinating therapies that have been, and are being, evaluated and discuss the 
best approach to measure remyelination in people, which is proving increasingly 
essential in order to translate promising preclinical research into clinical trials. 
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Aetiology of multiple sclerosis 
 
The causation of multiple sclerosis is multifaceted, but inevitably the result of 
interactions between genetic, epigenetic and environmental risk factors. Some of 
these, particularly vitamin D deficiency, smoking and obesity, are potentially 
modifiable prior to the development of MS, but also impact the disease course and 
efficacy of different treatments.35   
 
Obesity 
Elevated body mass index (BMI) in young adults increases the risk of developing MS 
across a range of observational studies.36-39 For example, in the nurses’ health 
study, women with a BMI ≥30 at age 18 had a relative risk of developing MS of 2.25 
(95% CI 1.50, 3.37).38 In a mendelian randomization analysis, the genetic factors 
that influence BMI similarly increase the odds of MS, strengthening BMI’s position as 
an MS risk factor, outside of its potential confounding factors.40 Meanwhile, speaking 
to an ongoing contribution of adiposity to the course of disease in MS, 
hyperlipidaemia increases relapse rates (HR 1.67, 95% CI 1.07, 2.61),41 disease 
activity,42 and disability progression.43 BMI also affects paraclinical measures of 
progression, being negatively correlated with grey matter volume and brain 
parenchymal fraction in people with RRMS and clinically isolated syndrome,44 and 
negatively correlated with the ganglion cell inner plexiform layer (GC-IPL) at optical 
coherence tomography;45 though these were both uncontrolled studies and, given 
elevated BMI has been associated with brain volume loss in the general 
population,46 a disease-specific effect beyond this trend has not been demonstrated. 
Mechanistically, there is evidence that obesity has pro-inflammatory effects in a 
myriad of autoimmune diseases,47 and perhaps most pertinently for MS, it directs 
macrophages toward a pro-inflammatory M1 polarization,48 while adiposity-related 
factors, such as leptin, promote a pro-inflammatory TH1 profile.49  
 
Vitamin D 
The primary source for vitamin D is from UV exposure, but it is also available from 
dietary sources: it is converted to 25(OH)D3 (which gives a measure of vitamin D 
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status) and then to 1,25(OH)2D3 (the biologically active form). Prospective studies of 
25(OH)D3 collectively show a 50-60% reduced risk of MS with levels ≥75 nmol/L, 
and a 2-fold increased risk of MS with levels <30 nmol/L.50-52 Meanwhile, higher 
25(OH)D3 is predictive of reduced relapse rates, fewer new active lesions, and 
reduced T2 lesion volume.53 Alternative explanations for these associations include 
other immunosuppressive effects of sunlight (outside of the vitamin D pathway)54 or 
of other nutrients that tend to be grouped with dietary vitamin D (e.g. polyunsaturated 
fatty acids).55 However, akin to BMI, mendelian randomisation studies do support an 
independent role of vitamin D.56 The correction of vitamin D insufficiency has 
therefore been posited as a strategy to prevent multiple sclerosis,57 yet limitations in 
observational studies restrict the extent to which such inverse associations can be 
attributed specifically to vitamin D.58 Additionally, vitamin D supplementation has, 
thus far, not led to improved clinical outcomes in trials of people with MS.59,60 
Conclusive testing in large prevention and treatment trials is required, but issues 
such as sample size, suitable populations, and appropriate dosing of vitamin D are 
challenges to their design. 
 
Cigarette smoking 
The increased susceptibility risk afforded by smoking tobacco increases with 
intensity and duration61-63 and is greater in men than in women.64 Smoking also 
interacts with some of the strongest associated risk genes (such as the presence of 
HLA-DRB1*15:01 and absence of HLA-A*02), suggesting that a priming of the 
immune response in the lungs may lead to MS in genetically susceptible 
individuals.65 Similar results have been seen in those exposed to organic solvents.66 
Smoking is additionally associated with a worse disease course,67 with the 
development of antibodies to interferon-β-1a and natalizumab;68,69 while smoking 
cessation has been shown to delay the conversion to SPMS.70   
 
Epstein-Barr virus 
The notion that MS might be a late complication of a viral infection in genetically 
susceptible individuals has long been speculated and, while a causative virus has 
never been found, a link to EBV seems likely. Nearly all people with MS are 
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seropositive for antibodies to EBV nuclear antigen 1 (EBNA1) or its viral capsid 
antigen (VCA),71 almost all EBNA1-negative individuals serologically convert prior to 
MS onset,72 and the relative risk of MS conferred by a history of infectious 
mononucleosis in a meta-analysis of 19,390 patients was 2.17 (95% CI 1.97, 2.39).73 
Synergy has been shown with the presence of HLA-DRB1*15:01;74 molecular 
mimicry is a likely candidate mechanism. 
 
Genetic susceptibility 
The increased heritability within families and increased risk with degree of 
relatedness provided early evidence that genetic factors are implicated in the 
development of MS.75,76 Comparisons of risk between relatives (segregation 
analysis) has generally suggested a polygenic model in which risk is determined by a 
single moderate-effect allele (OR 3-4) and many smaller-effect alleles (OR <1.5), 
with interactions between such risk alleles accounting for much of the apparent 
heritability of the disease.77 Genome-wide association studies have now 
characterised more than 200 gene variants that increase the risk of the disease, 
revealing a significant overrepresentation of immunologically relevant genes;78 a 
finding consistent with the assertion that autoimmune mechanisms are central to the 
development of MS (discussed below).2 It is noteworthy that not one gene implicated 
in the susceptibility to MS has a clear link to oligodendrocytes or myelination; while 
one of the most strongly associated SNPs occurred in a region associated with the 
galactosylceramidase (GALC) gene79 –  the product of which is an essential 
component of myelin – this is in tight linkage disequilibrium with G protein coupled 
receptor 65 (GPCR65), itself involved in T cell apoptosis.80 The main risk allele for 
MS, HLA-DRB*15:01, confers an odds ratio of 3.10.79 However, this is present in 
13.3% of the UK population, while fewer than 0.3% of people carrying it develop MS, 
and significant numbers without the allele also develop MS.77 Thus, genetic risk 
factors are not in themselves sufficient to cause MS, contributing in the region of a 
third of the overall MS disease risk.81 
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The immunopathogenesis of multiple sclerosis 
 
MS is characterised by imbalanced interactions between effector and regulatory 
subpopulations of immune cells.82 The aforementioned genome wide association 
studies,78,83 supported by recent work with MS-discordant monozygotic twins,84 
highlights a genetic predisposition largely centred on immune pathways involving T 
and B cells, ultimately resulting in autoreactive cells that are capable of infiltrating 
and promoting damage within the CNS.85 However, CNS-resident cells, particularly 
microglia, are also implicated in genetic risk.86 
 
How autoreactive T cells become activated in the periphery is still a matter of debate. 
One option is molecular mimicry (e.g. in the context of systemic infection), in which T 
cells against non-self epitopes cross-react with self-myelin epitopes.87-89 Another is 
through recognition of CNS sequestered antigens that are released into the 
periphery as neo-antigen (either by drainage to the lymph nodes or through carriage 
by antigen presenting cells).90 Whatever the inciting event, the result is a cycle of 
tissue damage yielding the generation of pathogenic CD4+ T helper 1 (TH1) cells 
and TH17 cells, which enter the circulation, translocate to the CNS, and exert their 
effector functions.3 Of course, in health, peripheral tolerance mechanisms would be 
expected keep such autoreactive cells at bay: in MS, reduced regulatory T cell 
function or resistance of effector T/B-cells to suppressive mechanisms leads to a 
breakdown of self-tolerance.91 
 
In MS, there is a predilection for inflammatory cell infiltrates to accumulate in certain 
regions: around the lateral ventricles and corpus callosum, in the juxtacortical areas, 
cortex, optic nerves and brainstem, and throughout the spinal cord.1,92-94 In early 
disease, there is little damage outside of these so-called MS lesions. CD8+ T cells 
predominate in a perivascular inflammatory infiltrate, while macrophages, B cells and 
plasma cells can also be found.95 The particular immunologic patterns of 
demyelination in active lesions are heterogenous.96 The most common types 
(patterns I and II) show an activated macrophage/microglial inflammatory 
background, with a perivascular and parenchymal infiltration of T cells; pattern II is 
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additionally distinguished by immunoglobulin and complement deposition. Less 
commonly, in about 25% of biopsied lesions, oligodendrocyte apoptosis 
predominates on an inflammatory background (pattern III).96 
 
What determines the long-term fate of a given lesion – whether inflammation 
resolves or smoulders and whether regeneration takes place – is not well 
understood.2 Longitudinal imaging studies suggest that lesions forming in younger 
people repair more effectively,97 a finding in line with evidence that ageing is 
associated with a declining ability of the immune-system to clear myelin debris and 
of oligodendrocyte progenitors to facilitate remyelination.98-100 (The myriad reasons 
for remyelination failure will be considered in a subsequent section.) In chronically 
demyelinated lesions, denuded axons remain vulnerable and degenerate: leading 
candidate mechanisms include energy deficiency on account of mitochondrial 
oxidative stress101,102 and loss of ionic homeostasis following ion channel 
redistribution.103-105 Additional damage occurs in those lesions with persistent 
inflammation: a smouldering lesion is formed, characterised by a slowly expanding 
rim of activated macrophages/microglia surrounding an inactive centre.106  
 
As MS progresses, a more diffuse inflammatory T cell and B cell infiltrate, coupled 
with widespread microglial and astrocyte activation is seen; inflammation becoming 
organised in the CNS and proceeding in the absence of continued immune cell 
infiltration from the periphery.85 Very few breaches seem to exist in the blood-brain 
barrier by this point,107,108 leading to a compartmentalised inflammation driven by a 
diffuse microglial inflammation which seemingly drives expansion of demyelinated 
lesions.109 There is also increasing cortical involvement, particularly at subpial 
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The phenotype and diagnosis of multiple sclerosis 
 
The advent of effective treatments for MS has reinforced the need for making an 
early yet secure diagnosis. In the majority, clinical features indicate involvement of 
motor, sensory, visual and autonomic systems, nonetheless many other symptoms 
and signs may be present. Unfortunately, none are specific to MS, though 
Lhermitte’s symptom (neck flexion resulting in an electric-shock sensation running 
down the spine and limbs) and Uhthoff’s phenomenon (the worsening of symptoms 
and signs with increasing body temperature, for example during a hot bath) are 
particularly characteristic.1 Diagnosis therefore requires the synthesis of clinical, 
imaging and laboratory findings, to demonstrate dissemination in space and time, 
while excluding other neurological conditions (Table 1.1).111  
 
The McDonald diagnostic criteria were developed in 2001112 and have been 
increasingly refined over the course of revisions in 2005,113 2010,114 and 2017.115 
They are particularly helpful in the setting of a single episode when the diagnosis of 
multiple sclerosis is suspected, typically termed a clinically isolated syndrome (CIS), 
by defining the clinical and paraclinical findings required to fulfil dissemination in time 
(DIT) and dissemination in space (DIS). The MRI criteria were established in their 
current format in 2010, such that DIS can be demonstrated with a T2 lesion in at 
least 2 out of 4 locations characteristic of MS (juxtacortical, periventricular, 
brainstem, and spinal cord), while DIT can be exhibited by the presence of new T2 
lesions on serial imaging, or the co-occurrence of gadolinium-enhancing and non-
enhancing lesions.114 Now, following the most recent 2017 revisions of the McDonald 
criteria, the presence of CSF-specific oligoclonal bands can establish DIT, and (if 
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Concurrent optic neuritis 
and transverse myelitis; 
intractable hiccough or 
nausea/vomiting 
Longitudinally extensive (>3 
vertebral segments) cord 
lesion, chiasmal involvement. 
Serum antibodies to AQP-4 







typical, often monophasic, 
encephalopathy common. 
Often in context of 
antecedent viral illness 
Spectrum of inflammatory 
demyelination on MRI from 
small lesions to large 
tumefactive lesions with mass 
effect. Can impact any region 
of the CNS. CSF pleocytosis 
Neurosarcoidosis Meningitis, myelopathy, 
cranial nerve involvement 
(VII and II primarily), raised 
intracranial pressure 
Meningeal enhancement. 
Brain white matter lesions. 
Raised serum and CSF ACE. 
CSF OCB sometimes present 
CNS vasculitis Confusion, headache, 
personality change, stroke-
like presentations, seizures 




microbleeds. Serum ANCA 




Visual loss, sensorineural 
hearing loss, headache, 
memory loss, 
encephalopathy 
Snowball lesions in corpus 
callosum, leptomeningeal 
enhancement, focal and small 











Brain infarcts and 
haemorrhage, venous sinus 
thrombosis. Subcortical and 
cord lesions. Positive ANA, 






Large brainstem lesions, 
subcortical and spinal cord 
lesions, venous sinus 
thrombosis. CSF pleocytosis. 
HLA-B51 
Table 1.1. Non-exhaustive differential diagnosis of multiple sclerosis. AQP-4, 
aquaporin-4; MOG, myelin oligodendrocyte glycoprotein; CSF, cerebrospinal fluid; 
OCB, oligoclonal bands; ACE, angiotensin converting enzyme; ANCA, anti-
neutrophil cytoplasmic antibody; WM, white matter; GM, grey matter; SLE, systemic 
lupus erythematosus; ANA, anti-nuclear antibody; HLA, human leukocyte antigen. 
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Number of 
clinical attacks 
Number of lesions 
with objective 
clinical evidence 
Additional findings required for a 
diagnosis of MS 
≥2 ≥2 None 
≥2 1 (as well as clear 
historical evidence of 
a previous attack 




≥2 1 DIS evidenced by additional clinical 
attack implicating a different CNS site, 
or by MRI 
1 ≥2 DIT evidenced by additional clinical 
attack or by MRI OR demonstration of 
CSF-specific oligoclonal bands 
1 1 DIS evidenced by an additional clinical 
attack or MRI implicating a different 
CNS site AND DIT evidenced by an 
additional clinical attack OR new lesion 
by MRI OR demonstration of CSF-
specific oligoclonal bands 
Table 1.2. The 2017 McDonald criteria for the diagnosis of multiple sclerosis. 
CNS, central nervous system; DIS, dissemination in space; DIT, dissemination in 
time. 
 
The diagnosis of primary progressive MS is similarly established in the McDonald 
criteria.115 This requires at least one year of progression in disability independent of 
clinical relapses, plus the presence of 2 of: (i) one or more T2-hyperintense lesions 
in areas characteristic of multiple sclerosis in the brain, (ii) two or more T2-
hyperintense lesions, and (iii) the presence of CSF-specific oligoclonal bands.  
 
The diagnosis of secondary progressive MS is, however, more challenging. In most 
clinical contexts, SPMS is defined by a history of gradual accumulation of disability 
after an initial relapsing remitting course, yet there remain no universally accepted 
criteria to determine the point at which one transitions from RRMS to SPMS.116 
Instead, the diagnosis of SPMS is often made in retrospect, with the benefit of years 
of gradual progression. One study reported that, on average, a transition period of 
three years elapsed between the possibility of SPMS being first entertained to the 
diagnosis being definitively made.117 Disentangling the residual effects of relapses 
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and disability progression adds a further layer of complexity; relapses are not 
uncommon in SPMS, occurring in 12% and 24% of those with SPMS allocated to 
placebo over 2 years of follow-up in two recent clinical trials.118,119 In an effort to 
establish an objective SPMS definition that is predictive of long-term disability 
outcomes, a recent study compared 576 different definitions of SPMS across 17,356 
patients, and found the best performance required 3 months of confirmed disability 
progression in the absence of relapse (if the EDSS step was 5.5 or less, an increase 
of 1.0 or more was required; if the EDSS was 6.0 or above, an increase of 0.5 was 
needed), requiring an eventual EDSS step of ≥4.0 and pyramidal score of ≥2.120 
Experimental medicine trials, meanwhile, have typically required two years of 
progression for participant inclusion.118,119,121  
 
Yet, from the perspective of selecting treatments, a perhaps more biologically 
important distinction for people with progressive MS is to characterise whether the 
illness is active – that is to say, have evidence of new focal inflammation as 
determined by clinical relapses and/or development of new lesions at MRI – and 
whether it is progressing in the absence of inflammation, as recognised in the 2013 
consensus criteria.116 
  
 - 32 - 
The management of multiple sclerosis 
 
Management of acute relapses 
 
A relapse is defined by patient-reported symptoms or objectively observed signs that 
are typical of an acute inflammatory demyelinating event in the central nervous 
system, with a duration of at least 24 hours, in the absence of fever or infection.115 
The latter point is particularly important, as fluctuations in symptoms can occur for 
reasons other than a relapse, for example due to fatigue, fever, infection, and heat 
(often termed a pseudo-relapse). Clinical guidelines therefore encourage physicians 
to first rule out infection (particularly of the urinary and respiratory tract) before 
diagnosing relapse and contemplating treatment.122 
 
The mainstay of treatment is with corticosteroids. These curtail the duration of the 
relapse,123 but are widely stated to have no effect on the extent of the recovery that 
is eventually made.124-126 Taken together with the potential side effect profile of even 
short courses of steroids – including, but not limited to, insomnia, dysphoria, 
hyperglycaemia, gastrointestinal distress, osteonecrosis of the femoral head, and 
cataracts – it is widespread practice to reserve courses of steroids for those relapses 
that are particularly disabling. Helpfully, oral administration of high-dose 
methylprednisolone is not inferior to intravenous administration,127 and so relapses 
do not typically require hospitalisation. Steroid-refractory relapses meanwhile, can be 
treated with plasmapheresis.128 Indeed, as might be expected, patients exhibiting 
lesions with a predominance of immunoglobulin deposition (immunopathological 
pattern II), are the most likely to respond to therapeutic plasma exchange.129 
However, as with corticosteroids, there is no clear evidence that this impacts long 
term functional recovery. 
 
Management of acute optic neuritis 
 
The discussion of relapse management would not be complete without consideration 
of acute optic neuritis (AON). Prospective trials have demonstrated a reproducible 
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benefit of high-dose corticosteroids, perhaps most notably with the optic neuritis 
treatment trial (ONTT)130 in which 457 participants were randomised within 8 days of 
AON to receive either placebo, oral prednisolone (1 mg/kg/day for 14 days), or 
intravenous methylprednisolone (250 mg 4 times daily for 3 days, followed by 
prednisolone 1 mg/kg/day for 11 days). The rate of visual recovery over the first 15 
days was greater in the intravenous methylprednisolone group, while contrast 
sensitivity and colour vision (though not visual acuity) were improved at 6 months.130 
However, by 12 months, there was no difference in visual function, compared to 
placebo;131 the conclusion that high-dose corticosteroids hasten recovery, but do not 
change long term functional outcome, has been reinforced by subsequent meta-
analyses.132 
 
Meanwhile, the ONTT also reported an unexpected result: oral (intermediate dose) 
prednisolone increased the risk of recurrent optic neuritis compared to both 
intravenous methylprednisolone and placebo.130 While this particular conclusion has 
been disputed,133 taken together with an evident lack of efficacy over placebo, only 
high-dose corticosteroids are now recommended for AON. More recent studies have 
established that oral high-dose methylprednisolone is not demonstrably inferior to 
intravenous high-dose methylprednisolone in the treatment of AON,134,135 thereby 
negating the cost and tolerability concerns of repeated hospital attendances to 
receive IV steroids. 
 
So, alike MS relapses affecting other locations in the nervous system, high-dose 
corticosteroids seemingly hasten the speed, but not the extent, of functional 
recovery. Yet, the definition of recovery needs to extend beyond high-contrast visual 
acuity; in the ONTT, >90% of participants, regardless of treatment group, recovered 
to, what the authors described as, a “normal” visual acuity of 20/50 by 6 months, 
creating an erroneous impression that most make an excellent recovery following 
AON.130 However, a follow-up study 5-8 years later, found persistent abnormalities of 
affected eyes compared to fellow eyes in contrast sensitivity (58% vs 17%), visual 
fields (33% vs 12%), colour vision (37% vs 18%) and visual acuity (39% vs 16%).136 
Similarly, electrophysiological and structural techniques such as visual evoked 
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potentials and optical coherence tomography reveal persistent demyelination and 
neuroaxonal loss as sequelae of AON.137 Thus, the recovery from AON is not 
complete, and can therefore provide a unique model for evaluating treatment 
response to drugs capable of promoting remyelination and preventing 
neurodegeneration.138 
 
Treatment of relapsing remitting multiple sclerosis 
 
The last 25 years have seen an expanding repertoire of anti-inflammatory disease 
modifying treatments (DMTs) deployed in the treatment of relapsing remitting 
multiple sclerosis (RRMS) and clinically isolated syndrome (CIS). There are currently 
nine DMT classes approved for use in RRMS: glatiramer acetate, β interferons, 
dimethyl fumarate, sphingosine 1-phosphate receptor modulators (fingolimod and 
siponimod), teriflunomide, cladribine, natalizumab, alemtuzumab and B-cell targeted 
monoclonal antibodies (ocrelizumab and rituximab). With contrasting mechanisms of 
action, efficacy and safety, weighing treatment decisions has become increasingly 
complex for patients and clinicians alike.3 
 
Injectable therapies (Table 1.3) 
The injectables were the earliest type of DMT to be approved for the treatment of 
RRMS; the first interferon-β preparations in 1993 and glatiramer acetate in 1996 
(Table 1.3). In clinical trials, these drugs reduced the annualised relapse rate (aRR) 
by in the region of 30% compared to placebo, and modestly prolonged the time to an 
increase in disability.12,13,139,140 They were also of similar efficacy in comparative 
trials.141,142 Since the introduction of these drugs, new preparations have followed 
that have allowed a reduction in the frequency of administration.143,144 An additional 
benefit of these drugs is the rarity with which any serious adverse events – such as 
hepatitis and pulmonary hypertension145,146 – occur. However, tolerability, particularly 
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Table 1.3. The injectable disease modifying treatments. MBP, myelin basic 
protein; SC, subcutaneous; IFN, interferon; IM, intramuscular; CNS, central nervous 
system; FBC, full blood count; UEs, urea and electrolytes; LFTs, liver function tests; 
TSH, thyroid stimulating hormone. 
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Monoclonal antibodies (Table 1.4) 
After 10 years of using injectables alone, the inception of natalizumab, a humanised 
antibody against α-4 integrin on the surface of lymphocytes capable of reducing their 
translocation into the CNS,149 resulted in a substantial step up in terms of efficacy. 
The AFFIRM trial showed a reduction of the aRR by 68% and of sustained disability 
progression by 42% compared to placebo.18 Unfortunately, this improvement in 
efficacy is counterbalanced by the risk of progressive multifocal 
leukoencephalopathy (PML), an opportunistic infection of the CNS by the JC virus,150 
which carries a 23% mortality rate. The major risk factors for PML are a positive anti-
JCV status, prior immunosuppressant use, and a long treatment duration with 
natalizumab; anti-JCV antibody index and duration of natalizumab treatment can be 
used to estimate risk.151 An additional concern is rebound of disease activity upon 
treatment discontinuation.152,153 It is therefore more usually reserved for those with 
rapidly evolving severe MS: typically requiring 2 clinically disabling relapses in the 
last year and, on imaging, one or more gadolinium-enhancing lesions or an 
increasing T2 lesion load. 
 
Another highly effective treatment for MS is alemtuzumab, a humanized monoclonal 
antibody directed against CD52, which causes lymphopenia followed by homeostatic 
reconstitution resulting in a prolonged alteration of the immune response.154 It was 
first trialled in patients with progressive MS, where it did not impact clinical disability, 
but did significantly reduce the formation of new MRI lesions.155 Ensuing studies in 
RRMS showed reductions in relapse rates of 91-94% compared to placebo156,157 and 
of 49-55% compared to interferon-β;19,20 taken together, this experience led to the 
hypothesis that there is a ‘therapeutic window’ whereby immunotherapies are 
beneficial if started early in the disease.22 Additionally, the benefits of alemtuzumab 
were shown to be durable, with efficacy maintained for over 5 years in >70% of 
patients who had received two courses of alemtuzumab.158 Adverse events of 
alemtuzumab treatment include infusion reactions on account of cytokine release 
syndrome (which are treated with steroids and anti-histamines), and herpetic 
infections (that can be countered by prophylactic acyclovir); human papilloma virus 
(HPV) infection (with the potential corollary of cervical dysplasia) is an additional 
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consideration, though unpublished data from England and Wales shows no 
difference from the population mean (personal communication). Secondary 
autoimmunity is also a consequence, usually occurring 2-3 years after treatment, 
which includes thyroid disorders (in >30%), thrombocytopenia (in 1-3%) and 
glomerulonephritis (in <1%).154 Unfortunately, since regulatory approval, there have 
been reports of other severe adverse events including listeriosis,159 haemolytic 
anaemia with necrotizing leukoencephalopathy,160 alveolar haemorrhage,161 
hemophagocytic lymphohistiocytosis162 and stroke.163 This triggered a review of 
alemtuzumab by the European Medicines Agency in 2019, and its use has since 
been refined to those with rapidly evolving severe MS (as above), with no concurrent 
autoimmune disease, and those suffering relapses despite other DMTs. 
 
Finally, positive results from clinical trials of antibodies to CD20, which deplete 
mature B cell pools, suggests that these have a central role in MS pathogenesis. 
While rituxumab was subject of a positive phase II study,164 it is ocrelizumab that has 
come through phase III trials of RRMS, reducing the aRR by 47% and disability 
progression by 40% compared to IFNβ -1a.21 This is also the only drug to have 
shown evidence of efficacy in PPMS (discussed below).24 
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Table 1.4. Monoclonal antibody treatments of multiple sclerosis. BBB, blood-
brain barrier; FBC, full blood count; LFTs, liver function tests; UEs, urea and 
electrolytes; TFT, thyroid function tests; JCV, JC Virus; VZV, varicella zoster virus; 
HIV, human immunodeficiency virus; HBV, hepatitis B virus; HCV, hepatitis C virus; 
HSV, herpes simplex virus; PML, progressive multifocal leukoencephalopathy; TFTs, 
thyroid function tests; TB, tuberculosis; ITP, immune thrombocytopenic purpura; 
HLH, hemophagocytic lymphohistiocytosis. 
 
 
Oral treatments (Table 1.5) 
Fingolimod, the first licensed oral treatment for RRMS, is a relatively non-selective 
sphingosine-1-phosphate (S1P)-receptor modulator that prevents lymphocyte egress 
from lymph nodes. Its efficacy has been shown across several trials with reductions 
of relapse rates of 48-55% compared to placebo16,165 and by superiority to 
intramuscular interferon-β.166 It is, however, associated with an increased risk of 
infections (in particular herpes zoster, but also PML), deranged LFTs, basal cell 
cancer, and macular oedema. It can also cause bradycardia and so participants are 
typically observed for 6-12 hours after the first dose. In the UK, fingolimod can be 
prescribed if patients are still having relapses after taking one of the interferons, 
glatiramer acetate, or dimethyl fumarate. It can also be prescribed to a patient 
previously on natalizumab whom has a high risk of PML. Some of the safety 
concerns are expected to be addressed by ozanimod, a selective modulator of S1P1 
and S1P5 receptors.167 
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Teriflunomide was the second oral treatment to be licensed for RRMS: it is a 
metabolite of leflunomide that inhibits proliferation of B and T cells and, while it has 
comparable efficacy to interferon, it has a more significant adverse event profile 
including diarrhoea, nausea, hair thinning, increased levels of liver enzymes (in 7%) 
and teratogenicity.14,168-170 It is therefore not commonly prescribed in the UK as other 
oral treatments and injectables are usually preferred. 
 
Dimethyl fumarate (DMF) is the most commonly prescribed oral MS drug. It has 
many effects. In particular, it induces a shift in the cytokine profile of T helper (TH) 
cells from pro-inflammatory (TH1) to an anti-inflammatory (TH2) profile,171 and it 
regulates redox balance in monocytes and T cells through activation the transcription 
factor nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway.172 Over two phase III 
trials, DMF led to a reduction in the aRR by 44-53% and reduced the risk of disability 
progression over 2 years by 35% compared to placebo.15,173 No increased risk of 
malignancy or serious infection has been observed but PML has occurred, usually in 
the setting of lymphopenia (<0.5 x109/L). 
 
Cladribine is the most recently added oral option for RRMS. It is a prodrug, 
converted by intracellular phosphorylation to the active purine analogue, 2-
chlorodeoxyadenosine triphosphate, which disrupts cell metabolism and inhibits DNA 
synthesis and repair in lymphocytes.174 In a phase III study of 1,326 people with 
RRMS this led to a reduction in relapse rate of 58% and a lower rate of sustained 
disability progression compared to placebo.17  
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Table 1.5. Oral DMTs used in the treatment of multiple sclerosis. ECG, 
electrocardiogram; OCT, optical coherence tomography; FBC, full blood count; LFTs, 
liver function tests; VZV, varicella zoster virus; BP, blood pressure; PML, progressive 
multifocal leukoencephalopathy; UEs, urea and electrolytes; HIV, human 
immunodeficiency virus; HBV, hepatitis B virus. 
 
The long-term effects of disease modifying treatments 
 
The pivotal studies that demonstrated the efficacy of disease modifying treatments 
have largely focussed on reductions in relapse rates and disability progression, often 
alongside MRI measures of disease activity, over short duration clinical trials.177 
However, while it seemed intuitive that these treatments would be beneficial in the 
long term, evidence for this is more recent, perhaps reflective of the challenges to 
conducting and controlling observational cohort studies over extended time periods. 
 
An early approach was to interrogate potential links between DMT exposure and 
mortality. For example, Goodin et. al. performed long term follow up of participants 
from the pivotal interferon β-1b randomised clinical trial;178 they showed that after a 
median follow up of 21.1 years, all-cause mortality was significantly lower in those 
that had been treated with IFNβ-1b, when compared to those that had been treated 
with placebo (HR 0.532 p=0.017, 95% CI 0.314, 0.902). Similar results were 
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returned in a study of the effects of β-interferon in a population cohort: increased 
survival was observed in those who had been treated with β-interferon for ≥3 years 
when compared to matched controls (HR 0.44; 95% CI 0.30, 0.66).179 
 
The demonstration that DMTs are effective in preventing long term disability 
progression has been similarly challenging. Cohort studies have reported a declining 
rate of conversion from relapsing MS to secondary progressive MS compared to 
earlier natural history studies, and posited that this is representative of progress 
following the advent of DMTs.180 Yet, robust evidence that DMTs impact disability 
progression has been a recent development.23 Utilising a real-world, prospective, 
observational cohort study – the MS Base database – Brown and colleagues made a 
series of important observations. First, that treatment significantly lowered the 
probability of secondary progression compared to untreated controls: for interferon-β 
or glatiramer acetate (HR 0.71 p<0.001 95% CI 0.61, 0.81), for fingolimod (HR 0.37 
p<0.001 95% CI 0.22, 0.62), for natalizumab (HR 0.61 p = 0.005 95% CI 0.43, 0.86) 
and for alemtuzumab (HR 0.52 p=0.009 95% CI 0.32, 0.85). Second, that the 
probability of conversion to secondary progressive MS was lower if treated within 5 
years of disease onset (for interferon-β and glatiramer acetate, HR 0.77 p=0.03 95% 
CI 0.61, 0.98). And third, that patients initially receiving fingolimod, alemtuzumab, or 
natalizumab had a significantly lower risk of converting to secondary progressive MS 
than matched controls who were initially treated with the (lower efficacy) glatiramer 
acetate or interferon-β (HR 0.66 p=0.046 95% CI 0.44, 0.99).23  
 
 
Treatment decisions in relapsing remitting multiple sclerosis 
 
Following a first clinical attack of multiple sclerosis (a clinically isolated syndrome), 
there is evidence, from randomised trials and open label extension studies, that first-
line therapies might reduce the conversion to clinically definite MS.181,182 However, 
the 2010 and 2017 revisions of the McDonald diagnostic criteria have changed the 
conditions for these diagnoses;114,115 the latest revisions now allow the earlier 
diagnosis of RRMS, and DMTs are not recommended outside of satisfying these 
criteria. Whether or not to start treatment following recognition of radiologically 
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isolated syndrome has similarly been controversial.183 First line therapies are 
presently considered in the setting of 2 relapses in the past 2 years, 1 relapse in the 
past 2 years with radiological activity, or in rapidly evolving severe MS.184 
 
A particular distinction in first-line treatment strategies is whether to advocate an 
escalation strategy (initially commencing moderately efficacious DMTs, which have 
generally good safety profiles, and escalating to higher efficacy DMTs in the 
circumstance of breakthrough disease activity (clinical relapse and/or new lesions at 
MRI)) or whether to deploy an induction strategy (choosing high-efficacy drugs from 
the outset).185 Population level data has indicated that early intensive treatment is 
superior to moderate efficacy DMTs in reducing the accumulation of disability,23,186 
but this is yet to be demonstrated in a comparative trial. The DELIVER-MS study 
(NCT03535298), which will test the effects of these contrasting strategies on brain 
volume loss and disability, seems likely to be informative in shaping these different 
treatment approaches. Of course, particular attention will be needed to account for 
the safety considerations of these approaches when strategizing treatment 
approaches, which has not yet been done in any systematic way. 
 
Ultimately, with no biomarker currently able to identify the optimum treatment for a 
particular patient at a particular timepoint, the decision of when and how to treat a 
patient is reliant on patient characteristics and preferences.187 Treatment algorithms 
have been developed to help guide appropriately evidence-based selections based 
on such patient characteristics,184,188 and consensus statements made on important 
considerations such as pregnancy.189 Clearly, eliciting patient preferences must be 
optimised when balancing the potential benefits against side effect profiles and the 
burden of adherence to safety monitoring.190 
 
Treatments for progressive forms of multiple sclerosis 
 
The expanding repertoire of anti-inflammatory disease modifying treatments for 
RRMS contrasts with a paucity of effective therapies for the 15% of people that 
present with progressive disability (primary progressive MS; PPMS), and indeed the 
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80% of RRMS patients who develop progression after RRMS (secondary 
progressive MS; SPMS);191 most immunotherapies have failed in non-active 
progressive disease.192  
 
With regard to SPMS, the first positive randomised placebo-controlled phase III trial 
was for interferon β-1b, which significantly delayed time to 12-week confirmed 
disability progression (OR 0.65 p=0.0008; 95% CI 0.52, 0.83), reduced relapse rate 
(IFN-β-1b 0.44 vs placebo 0.64, p=0.002) and reduced the proportion of patients 
with active scans (p=0.0046),193 though it did not influence brain atrophy.194 The 
IMPACT trial of intramuscular interferon β-1a similarly met its primary endpoint: the 
multiple sclerosis functional composite (MSFC) of the 25-foot walk, paced auditory 
serial addition test (PASAT) and 9-hole peg test (9HPT);195 a result driven by an 
effect on the 9HPT. Unfortunately, these effects were not replicated in subsequent 
studies;196,197 it seems likely, given the higher relapse rates in the former (positive) 
trials, that interferon-β has an impact on relapse-related disability only. 
Consequently, current NICE guidance advises the use of interferon-β among people 
with SPMS if they are continuing to have relapses. Natalizumab has also been the 
subject of intensive investigation in SPMS. ASCEND was a phase III, randomized, 
double-blind, placebo-controlled trial, which showed no between-group difference in 
a multicomponent measure of disability progression (formed of the EDSS, timed walk 
and 9HPT).198 Natalizumab-treated SPMS patients did have reduced 9HPT 
progression however, which led the authors to conclude that Tysabri reduced 
progression in upper limb function and might, over a duration longer than 2 years, 
improve ambulation. Yet, the study that seems most likely to change practice in 
SPMS is the EXPAND trial of the sphingosine 1-phosphate receptor antagonist, 
siponimod.25 This met its primary endpoint, demonstrating a reduction in time to 12-
week confirmed disability progression (HR 0.79 p=0.013 95% CI 0.66, 0.95), 
alongside other positive endpoints including percentage brain volume change 
(p=0.0002). This has not yet been demonstrated to be superior to interferon β-1b, 
but has now been licensed in the US and EU, as well as being approved by NICE, 
though only for those SPMS patients with relapses or imaging features suggestive of 
inflammatory activity. 
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For PPMS, the results of trials of immunotherapies have been more clearly and 
consistently negative.199,200 The only positive phase III trial has been the ORATORIO 
trial in which ocrelizumab reduced 12-week disability progression by 6.4% compared 
to placebo (HR 0.76; 95% CI 0.59 – 0.98),24 though it is noteworthy that all 
participants in this trial were ambulant, the mean age of the population was 44 years, 
all had a disease duration of ≤15 years, and 28% of patients on the study drug had 
gadolinium enhancement at baseline. Consequently, these results are not 
generalisable to the entire population of people with PPMS, and this is reflected in 
NICE’s approval which requires patients be ambulant up to 20 metres, have had 
symptoms for ≤15 years and evidence of MS activity at MRI. From the phase II 
perspective, another notable result for an anti-inflammatory agent has been the 
SPRINT MS trial of ibudilast, which led to significant reductions in brain parenchymal 
fraction loss compared to placebo (p = 0.04).201 
 
In contrast, neuroprotective and remyelinating therapies may have a wider window of 
opportunity than immunotherapies and address the pathogenic mechanisms of 
progressive MS not controlled by DMTs.202 Several phase II trials have been 
completed, but we are yet to see robust evidence of efficacy of such a drug in a 
phase III trial.192 While remyelinating therapies will be discussed in more detail in the 
next section, one of the most promising agents currently at this stage is simvastatin. 
In the MS-STAT trial, 140 SPMS patients were randomised 1:1 to receive 
simvastatin 80 mg or placebo, which yielded a 43% reduction in mean annualized 
rate of brain atrophy (p = 0.003).118 MS-STAT2 is currently testing this in 1180 SPMS 
patients in a phase III study (NCT03387670). Similarly high hopes had been had for 
amiloride, fluoxetine and riluzole, but when tested in the MS-secondary progressive 
multi-arm randomisation trial (MS SMART) study in 445 people with SPMS, no 
treatment effect on brain atrophy (percentage brain volume change) was seen over 2 
years.119 However, one of the legacies of this trial will be its demonstration of the 
feasibility and efficiency of multi-arm trials, in particular in the testing of repurposed 
drugs.192 Indeed, preparative work for this adaptive trial is the rationale for my work 
with the MS Society’s treatment selection group, discussed in Chapter 6.  
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Remyelination in multiple sclerosis 
 
The roles of myelin and oligodendrocytes 
 
Myelination offers a far better way of increasing the conduction velocity of nerve 
fibres than simply increasing axon size. Myelin increases the transverse, insulating, 
resistance of the axon membrane while the voltage-gated sodium and potassium 
channels are virtually confined to short unmyelinated nodes of Ranvier. The action 
potential is therefore propagated by the comparatively rapid and energy efficient 
process of saltatory conduction.203 It follows that loss of myelin leads to slower 
transmission of the action potential, and hence prolonged latency, but can also lead 
to conduction block.204 Remyelination is therefore a way to restore saltatory 
conduction,205 and clinical function,206 after demyelination. 
 
Additionally, oligodendrocytes directly support the neuron, for example through 
providing lactate for metabolism and generation of ATP.30-32 Pathological studies and 
animal models also suggest that axonal degeneration is reduced in remyelinated 
areas.29,33,34 Taken together, a remyelinating therapy has the potential to restore 
function and prevent neurodegeneration in multiple sclerosis. 
 
Meanwhile, it is increasingly apparent that myelin regulation is a dynamic process in 
which both newly formed oligodendrocytes and pre-existing oligodendrocytes 
remodel myelin, often in response to activity, to facilitate learning and plasticity.207 
Whether activity-dependent remyelination could be restored by the proposed 
remyelination treatments remains an unanswered question. 
 
Mechanisms of remyelination 
 
Demyelination (induced experimentally or by disease), can be followed by this 
regenerative response leading to the formation of new myelin sheaths around 
denuded axons by newly formed oligodendrocytes.28,208-211 Histopathological 
assessments have highlighted that this can occur extensively in some people with 
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MS,212 but it is inadequate in a significant proportion.213,214 For example, one study 
analysed forebrain tissue from 51 MS patients and found widespread remyelination 
in 20% of individuals, yet 34 cases remyelinated fewer than 25% of their lesions.214 
Such high inter-subject and inter-lesional variability in remyelination capacity is 
supported by dynamic myelin imaging using positron emission tomography (PET).215 
When combined with evidence that those demonstrating more remyelination display 
lower levels of disability,216 it underscores the therapeutic promise of a remyelinating 
treatment. Consequently, efforts have been made to understand the mechanisms of 
remyelination and why this fails in MS, in the hope of defining druggable targets to 
enhance this process. 
 
In animals, pre-existing mature oligodendrocytes are able to increase the number of 
internodes they generate, and therefore contribute to recovery after demyelination,217 
but they do not add to the pool of new myelinogenic oligodendrocytes that are 
required for remyelination.218 Thus remyelination is crucially dependent upon adult 
oligodendrocyte progenitor cells (aOPCs), themselves derived from neonatal OPCs 
(nOPCs),219 which have been shown by genetic fate-mapping to be the cells 
responsible for generation of the majority of new oligodendrocytes in the adult 
nervous system.220,221 These cells are maintained in sufficient quantities 
predominantly by their own self-renewal, rather than by replacement from neural 
stem cell niches in the CNS.222 
 
Following damage to myelinated areas, aOPCs follow a choreographed process of 
activation, migration, proliferation and differentiation before culminating in the 
formation of new myelin sheaths.220 The final product is a compacted layer of myelin 
that is thinner and shorter than those formed during developmental myelination,223 a 
fact often used to identify remyelination histologically when the process is studied in 
animal models (Box 1.1). Mechanistically, remyelination might fail due to a defect 
anywhere in this sequence; a paucity of pro-regenerative factors, or excess of 
inhibitory factors, as can be seen in MS lesions, combined with the intrinsic 
composition of the aOPC, can all limit capacity to remyelinate.28 
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BOX 1.1: Animal models used to study remyelination 
Remyelination has been studied in several animal models: 
• Experimental autoimmune encephalomyelitis (EAE): this model of 
autoimmune inflammation, driven by injection of a myelin peptide alongside 
an adjuvant, sees inflammation and remyelination occurring concurrently. 
However, when used experimentally to explore potential medicines, it is 
often hard to distinguish an effect of attenuation of inflammation from 
promotion of remyelination. Hence non-inflammatory models have been 
developed, as below. 
• Gliotoxin injections: lysolecithin and ethidium bromide (EB) are toxic to 
oligodendrocytes yet spare axons. Experimentally they can be injected into 
the CNS of animals to induce demyelination. Their particular benefit has 
been that the kinetics of demyelination and remyelination can be closely 
studied.224 The limitation is that the lesions do not necessarily model the 
complexity of those in multiple sclerosis, which contain a myriad of 
remyelination inhibitors and inflammatory cells. 
• Oral cuprizone administration: dietary ingestion of the copper chelator 
cuprizone results in demyelination of white matter tracts, particularly in the 
corpus callosum.225 It models remyelination, on-going in the face of 
continued demyelination. However, the normally small diameter axons seen 
in the corpus callosum makes distinguishing a remyelinated from an 
unaffected axon challenging, and interpretation correspondingly difficult. 
The best model for progressive MS is debated and variations of these employed 
(reviewed in 226). For reasons that will become apparent, when studying the 
underlying mechanisms of remyelination failure in progressive MS, these 
experiments are best performed in aged animals. 
 
Given that large numbers of aOPCs are seen in chronically demyelinated MS 
lesions,227 it is often stated that remyelination fails as aOPCs become quiescent and 
unable to differentiate. As a consequence, increasing research has been deployed to 
elucidate the key regulators of differentiation228-231 and identify agents capable of 
enhancing this process for clinical use, which is discussed further below.  
 
However, it should be acknowledged that in humans aOPC differentiation may not 
universally be the rate-limiting step. It has previously been established that aOPCs 
do migrate to sites of injury and evenly distribute themselves to facilitate 
remyelination,232 though they probably do so over short distances.233 Additionally, 
while aOPCs are responsible for the majority of remyelination in the adult CNS in 
experimental models, they may not be the only cell contributing to remyelination in 
humans. Subventricular zone (SVZ) progenitors are also able to differentiate into 
myelinating oligodendrocytes within the adult CNS234 though, while myelin derived 
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from these progenitors is thicker and more functional than that derived from 
parenchymatous OPCs,235 their effects are restricted to areas neighbouring the 
SVZ.236 Moreover, two recent papers have provided evidence that mature 
oligodendrocytes may contribute to lesion repair in humans after all. Yeung and 
colleagues, utilising a novel method of dating of oligodendrocytes in post-mortem MS 
brains by analysis of nuclear bomb test derived 14C, indicated that the 
oligodendrocytes in shadow plaques (areas believed to have undergone at least 
partial remyelination) were not the result of new oligodendrogenesis.237 Similarly 
another study, using single nucleus RNA sequencing in post-mortem MS tissue, 
showed that oligodendrocytes expressing mature markers could participate in 
remyelination.238 This latter study also highlighted changes in oligodendrocyte gene 
expression profiles between areas of normal appearing white matter of MS brains 
and healthy controls, implying that the pathology seen in lesions may not reflect the 
global cellular changes occurring in MS. Therefore, in the adult CNS, it seems 
probable that both adult OPCs and mature oligodendrocytes, with a small 
contribution from subventricular zone progenitors, participate in the repair process.  
 
In line with this recent challenge to the view of OPC differentiation as the rate-limiting 
step in humans, Kuhlmann and colleagues have additionally shown that the barrier 
to successful remyelination can vary with lesion stage. In an analysis of 153 lesions 
across specimens from 62 humans, they demonstrated that in active/demyelinating 
lesions, the process of myelin sheath formation, but not reduced oligodendroglial 
differentiation, was responsible for the lack of remyelination; oligodendroglia were 
plentiful and there was minimal OPC differentiation in remyelinating active lesions.239  
 
Finally, interactions between other glial cells and OPCs are also being increasingly 
clearly defined. Reactive astrocytes found at the site of demyelination, for example, 
secrete inhibitors of remyelination such as Endothelin-1240 and the recent description 
of A1 reactive astrocytes, which contribute to the death of oligodendrocytes,241 
needs to be incorporated into the current model of remyelination and potential 
therapeutic targets explored. In parallel, the demonstration that protein synthesis in 
OPCs is modulated by axonal action potentials242 speaks to an underlying symbiosis 
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between the neuron and the cells responsible for its myelination. In the peripheral 
nervous system, there is a necessary relationship between axon and Schwann cell, 
exemplified by dependency on the neuron-derived growth factor Neuregulin 1 to 
drive peripheral nerve myelination.243 In the CNS, OPCs are able to differentiate 
even in the absence of axons244,245 and, as will be discussed below, in culture are 
able to myelinate inert axon-like substrates.246,247 Yet, while oligodendrocytes have a 
default ability to differentiate and myelinate axons, this is modulated by axon 
diameter and activity, implying a requirement for intact axons in vivo.248  
 
The corollary of these points is that a treatment strategy that enhances aOPC 
differentiation alone may not be sufficient to address remyelination across a 
population of heterogenous MS patients with lesions of different ages. It seems 
increasingly probable that combinations of drugs, acting on different processes, will 
be required to facilitate remyelination, and that these will be most effective when 
there is a sufficiently preserved demyelinated axon. This latter point forms the 
rationale for many phase II studies first focussing on people with RRMS, in whom it 
is anticipated that fewer axons will have degenerated. 
 
The failure of remyelination in MS 
 
To understand why remyelination fails in MS, one must look at two crucial 
contributory processes – namely those of age and the immune system. 
 
While the immune system is often seen as having a detrimental role in MS, the 
innate immune system has been shown to be essential in the biology of 
remyelination.249 Myelin debris contains inhibitors of aOPC differentiation and so its 
clearance, by phagocytosis, is an important step in the regeneration of the myelin 
sheath.250-253 Similarly, infiltrating macrophages and activated microglia secrete a 
myriad of neurotrophic factors, which have direct effects on aOPCs.254 Indeed, in 
order to facilitate robust remyelination in vitro, the polarization of the macrophage 
response to an immunoregulatory, “M2”, phenotype is required.255 It is not clear how 
these findings relate to the behaviour of monocyte-derived macrophages and 
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microglia in vivo, yet they emphasise how improving our understanding of 
subpopulations of macrophages/microglia and lymphocytes in the brain is essential 
to developing treatments that prevent demyelination while promoting remyelination. 
 
The potential for endogenous remyelination is both age- and disease duration-
dependent: remyelination is greatest in people aged less than 55 years and within 
the first 10 years of disease onset.98,106,210 Disentangling the relative contribution of 
age versus duration of lesion demyelination to remyelination failure remains to be 
done, but clinical evidence would suggest age is especially pertinent as patients 
reach disability milestones at similar ages whether they have relapsing or 
progressive symptoms at onset.98,256 Similarly, lesional magnetization transfer ratio 
(MTR) – a putative marker of remyelination – also shows age-dependent decline.257 
Remyelination is therefore akin to other regenerative processes258 in becoming less 
efficient with time;259-263 I therefore set out to investigate the relationship between 
age and the treatment response to bexarotene – as measured by MTR and visual 
evoked potentials – during this PhD (Chapter 3). 
 
Understanding age-associated remyelination failure is essential in treatment 
development. Mechanistically, in this circumstance, the rate-limiting step is more 
clearly differentiation of the aOPC, as increasing aOPC recruitment does not lead to 
enhanced remyelination in aged mice.264 Studies of how extrinsic factors vary with 
age have implicated a declining efficiency of the inflammatory response;265 as noted 
above, macrophages produce pro-differentiation factors and clear debris by 
phagocytosis,253,266,267 which is essential for remyelination. That this process might 
be modifiable was demonstrated by the reversal of a deficit in remyelination of an 
aged mouse by twinning its circulation with a young animal by heterochronic 
parabiosis.268  
 
In a similar way, small molecule treatments can be used to promote endogenous 
remyelination, even in aged animals. A detailed understanding of the intrinsic age-
related changes in aOPCs is a recent development in the field following work by 
Neumann and colleagues.100 They demonstrated that aged aOPCs become less 
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responsive to factors that induce differentiation, contributing to the reduced 
remyelination capacity seen in many non-remyelinating chronic MS lesions.269 
Moreover, RNA sequencing from young and aged aOPCs highlighted a significant 
contribution from the mTOR pathway. This led to the novel observation that 
manipulating this pathway in aged rats with caloric restriction (three non-consecutive 
days of fasting per week over six months), or with the AMPK-agonist metformin (over 
three months), reverses the diminished differentiation capacity of aOPCs and 
restores their ability to remyelinate. As a result, manipulation of intrinsic changes in 
these stem cells is emerging as a promising treatment strategy; one which I intend to 
test in the development of CCMR Two (Chapter 5). 
 
Finally, there are also anatomical variations to the extent of remyelination within 
different lesions in the same individual. For example, periventricular lesions are less 
amenable to remyelination than subcortical lesions,98,214 while grey matter lesions 
remyelinate more than those in the white matter.270,271 This might reflect an 
underlying heterogeneity in OPCs or in locational differences in permissibility for their 
differentiation;272 there are fewer inhibitors of remyelination in the cortex.270 Or, it 
could also be due to the importance of neuronal activity to remyelination, which is 
more likely to occur closer to the soma. Regional variations in remyelination within 
an individual is an opportunity to investigate barriers to enhancing remyelination, but 
also raises questions about which lesions should be tested in clinical trials. 
 
Identification of remyelination drugs 
 
An enhanced understanding of the intrinsic and extrinsic regulatory pathways 
implicated in remyelination has identified a multitude of sensible targets for 
therapeutic manipulation. An example of this has been the development of 
opicinumab to inhibit Lingo-1 (leucine-rich repeat and immunoglobulin-like domain-
containing nogo receptor-interacting protein 1), a negative regulator of 
differentiation.273 
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Another fruitful technique has been high-throughput screening of libraries of 
compounds, looking for an effect on aOPC differentiation.274 One such study 
focussed on the ability of candidate compounds to promote differentiation of rat optic 
nerve-derived progenitor cells as evidenced by their production of oligodendrocyte 
differentiation markers.275 This revealed that antagonism of muscarinic receptors, 
with the antihistamine/anticholinergic benzatropine, promotes OPC differentiation in 
vitro, which translated into a remyelinating effect in both EAE and cuprizone mice 
models. Similarly, Najm et al. screened a library of bioactive small molecules, this 
time on mouse pluripotent epiblast stem cell-derived OPCs.276 They discovered that 
the topical corticosteroid, clobetasol, and the anti-fungal, miconazole, as well as 
benzatropine, leads to a mature oligodendrocyte morphology, and improved 
remyelination in a lysolecithin-induced mouse model of focal demyelination.  
 
A slightly different approach has used concentric wrapping of myelin around 
micropillars as an end point rather than differentiation per se. Mei et al. assessed the 
ability of 1000 FDA-approved small molecules to promote OPCs and 
oligodendrocytes to ensheath these cone-like structures with myelin.246 In this way 
they identified a cluster of compounds with an anti-muscarinic effect: atropine, 
ipratropium, oxybutynin, trospium, quetiapine, benzatropine and clemastine. This 
work was quickly translated into the phase II trial of clemastine as a remyelinating 
therapy,277 discussed below. 
 
Such small molecules may not have their remyelinating effect through an exclusive 
action at their canonical targets. The closest to a unifying mechanism has been 
through demonstration that a wide range of these, including clemastine, benztropine, 
miconazole and ketoconazole, might promote remyelination through a altering the 
sterol landscape in the OPC to favour accumulation of 8,9-unsaturated sterols.278  
 
However, these techniques predominantly rely on the assumption that OPC 
differentiation is the rate-limiting step in remyelination237,238,279. The micropillar array 
is also limited in its ability to test the development of functional architecture in the 
form of nodes and internodes.  It follows that combination therapies may be 
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necessary to optimise an effect across the population of MS lesions. Moreover, such 
efforts will inevitably be hampered by the lack of an animal model that encapsulates 
the entire complexity of the MS lesion; there is a risk that agents showing promise in 
preclinical work do not translate into a beneficial effect in humans or indeed that a 
potentially useful treatment effect is missed in such models, halting progression 
towards clinical studies.28  
 - 56 - 
Clinical trials of remyelinating drugs 
 
The identification of agents that therapeutically enhance endogenous remyelination 
in preclinical models has led several to be translated into clinical trials and the 
possibility of a remyelinating treatment in MS looks increasingly likely. In Table 1.6 I 
summarise the clinical trials that have been performed while considering a few in 
more detail below. 
 
Clemastine  
This is a first generation anti-histamine that was identified in the micropillar array as 
being capable of stimulating OPCs to differentiate and carry out the first stages of 
myelination.246 This was confirmed in a further screen275 and shown to occur via an 
off-target anti-muscarinic action, likely a specific effect on the M1 muscarinic 
receptor.34 Ensuing work would confirm its remyelinating effect in multiple animal 
models.34,280,281  
 
As clemastine has been licenced for allergic rhinitis since 1992, it was readily 
translated into a clinical trial.277 The ReBUILD study was a single-centre, double-
blind, randomized, placebo-controlled, phase II, crossover trial, which specifically 
investigated the remyelinating potential of clemastine in patients with RRMS and 
evidence of chronic demyelinating optic neuropathy. Their inclusion criteria ensured 
that there was detectable demyelination in the optic pathway (evidenced by a visual 
evoked potential (VEP) P100 latency >118 ms in at least one eye), but also sufficient 
axons to regenerate (with a retinal nerve fibre layer thickness (RNFL) >70 μm in the 
qualifying eye when measured with optical coherence tomography (OCT)). 
Meanwhile, the remyelination that might be expected in the natural history of optic 
neuritis was excluded by selecting only those without a history of acute optic neuritis 
in the qualifying eye within the last 5 years, or in either eye in the last 6 months.    
 
The study design saw participants divided into two groups but ensured that all had 
access to the study drug (which is readily available in the US without prescription).  
In a double-blind design, 25 were given 5.36 mg of clemastine twice daily for 90 days 
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followed by placebo for 60 days (group 1), while a further 25 patients were given 
placebo for 90 days followed by clemastine for 60 days (group 2).  
 
The results of this were rather promising. The primary endpoint, VEP P100 full-field 
latency, was reduced by 1.7 ms/eye (p=0.0048) in the cross over model. 
Furthermore, the effect of clemastine on VEP latency was sustained in group 1 after 
switching to placebo. Thus, the cross-over model underestimates the actual effect, 
later demonstrated to be a 3.2 ms reduction in P100 latency. Further, there was a 
significant improvement in a functional outcome, low contrast letter acuity, when the 
delayed treatment analysis was employed. All the while, the drug was well tolerated, 
though was associated with fatigue. Secondary endpoints were negative however, 
including MRI assessments of myelin water fraction (MWF), whole brain MTR, white 
matter MTR, and white matter fractional anisotropy (FA).  There was no effect on the 
expanded disability status scale (EDSS), a timed 25-foot walk or the 6-minute walk 
test.  
 
This positive trial has provided some optimism about clemastine, though its selective 
inclusion criteria, investigating just those persons with chronic optic neuropathy, 
raises the possibility that the results are not generalisable; 75 patients were excluded 
because their VEPs did not meet the threshold latency of 118 ms. The ReCOVER 
trial (NCT02521311) is currently testing clemastine in patients following a relapse 
(4mg three times daily for 1 week, followed by 4mg twice daily until 3 months 
following an episode of acute optic neuritis). While promising, there is still much work 
to be done: clemastine requires progression to phase III studies, it should be trialled 
in progressive cohorts, and the possibility of combining treatments, such as with the 
potential synergistic effect of metformin, requires investigation (Chapter 5). 
 
Opicinimab  
As mentioned above, Lingo-1 is a negative regulator of oligodendrocyte 
differentiation and its antagonism has been shown in vitro and in animal models of 
CNS demyelination to enhance remyelination.282 The human monoclonal antibody 
opicinumab (anti-Lingo-1) showed remyelinating activity in preclinical studies283 and 
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therefore its utility was explored in early clinical trials. After passing safety analyses 
in a phase I trial,284 there was a phase II, randomized, double-blind, placebo-
controlled, clinical trial (RENEW) in 82 patients with a first episode of acute optic 
neuritis (but not necessarily a diagnosis of MS).285 The primary outcome measure 
was the recovery in VEP P100 latency in the affected eye, referenced to the 
unaffected eye, over 24 weeks of treatment (at 100 mg/kg) after an episode of optic 
neuritis. The mean treatment difference of opicinumab (17.3 ms) versus placebo 
(20.8 ms) was -3.5 ms (95% CI -10.6, 3.7; p=0.33) in the ITT population, and −7·6 
ms in the PP population (95% CI -15.1 to 0.0; p=0.050). The authors attributed these 
between-sample differences to adverse events leading to early withdrawal at a time 
when latency delay was severe: this applied to four (10%) participants in the placebo 
group and seven (17%) participants in the opicinumab group. No change was 
observed in the secondary endpoints, though this did not include MRI sequences 
such as MTR. 
 
The SYNERGY trial followed: a dose-ranging study including 418 people with RRMS 
and SPMS whom were taking interferon-β1a.286 The primary outcome measure was 
the percentage of participants achieving confirmed disability improvement over 72 
weeks, measured as a composite of ambulation (25-foot walk), upper extremity 
function (9HPT), cognition (3-Second Paced Auditory Serial Addition Test; PASAT) 
and the EDSS. Confirmed disability improvement was seen in 49% of participants on 
placebo, 47% on opicinumab 3 mg/kg, 63% on 10 mg/kg, 65% on 30 mg/kg, and 
40% on 100 mg/kg; a linear dose response was not seen but the increase in 
percentage of responders in those treated with the mid-range doses of 10 and 30 
mg/kg has led to Biogen proceeding with a refined phase II trial (AFFINITY) in 
addition to an extension study (RENEWED, NCT02657915) of the RENEW trial. 
 
GSK239512 
This H3-receptor antagonist was originally developed to treat Alzheimer’s 
disease287,288 and was put forward as a potential remyelinating agent because H3 
negatively regulates oligodendrocyte differentiation.289 A phase II, randomised, 
placebo-controlled study in people with RRMS on interferon or glatiramer acetate, 
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tested the remyelinating effects of one-year of treatment with GSK239512 on acute 
lesions measured through two co-primary endpoints. First, the mean change in MTR 
post-lesion compared with pre-lesion in newly developed (on trial) gadolinium-
enhancing (GdE) lesions. And second, the mean change in MTR for acute lesions 
defined by Delta-MTR: regions experiencing a decrease greater than the 99th 
percentile of the normal variation measured in white matter from one scan to the 
next.257 Among the secondary outcomes was the mean change in (chronic) T2 lesion 
MTR. The mean change in MTR was modelled separately for each lesion within 
each patient, allowing for variation in effects between patients and between different 
lesions, within patients. Treatment effects, relative to placebo, were given as the 
treatment difference divided by the standard deviation (estimated as the between-
group variability) of the treatment difference. From 131 randomised participants, 92 
GdE lesions from 27 patients and 69 Delta-MTR-defined lesions from 24 patients 
were identified in the GSK239512 group. Meanwhile, 97 GdE lesions from 28 
patients and 77 Delta-MTR lesions from 29 patients in the placebo group were 
included. The active arm was associated with positive effect sizes of 0.344 (90% CI 
0.012, 0.671) and 0.243 (90% CI, -0.112, 0.598) for GdE and Delta-MTR lesions 
respectively.290 However, there was no active-placebo difference in mean MTR 
change for chronic T2-weighted lesions: -0.022 (90% CI -0.052, 0.009) percentage 
units. While this trial indicated a statistically significant effect of the drug on GdE 
lesions, fewer than half of the participants contributed to the analysis, raising 
questions about generalisability of the results. The trial design additionally 
highlighted the low yield of acute lesions at MRI in participants on (even low-efficacy) 
DMTs; as discussed below 1179 MRI brain scans were undertaken in this trial to 
detect just 189 acute lesions. 
 
Bexarotene 
Another positive regulator of OPC differentiation is the retinoid acid receptor (RXR)-
γ.291 In remyelinated MS lesions, RXR-γ is expressed in cells of the oligodendrocyte 
lineage, and knockdown of the receptor in culture inhibits human OPC differentiation. 
Meanwhile, administration of the RXR agonist 9-cis-retinoic acid to demyelinated 
cerebellar slice cultures, and to aged rats after demyelination, promotes 
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remyelination.291 There are no licensed selective RXR-γ agonists292 but bexarotene, 
a non-selective agonist of the α, β, and γ retinoid X receptors (RXR), is licenced to 
treat cutaneous T-cell lymphoma.293 The results of the CCMR One study, which 
tested the effects of bexarotene on demyelinated lesions, are presented in Chapter 2 
of this thesis. 
 
Biotin 
Biotin is postulated to promote remyelination when given in high-doses through its 
role as a cofactor for carboxylases required for fatty acid synthesis in 
oligodendrocytes.294 To date, clinical trials have mostly focussed on cohorts of 
progressive patients. In the MS-SPI study, 13 (12.6%) participants in the active arm 
(compared to 0 in the placebo arm) achieved the primary endpoint of sustained 
disability reversal (decrease in EDSS or timed 25-foot walk).295 Unfortunately, this 
failed to be replicated in the ensuing MS-SPI2 study.296 The MS-ON study similarly 
returned a negative result when change in visual acuity was employed as the 
primary endpoint.297 It therefore seems unlikely that high-dose biotin could be a 
clinically useful treatment for people with MS.298 
 
Cell-based therapies 
Outside of enhancing the activity of endogenous oligodendrocyte progenitors, other 
non-ablative cell-based approaches are generating substantial interest (reviewed in 
299): transplantation of mesenchymal stem cells (MSCs), derived from bone marrow 
or other tissues, or transplantation of OPCs, derived from foetal tissue, embryonic 
stem cells or induced pluripotent stem cells (iPSCs)300,301 are viable options, but 
remain experimental. Challenges exist for each with regards to cell production, mode 
of delivery, tumour-forming potential, and requirements for immune suppression, 
although using autologous sources may abrogate the need for the latter. One 
noteworthy, albeit uncontrolled, trial administered bone marrow-derived MSCs to ten 
patients with progressive MS, noting an improvement in VEP latency of 1.3 ms, 
interpreting the mechanism for this as a neuroprotective effect through the promotion 
of myelin repair.302 Larger phase II studies are underway,303 though there are many 
unresolved barriers to widespread application of a transplant-based approach MS. 
 - 61 - 












finding trial of 
liothyronine sodium 
(L-T3) given for one 
week to people with 

























group study in 150 
people with MS and 
















A phase II, 
randomised, double-
blind, placebo-
controlled trial of 50 
people with RRMS 

















A phase IV, 
randomised, open-
label study of ACTH 
gel on remyelination 
in patients with RRMS 

















A phase II, 
randomised, placebo-
controlled, single-
blind study in 131 





















A phase III, 
randomised, placebo-
controlled, double-
blind trial of high-dose 
biotin in 154 people 




















A phase III, 
randomised, placebo-
controlled, double-
blind trial of high-dose 
biotin in 642 people 
with SPMS or PPMS 








A phase III, 
randomised, placebo-
controlled, double-
blind trial of high-dose 
biotin in 93 people 












A phase Ib, 
randomised, placebo-
controlled, double-
blind trial of olesoxime 
compared to placebo 


















A phase II, 
randomised, placebo-
controlled, double-
blind, crossover trial 
in 50 people with 










reduction of 1.7 
ms in the 
crossover 
model and 3.2 






A phase II, 
randomised, double-
blind, placebo-








field VEP and 





 - 63 - 
Quetiapine 
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Domperidone 
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label, single-blind 
study of domperidone 
10mg three times 
daily in people with 

















trial of 10 sessions of 
transorbital electrical 
nerve stimulation over 
2 weeks after an 












double-blind, trial of 







Table 1.6. Clinical trials of remyelination treatments in multiple sclerosis. MTD, 
maximally tolerated dose; NABT, normal appearing brain tissue; MTR, magnetization 
transfer ratio; LCLA, low contrast letter acuity; Gd, gadolinium; MWF, myelin water 
fraction; DTI, diffusion tensor imaging; RRMS, relapsing remitting multiple sclerosis; 
SPMS, secondary progressive multiple sclerosis; PMS, progressive multiple 
sclerosis; IFN, interferon; VEP, visual evoked potential; EDSS, expanded disability 
status scale; T25FW, timed 25-foot walk; 9HPT, 9 hole peg test; PASAT, paced 
auditory serial addition task. 
  
 - 65 - 
Outcome measures for remyelination trials 
 
One of the foremost challenges to translating promising preclinical findings into 
clinical studies is uncertainty in the optimum way to demonstrate a remyelinating 
effect in living individuals. Given that the anticipated benefit to the patient – the 
prevention or delay to progression – only manifests over years, reliance on standard 
objective clinical markers of disability, for example the EDSS,309 as outcomes may 
miss a useful therapeutic effect over a comparatively short clinical trial. While such 
disability measures are undoubtedly of more importance to the patient, they are 
more suited to later stages of drug development; as established in the previous 
section, we are still at the stage of identifying agents which have any biological effect 
on remyelination. Using functional scores to study remyelination specifically is further 
complicated by other adaptations that occur in nerves in response to injury, such as 
ion channel redistribution and cortical plasticity/adaptation after demyelination.310,311  
 
There follows a reliance on paraclinical measures to determine a treatment effect. 
With no accessible tissue for histological examination, a combination of 
neurophysiological and imaging-based assessments that are more direct 
assessments of the pathological processes being targeted are typically required.312 
Of course, a related barrier to successful translation is uncertainty in the amount of 
remyelination that would be clinically meaningful, a point I will return to in my 
conclusions. Here, I describe the most prevalent outcome measures being used in 




From the imaging perspective, standard MRI sequences can be deployed to 
measure the number and size of lesions in the white matter (WM) and grey matter 
(GM), as well as atrophy of the brain and spinal cord. Yet these measures (such as 
T2 weighted and gadolinium-enhanced T1 weighted sequences) correlate only 
modestly with disability and lack the ability to differentiate between the different 
pathological correlates of MS: namely inflammation, oedema, axonal loss, 
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demyelination, remyelination and gliosis.313 As a result, advanced MRI techniques 
that interrogate tissue microstructure – including myelin water fraction (MWF),314,315 
diffusion tensor imaging (DTI)316,317 and magnetization transfer ratio (MTR),318,319 as 
well as positron emission tomography (PET),215,320 have been used to measure 
myelin dynamics.  
 
Lesions on MRI  
WM lesions are the most readily identifiable MRI abnormality in MS, though 
resolution at 1.5T still fails to identify a significant proportion: T2-weighted sequences 
can identify 63% of histopathologically demonstrated WM lesions, while 3D FLAIR 
increases this to 71%.321 Identifying GM lesions is more challenging still. For mixed 
GM-WM and deep GM lesions pathological studies suggest this figure is in the 
region of 40%. Yet fewer than 5% of cortical lesions can be identified with T2 and 3D 
FLAIR.321 Additional sequences, such as double inversion recovery (DIR) and phase 
sensitive inversion recovery (PSIR), can improve sensitivity to detecting cortical GM 
lesions,322,323 but even when these techniques are deployed with 3T, no more than 
20% of cortical GM lesions are seen.324 This is further compounded by the finding 
that fewer than 11% of subpial (type III) GM lesions, which account for two-thirds of 
all cortical lesions in people with progressive MS,92,93 are detectable with 3T MRI.324 
Consequently, MRI-determined normal appearing grey matter (NAGM) will contain 
significant numbers of occult lesions, and this may be more marked in the subpial 
region.  
 
Another consideration when selecting lesions that might be most amenable to 
remyelination is establishing their chronicity. The administration of intravenous 
gadolinium-based MRI contrast can lead to enhancement of new WM lesions for 2-8 
weeks, although typically <4 weeks.325 Additional methods of identifying acute 
lesions involve serial imaging, which enables detection of new areas of T2-
hyperintensity, or isolation of regions that experience a decrease in MTR (for 
example, a decrease greater than the 99th percentile of the normal variation 
measured in WM from one scan to the next).290 Unfortunately, the limitation of an 
imaging approach to a remyelination trial of acute lesions, is the necessity for 
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frequent MRI scans: Schwartzbach et. al. required their 131 participants (on low-
efficacy DMTs) to undergo 9 MRI scans every 6 weeks in their clinical trial of 
GSK239512, in order to detect 189 acute lesions.290 This return would be likely be 
even lower if participants were on more effective DMTs.  
 
Magnetization transfer ratio 
Magnetization transfer techniques investigate the exchange of magnetisation 
between protons in at least two pools: those that are mobile and those associated 
with macromolecules such as myelin or axonal membranes. Expressed as a ratio 
(MTR), it provides a quantitative measure of the proportion of protons bound to 
macro-molecular structures relative to those that are free in water and has been 
demonstrated to correlate with pathological quantification of myelin in both WM and 
GM lesions: demyelinated lesions have a significantly lower MTR than remyelinated 
lesions.319,326,327 MTR can be used to quantify myelin in several ways. One can use 
serial measures of mean MTR in white and grey matter,328 in chronic lesions,329 or in 
acute (gadolinium-enhancing) lesions.257 Indeed, as not all lesions remyelinate to the 
same extent, further refinements have been proposed. For example, in the CCMR-
one study of bexarotene (Chapter 2), the primary outcome measure was based on 
the change in mean MTR of established lesions with a low MTR at the baseline 
scan, thereby maximising sensitivity to an effect on lesions that are demyelinated at 
the outset.329 These aforementioned techniques have been used to show that mean 
MTR in white and grey matter remains static over time in people with MS treated with 
alemtuzumab, but deteriorates if not on disease modifying treatment,328 and that the 
anti-histamine GSK239512 has a positive effect on mean MTR in gadolinium-
enhancing lesions.290 
 
Diffusion tensor imaging 
Alternatively, DTI provides information about tissue microstructure by measuring 
water diffusion in vivo.330 Parameters derived from this include radial diffusivity (a 
marker of water motion perpendicular to the axon), mean diffusivity (an index of 
water diffusion regardless of direction), axial diffusivity (a marker of water motion 
parallel to the axon) and fractional anisotropy (a measure of the directionality of 
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water movement). Combined MRI and histopathological studies show that fractional 
anisotropy (FA) correlates with both axonal counts and myelin content,331,332 while 
radial diffusivity increases in demyelinated areas in experimental models.317 
However, a limitation of this technique is that these measures depend on the ability 
to detect the correct fibre-tract orientation per voxel, otherwise complex tissue 
microstructure such as crossing fibres, rather than pathology specifically, can impact 
on diffusivity.333 As a result, DTI is perhaps best used to assess white matter tracts 
such as the visual pathway;334 an attractive prospect given the potential to deploy 
this alongside functional measures of the same tract using visual evoked potentials.  
 
Myelin water fraction 
The myelin water fraction (MWF) infers the proportion of water trapped between 
myelin bilayers (‘myelin water’) relative to water inside and outside of axons (which 
have longer T2 relaxation times), and can be also as a proxy for myelin 
content.314,335 The multi-component T2 relaxation technique required for this is, 
however, constrained by long acquisition times, and there remains no 
histopathological evidence of greater sensitivity or specificity to myelin than MTR. 
 
Positron-emission tomography (PET) 
Outside of MRI, PET imaging, alongside a myelin-specific ligand such as Pittsburgh 
compound B ([11C]PiB), has the capacity to measure the extent of demyelination 
without incorporating biases from other pathological changes, such as gliosis or 
axonal loss.336 PiB binds in decreasing amounts to MRI-determined NAWM, 
gadolinium-enhancing lesions, perilesional WM, T2 lesions, and T1 black holes,215 a 
pattern that has been replicated with other ligands.337 In addition to affording the 
potential to explore changes over repeated scans, PET could also potentially be 
used to stratify the patients by their remyelination potential for clinical studies.215 
However, the issues of ligand (which often requires on site synthesis due to short 
half-lives) and scanner availability, as well as the consequences of radiation 
exposure, are likely to limit the role of PET to research studies.338 
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Brain atrophy 
Finally, brain atrophy, though clearly not a direct measure of remyelination, reflects 
the neuronal and axonal losses that a remyelinating therapy ultimately endeavours to 
prevent.339 Evident from the earliest stages of MS,340 brain atrophy continues at a 
rate of around 0.5-1% each year in people with MS,341 compared to around 0.1-0.3% 
per year in healthy controls,342 and occurs more in the GM than WM.343 It is typically 
assessed using semi-automated methods applied to the T1-weighted sequences, 
such as the SIENA344 and, for a 2-year trial duration, can be used as an outcome 
measure with feasible sample sizes.345 While unlikely to demonstrate an effect within 
a short phase II remyelination trial, brain atrophy is a sufficiently robust and clinically 
relevant outcome measure to be deployed as the primary outcome for both phase II 
and III trials – as it was in the MS SMART clinical trial.119,346 
 
The eyes and visual function 
 
Visual evoked potentials 
Evoked potentials allow for an assessment of nervous conduction along visual, 
somatosensory, auditory, and motor tracts in a way that correlates with function347-349 
and disability,350 but their clinical utility, particularly in diagnostics, has largely been 
replaced by MRI.351 However, such indices are proving invaluable as biomarkers in 
assessing remyelination; in the recent positive phase II trial of clemastine, it was a 
reduction in VEP P100 latency, rather than clinical or imaging markers, that 
confirmed the biological effect.277,352  
 
The pattern reversal full-field VEP represents the averaged recordable electric 
potential in the visual cortex in response to the presentation of an alternating 
checkerboard-patterned stimulus. VEPs are understood to be generated at the level 
of the striate cortex by the combined activity of postsynaptic potentials.353 The 
latency of the VEP consequently reflects the speed of conduction among the fastest 
conducting fibres along the retino-geniculate-striate pathway, while the magnitude of 
the VEP reflects the number of functional afferent fibres reaching the striate cortex 
and the degree of synaptic activity in V1. This technique is therefore a sensitive and 
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objective tool for quantifying dynamic changes in myelination through latency 
abnormalities in the visual pathway, while also being able to monitor conduction 
block and axonal loss through changes in amplitude.354  
 
In remyelination clinical trials, the main focus is on the positive deflection in the VEP 
waveform approximately 100 ms after the visual stimulus (the P100), which is the 
most reproducible part of the response.355 Following an attack of optic neuritis, VEP 
latencies are prolonged but a period of recovery follows, most significantly within the 
first 6 months, but for perhaps as long as 2 years.356,357 In contrast, in those with 
chronic stable optic neuropathy, a prolonged P100 latency is seen, which has been 
shown in longitudinal data to remain stable, or gradually lengthen, with time.358 As a 
result, in studies of patients without a recent bout of optic neuritis, improvements in 
VEP P100 latency can be used as a marker of remyelination; this was the rationale 
behind the ReBUILD trial.277 When studies have enrolled patients with acute optic 
neuritis meanwhile, such as in the RENEW study of opicinumab,285 values for the 
unaffected contralateral eye have been used as a control, and the outcome measure 
given as the change in latency difference between the two eyes.  
 
However, a limitation of full-field VEP is that macular overrepresentation in the visual 
cortex weights any latency abnormalities significantly to those in the central field; 
small or localised optic pathway demyelination or axonal loss is often not 
detected.359,360 This problem is compounded by the conventional electrode 
placement (frontal-occipital) which favours the response from the lower visual 
field.361 A further limitation, also attributable to the anatomy of the visual pathway, is 
phase cancellation. The retinotopic projection to the visual cortex means that the 
upper visual field projects to the lower bank (lingual gyrus) of the sulcus calcarinus, 
while the lower visual field projects to the upper bank (cuneus gyrus). As these face 
each other, the cortical dipoles from the upper and lower hemifields are almost 
opposite, resulting in a cancellation effect of amplitude in the unaffected eye.353 
Accordingly, another consequence of damage to a discrete location in the visual 
pathway, such as a multiple sclerosis lesion, can be that the recorded signal appears 
larger due to less cancellation effect. 
 - 71 - 
 
By contrast, the technique employed in multifocal VEP (MF-VEP) is to 
simultaneously stimulate multiple individual regions of the visual field.362 By cross-
correlating each sequence with the raw EEG signal, responses to unique sequences 
corresponding to each of the individually stimulated segments are extracted. This 
allows for an assessment of a much larger cross sectional area of the optic nerve, 
with better identification of regional changes in latency and amplitude, and potentially 
a more precise analysis of injury and repair following optic neuritis.363-365 For 
example, MF-VEP was deployed in a substudy of the RENEW trial of acute optic 
neuritis to compare mean changes in affected and fellow eye latencies and 
amplitudes from fellow eye baseline latency and amplitude.366 This showed trends to 
latency improvement (mean change of -11.78 ms between opicinumab and placebo 
(95% CI -24.28, 0.73, p=0.06)) and amplitude recovery (mean gain versus placebo 
was 22.32 nV (95% CI -1.26, 45.89 p=0.06)), but significant variation between 
subjects led the study authors to conclude that they were underpowered with only 39 
participants. It is now being used in clinical trials as a main outcome measure, such 
as in the clinical trial of nanocrystalline gold (NCT03536559), and will be similarly 
utilised in the CCMR Two trial of metformin and clemastine (Chapter 5). 
 
Optical coherence tomography 
Optical coherence tomography (OCT) is another tool being employed to study neural 
degeneration and regeneration in MS, and thus indirectly assess remyelinating 
therapies. This technique acquires high resolution images of the retina, allowing the 
measurement of the thickness of the retinal nerve fibre layer in both the peripapillary 
region and the macula (pRNFL and mRNFL; reflecting the integrity of axons), as well 
as the ganglion cell layer (GCL; neurons) and inner plexiform layer (IPL; 
dendrites).352 Myelination in the visual pathway begins at the lamina cribrosa, slightly 
behind the eye, and thus visualisation of these retinal layers provides insight into the 
proximal effects of a disease process that is most often found in the retrobulbar 
portion of the optic nerve.367  
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RNFL thickness is decreased following optic neuritis on account of retrograde axonal 
degeneration,368 and thinning occurs in people with MS even in the absence of 
ON.369 In a meta-analysis in 2010, Petzold showed that eyes with a history of AON 
had pRNFL thinning by a mean of 20.38 μm (95% CI 17.91, 22.86 μm), while MS 
eyes without an ON history had an average thinning of 7.08 μm (95% CI 5.52, 8.65 
μm) compared to disease-free controls.370 For comparison, a normal pRNFL 
thickness is in the region of 105 μm, though there is variation between individuals 
and physiological loss due to aging (approximately 10-20 μm loss over 60 years).371 
In terms of the time course of these changes after acute ON, Costello et al. showed 
that the majority sustain 10-40 μm pRNFL thinning within 3 to 6 months,372 while 
Henderson et al. showed the mean time to 90% maximum pRNFL loss was 2.38 
months.373 An additional important finding from the former study was the 
demonstration that 75-80 μm is something of a threshold level, below which there 
are severe decrements in visual function;372 as described above, in the ReBUILD 
study, a RNFL of >70 μm was required for an eye to be included in their study.277 
 
Yet, while the RNFL is a good measure of axonal degeneration, the GCL is perhaps 
the most attractive layer to monitor ON, since it is not affected by oedema and so its 
thinning is not masked by early inflammation.374 It also correlates better with markers 
of visual function, such as low-contrast letter acuity, in people with MS.375 This was 
the rationale for the RENEW study, which recruited people with acute ON to receive 
opicinumab, to monitor GCL/IPL thickness as a secondary outcome; no treatment 
effect was seen. 
 
In any case, while OCT outcomes are not themselves intrinsically representative of 
myelination, they may measure secondary neuroprotective effects. Thus far, no 
clinical trials of a remyelinating drug have shown a positive effect using OCT, and its 
use is perhaps best served as a selection criterion to ensure there are sufficient 
axons to remyelinate.277 
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Visual acuity 
Tests of low-contrast vision, in particular low-contrast letter acuity (LCLA), have a 
greater capacity to detect visual impairment in MS than high-contrast letter acuity 
(HCLA).376,377 MS patients have significantly lower LCLA scores than disease-free 
controls378,379 and, while visual recovery following AON is often said to be good with 
HCVA,380,381 studies in AON have shown persistent visual deficits in LCLA.382 Sloan 
LCLA charts were first used as an outcome in the IMPACT study of interferon β-1a, 
in which they showed superior performance in detecting worse visual function 
compared to Pelli-Robson contrast-sensitivity charts, and assessments of colour 
vision (L’Anthony D-15 DS colour test) and visual fields (Esterman binocular test).383 
Other studies have also revealed correlations of Sloan LCLA with OCT, MRI, VEP, 
and disability (both with the EDSS and MSFC).384 Consequently, Sloan LCLA has 
been increasingly used as an outcome measure, and proven sensitive to treatment 
effects in several clinical trials.385 
 
Sloan LCLA charts follow the standardised format of the Early Treatment Diabetic 
Retinopathy Study (ETDRS)386 and come in a variety of different contrast thresholds 
ranging from 1.25% to 100%. They are superior to standard Snellen charts: (i) each 
optotype is equally detectable for normal observers; (ii) each line has an equal 
number of letters (five per line); (iii) each line is spaced in equal logarithmic steps of 
the visual acuity (the resolvable angle). Meanwhile, reliability testing has led to the 
consensus that a loss of seven letters is a clinically meaningful change.378  
 
In remyelination trials, a positive effect on LCLA was seen as a secondary outcome 
of the ReBUILD study of clemastine: an increase of 1.6 letters per eye (95% CI 0.2, 
3.0; p=0.022) was observed.277 LCLA is also being used as the primary outcome 
measure for the clinical trial of nanocrystalline gold (Table 1.6; NCT03536559). It 
therefore remains an important component of the assessment of response to a 
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Other techniques 
 
Multi-modal evoked potentials 
The clinical heterogeneity of MS has already been described and extends beyond a 
consideration of optic neuritis; it is important to know if other tracts might be sensitive 
to change in remyelination trials. Given the emerging importance of 
neurophysiological measures in such studies, a potential biomarker in future trials 
might be a combination of VEPs, motor EPs (MEPs), somatosensory EPs (SSEPs), 
and brainstem auditory EPs (BAEPs).387 Such “multimodal” evoked potentials can be 
combined to give a “global” outcome, which has previously been shown to correlate 
with disability and inform disease progression,388 and have already been employed 
in the field of bone marrow-derived cell therapy.303,389  
 
Oculometry 
Meanwhile, other exploratory neurophysiological techniques have also been 
emerging as potential methods for detecting the functional consequences of 
remyelination. For example, a recent clinical study utilised measurements of 
saccadic eye movements in people with internuclear ophthalmoparesis to 
demonstrate improved conduction along the medial longitudinal fasciculus when 
treated with fampridine.390 While fampridine’s mechanism of action is through 
potassium channel blockade, the authors advocated the MLF as an additional MS-
relevant tract to monitor the consequences of remyelination. 
 
Additionally, it has previously been suggested that serial monitoring of saccadic 
latency parameters might be a sensitive measure of neuroprotection.391 One group 
has published four studies from one cohort of 25 subjects with MS.392-395. They 
reported to deficits in complex decision making, such as prolonged latency and 
increased proportion of errors (prosaccades) in the antisaccade task.394 They also 
reported that latency of memory guided saccades correlated with EDSS.393 In 
contrast to evoked potentials, saccadic latency depends on a large network of diffuse 
pathways. Yet, while an increase in latency over time could be due to multiple 
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aetiologies, a shortening in latency is likely to be more specifically due to 
remyelination; this has not been tested to date. 
 
Neurofilament 
Finally, it is noteworthy that there is currently no biomarker of myelin regeneration in 
biological fluids. That said, neurofilament light, a marker of axonal damage that 
correlates with MS disease activity and disability,396,397 has been postulated to be a 
valuable outcome measure for remyelination trials. The advent of high-sensitivity 
serum assays has made this increasingly simple to monitor axonal injury in people 
with MS.398 A subset of participants from the SYNERGY trial,286 for example, showed 
a trend toward neurofilament light decline among treatment responders.399 However, 
while serum neurofilament light measures the desired outcome from remyelination – 
the prevention of axonal degeneration – it is presently unvalidated in remyelination 
trials and, until that point, should remain exploratory.   
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Research questions 
 
1. Does bexarotene promote remyelination in people with relapsing remitting 
multiple sclerosis? 
2. Is the remyelinating effect of bexarotene affected by age? 
3. Is the remyelinating effect of bexarotene, as measured by visual evoked 
potentials, durable? 
4. Does the combination of metformin and clemastine promote remyelination in 
people with relapsing remitting multiple sclerosis? 
5. Which drugs should be repurposed or rescued for testing in clinical trials of 
people with progressive multiple sclerosis? 
6. What were the barriers to recruitment to interventional trials of COVID-19 
during the first wave of the pandemic in England; how might these impact the 
delivery of these studies? 
7. How are saccadic latency distributions affected by MS, do they correlate with 
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Chapter 2: The Cambridge Centre for Myelin Repair 
trial number One (CCMR One) 
 A randomised placebo-controlled trial of a retinoid-X receptor 
agonist’s ability to promote remyelination in people with 




The retinoid acid receptor RXR-γ is a positive regulator of oligodendrocyte precursor 
cell differentiation and remyelination in vitro, in animal models, and in human cells. 
Here, we assessed the safety and efficacy of bexarotene, a licensed non-selective 
RXR agonist, as a treatment for people with relapsing remitting multiple sclerosis. 
 
In this double-blind phase IIa trial (CCMR One, ISRCTN14265371) people with 
relapsing remitting MS aged 18-50 years, who had been on dimethyl fumarate for ≥6 
months, were randomly assigned bexarotene 300 mg/m2 or placebo for 6 months. 
The primary efficacy outcome was change in mean lesional magnetization transfer 
ratio (MTR) in submedian lesions (lesions below the baseline within-patient median 
MTR), analysed by intention to treat.  
 
52 participants were randomised. All those on bexarotene experienced adverse 
events: secondary (central) hypothyroidism (n=26, 100%), hypertriglyceridaemia 
(n=24, 92%), rash (n=13, 50%) and neutropenia (n=10, 38%). The primary efficacy 
outcome was not met: the bexarotene-placebo difference in adjusted mean 
submedian lesional MTR change was not statistically significant: 0.16 (95% CI -0.39, 
0.71) pu, p=0.554. However, prespecified exploratory analyses of all lesions found a 
statistically significant difference in treatment effects between submedian and 
supramedian lesions (interaction p=0.007) and a statistically significant MTR 
treatment effect on lesions in cortical grey matter (1.00 (95% CI 0.17, 1.83) pu, 
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p=0.023), deep grey matter (1.93 (95% CI  0.28, 3.59) pu, p=0.027) and the 
brainstem (1.75 (95% CI  0.86, 2.63) pu, p=0.0004); interaction p<0.0001. 
Bexarotene also reduced mean adjusted full-field visual evoked potential latency in 
eyes with prolonged baseline latency by 4.06 ms/eye (95% CI -7.68, -0.44; p=0.028).  
 
This is the first trial to show evidence of remyelination with converging evidence from 
both MRI and electrophysiology and, while poor tolerability of bexarotene will limit its 
clinical use, it provides compelling motivation for the development of RXR-γ-specific 
agonists and a framework for assessing remyelinating therapies. 
 
Contribution statement 
I was an evaluating physician and sub-investigator on this trial, recruiting and seeing 
participants, and monitoring drugs, for those based in Cambridge. I oversaw the VEP 
data acquisition and analysed the electrophysiology trial outcomes. I was additionally 
responsible for analysing the safety outcomes of the trial. I wrote the first draft of the 
trial manuscript, compiled all of the edits, submitted this for publication, and led the 
ensuing revisions. I was not involved in the development or set-up of this trial, which 
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Background 
 
Although many licensed drugs reduce inflammation effectively,177 they leave 
persistently demyelinated axons, which slowly degenerate through loss of trophic 
support, causing progressive worsening of disability.29 The most effective strategy to 
preserve demyelinated axons, and so delay or prevent disability progression, is to 
enhance endogenous remyelination.400,401 As OPCs are often found in chronically 
demyelinated MS lesions,28 it is widely held that remyelination failure can be 
attributed in part to impaired OPC differentiation.  
 
Studies to identify therapies capable of enhancing this rate-limiting stage246,275 have 
led to a number of clinical trials to treat chronic and acute demyelinating 
injuries,277,285,286,290 but only one was published prior to commencement of CCMR 
One: the phase II study of GSK239512, an H3 receptor antagonist, had shown a 
statistically significant improvement in the magnetisation transfer ratio (MTR) 
characteristics of gadolinium-enhancing lesions.290 Evidence emerging since then 
has included the phase II ReBUILD study of clemastine, which demonstrated a 
significant improvement in the latency of the full-field visual evoked potential 
(VEP),277 and the phase II RENEW trial of opicinumab (anti-Lingo1), which showed 
an improvement in VEP latency using a per protocol analysis of participants with 
acute optic neuritis.285 
 
Another positive regulator of OPC differentiation is the retinoid X receptor (RXR)-
γ,291 which is expressed in remyelinated MS lesions in oligodendrocyte lineage cells. 
Inhibition of RXR-γ signalling inhibits differentiation of rodent and human OPCs;402 
and the RXR agonist, 9-cis-retinoic acid, remyelinates both demyelinated cerebellar 
slice cultures, and focal toxin-induced demyelination in aged rats.291 There are no 
licensed selective RXR-γ agonists;292 however bexarotene, a non-selective agonist 
of the α, β, and γ isoforms, is licenced to treat cutaneous T-cell lymphoma. 
 
The hypothesis, that we tested in this study, was that bexarotene would promote 
remyelination in demyelinated lesions in people living with relapsing remitting MS. 
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We conducted a two-centre, phase II clinical trial to determine the safety, tolerability 
and efficacy of bexarotene to promote remyelination of demyelinated lesions in 
people with relapsing remitting MS, using an innovative lesional MRI MTR outcome 




Study design and participants 
The Cambridge Centre for Myelin Repair Trial Number One (CCMR One) was a 
randomised, double-blind, placebo-controlled, parallel-group, phase II study 
conducted at the Cambridge University Hospitals NHS Foundation Trust and the 
University of Edinburgh Anne Rowling Regenerative Neurology Clinic. We recruited 
participants that had relapsing remitting MS, were aged 18-50 years, had an 
Expanded Disability Status Scale (EDSS) score of ≤6.0 and had ≥ 5 T2 hyperintense 
MS lesions on MRI. In order to minimise any confounding effect on the MRI 
endpoints of heterogenous disease-modifying therapies, only participants who had 
been receiving dimethyl fumarate – which has been shown to have no statistically 
significant effect on MTR403 – for at least 6 months were selected, and this was 
continued on trial. Participants were ineligible if they had ever received a high-
efficacy disease modifying treatment, had a history of pancreatitis, fasting 
triglycerides >2.3 mmol/L, uncontrolled thyroid disease, or excessive alcohol 
consumption. Amendments to eligibility criteria were recommended by the trial 
steering committee during the trial, additionally excluding those with significant 
cardiovascular disease or lymphopaenia (<0.7 x 109/L within 6 months of screening) 
in view of adverse events (AEs) observed in early trial participants. 
 
The study was undertaken in accordance with the International Conference on 
Harmonisation Good Clinical Practice (GCP) guidelines and the Declaration of 
Helsinki, registered with the ISRCTN (14265371) and was approved by London 
Westminster NRES Committee (15/LO/0108).  All participants gave written informed 
consent.  
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Randomisation and masking 
A web-based system (Tenelea, https://www.aleaclinical.eu/), run by an independent 
statistician, was used to randomise participants (1:1) by probability-weighted 
minimisation using four binary factors (age (≤ 40, > 40 years), gender, EDSS (≤ 4.0, 
> 4.0), and treatment centre), to a pack of indistinguishable over-encapsulated 
capsules of the investigational medicinal product (IMP). Participants and 
investigators were masked to treatment allocation. MRI scans and VEPs were 
labelled with secondary codes that did not identify the trial participant and were 
analysed at the end of the study; the MRI scans were analysed by Dr Brown, and the 
VEPs by myself. All endpoint data were locked before the treatment allocation code 
was broken by the trial statistician. 
 
Procedures 
The investigational medicinal product (IMP) was unmarked capsules of 75 mg 
bexarotene (Targretin®; Eisai Ltd) or placebo, provided by the Royal Free Hospital 
Pharmacy Manufacturing Unit, dosed at 300 mg/m2 body surface area per day, 
rounded down to the nearest available number of whole (75 mg) capsules, not 
exceeding 750 mg per day. We saw participants weekly for one month then monthly 
for five months and finally at month 9. At each visit, safety blood tests included full 
blood count, creatinine, transaminases, fasting triglycerides, cholesterol and thyroid 
profile. In the event of hypertriglyceridaemia ≥10 mmol/L, fenofibrate 200 mg per day 
was commenced. If serum free thyroxine (FT4) fell below the lower reference limit, 
we prescribed levothyroxine 50 to 100 mcg and, when needed, increased the dose 
until FT4 normalised. Fenofibrate and thyroxine were stopped, per protocol, at month 
6 with the IMP. If a participant developed neutropenia (<1.0 x109/L), we reduced IMP 
doses to 200 mg/m2 and, if persistent, to 100 mg/m2.  
 
MRI scans were performed at baseline and 6 months using Siemens 3T Prismafit 
scanners (Siemens, Erlangen, Germany) with 20-channel head-neck coils at each 
site. Each scan included interleaved 3D magnetisation transfer imaging (for 
calculation of MTR maps), 3DT1 (for volumetric measures and segmentation), pre- 
and post-gadolinium T1 (for identification of enhancing lesions), interleaved proton-
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density/T2-weighted scans (for identification and contouring of T2 hyperintense 
lesions) and fluid-attenuated-inversion recovery (FLAIR, for lesion identification). 
Lesion identification, contouring and checking were performed by blinded observers 
at the Queen Square MS centre. These baseline lesion masks were overlaid on the 
follow-up scans to ensure that the same tissue was examined at both timepoints 
(though did not accommodate dynamic effects from shrinking or expanding lesions). 
Lesions were automatically classified by location using the brain parcellation from 
the volumetric T1 scan.  
 
Monocular full-field pattern-reversal visual potentials (VEPs) were performed at 
baseline and 6 months with check size 60-min of arc using a Nicolet Viking Select 
System (Natus Neurology Inc, USA) in Edinburgh and a Synergy System (Optima 
Medical Ltd, UK) in Cambridge. At least 100 stimuli were averaged per recording, 
and at least 2, but up to 4, recordings were taken from each eye at each visit. Using 
the Cambridge system, VEP recordings were extracted from their native software, 
anonymised by two members of the trial team, and exported into the Origin graphical 
application. From here I assessed each signal for quality control, removing those 
affected by muscle artefact or noise, while blinded to participant identity and 
treatment allocation. I was then able to extract the N75, P100 and N145 latencies for 
each waveform; the amplitude of the VEP was taken as the maximal N75-P100 
peak-trough measure in µV and the values from repeated waveforms were averaged 
(Figure 2.1). The equivalent process was not possible technically with the Edinburgh 
electrophysiology equipment and instead anonymised reports were provided of the 
signal distributions of each VEP. This enabled me, in a blinded fashion, quality 
control each VEP by a similar manner of visual inspection.  
 
The Expanded Disability Status Scale (EDSS) was assessed by a single clinician at 
each centre, blinded to all other assessments. Visual acuity was measured as the 
logarithm of the minimum angle of resolution (logMAR) for each corrected eye at a 
100% contrast level. 
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Figure 2.1. Representative averaged VEP signals from the right eye of a 
participant from CCMR One. At each visit, baseline and month 6, 3 recordings 
were taken, (blue traces at baseline, red/yellow at M6). These were then screened 
for quality control, and latencies and amplitude measures taken for the N75, P100, 
and N145 of each. These were averaged across a visit, to generate the values as 
shown; this participant had an improvement in P100 latency of 1.7 ms. (This 
participant reported no history of acute optic neuritis in this eye and was allocated to 




The safety outcomes were adverse events and withdrawals attributable to 
bexarotene. I organised the AEs according to the MedDRA (the Medical Dictionary 
for Regulatory Activities) coding system. The primary efficacy outcome was the 
patient-level change in mean lesional MTR between baseline and month 6 for those 
lesions whose MTR was below the within-patient median at baseline. Prespecified 
exploratory lesion-level MRI analyses examined whether subgroups of lesions might 
better detect a treatment effect and included comparing treatment differences in 
mean lesional MTR (i) for lesions whose MTR was above versus below the within-
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The main electrophysiological outcome for the trial were changes in P100 latency 
using full-field, pattern-reversal, VEPs, with separate analyses for all eyes and for 
those eyes with a baseline latency >118 ms (which are considered to be prolonged), 
and those with a past history of optic neuritis, with a per-protocol analysis pre-
specified if treatment non-adherence was greater than 10%. I similarly assessed the 
changes in the N75 and N145 latencies and change in the N75-P100 amplitude.  
 
Power calculation 
Our trial used a novel primary efficacy endpoint, so could not draw on previous trial 
data for estimates of treatment effect. The rationale for our power calculations is 
described elsewhere.329 In brief, we previously observed a difference between mean 
MTR of normal-appearing white matter (NAWM) and MS lesions of 5.92 pu. We 
assumed that only half of lesions would be amenable to remyelination and so 
estimated that a 100% treatment effect would be 0.5 × 5.92 = 2.96 pu. We chose a 
sample size sufficient to detect a 40% treatment effect (corresponding to a difference 
of 1.18 pu). The power of the baseline adjusted (ANCOVA) comparison method is 
dependent also on the correlation coefficient between MTR values at baseline and 
follow-up. A correlation of 0.73 was observed over a 12 month interval in the pilot 
data;329 using a conservative correlation of 0.7 (since a higher correlation would be 
expected over six months), a sample size of 21 in each group is sufficient to detect 
the 40% treatment effect with 80% power at 5% significance. We chose 25 per group 
to allow up to 15% dropout. 
 
Statistical analysis 
The primary efficacy outcome, mean within-patient submedian lesion MTR, was 
chosen to guarantee that each patient would contribute lesions: those below the 
patient-specific lesion median MTR; using an all-lesion threshold instead might have 
resulted in some patients not contributing to the primary outcome.  Treatment effect 
was estimated using multiple regression of the outcome measure on a group 
indicator with the following prespecified trial covariates: the baseline value of the 
outcome measure and the four binary minimisation factors: age (≤ 40 /> 40 years), 
gender, trial centre/scanner (London/Edinburgh) and EDSS (≤ 4.0/> 4.0 score).  The 
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lesion-level MTR analyses used linear mixed models for lesions nested within 
patients, with patient random intercepts; these models regressed lesion MTR on the 
same prespecified covariates but with lesion-subgroup interaction terms to estimate 
lesion-subgroup specific treatment differences and test for variation between these 
differences.  These interaction tests were relatively highly powered because a strong 
within-patient component increased precision, whereas treatment difference 
estimation was entirely between-patient.  Although lesion-level analyses are more 
flexible and powerful, they are vulnerable to selection bias since patients not lesions 
are randomised, so the patient-level comparison was designated primary. 
 
Similar mixed models were also used for the VEP analyses, but with eyes nested 
within patients. In exploratory analyses, outside of the main trial results, I performed 
a joint test of the 6 latency points (3 latencies x 2 eyes) by the fitting a multivariate 
model which regresses all six outcomes simultaneously, taking into account 
correlation between the outcomes: the more correlated the outcomes, the less 
weight of evidence is given to a number of similar treatment effects. (In an extreme 
case where essentially the same measure is compared six times, with almost perfect 
correlation between the six measures, there is no additional evidence, provided by 
the joint test of the six virtually identical measures, compared to that provided by a 
single comparison.) This tests the null hypothesis that there is in truth no active vs 
placebo difference in any of the six comparisons. Such a null hypothesis is less likely 
to be true, and its rejection more likely to be interpretable, when most or all results 
fall in the same direction. Then if this null hypothesis is rejected with a single p-value, 
it provides overall evidence that there is a true active vs placebo difference, in the 
prevalent direction, in at least one, and of course possibly in more than one, of the 
six separate comparisons; and if this null hypothesis is rejected, it inspires 
confidence that if, for example, only some of the six are statistically significant at the 
5% level, these are not just spurious false positives. Joint tests of this sort thus 
provide a more informed alternative to “corrections” for multiple comparisons which 
do not quantify the similarity of the outcomes tested. 
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For EDSS, a corresponding multiple regression was checked using a non-parametric 
bias-corrected and accelerated bootstrap404 with 1000 replicates. For both 
regression and mixed models, residuals were examined for departures from 
normality and homoscedasticity, and satisfied assumptions. Statistical significance 




Between Jan 17th, 2017 and May 17th, 2019, we randomly assigned 52 patients to 
receive 6 months of bexarotene (n=26) or placebo (n=26; Figure 2.2). Two 
participants randomised to placebo were withdrawn before receiving the IMP: one 
was unable to tolerate the baseline MRI, while another had a new lesion on their 
baseline scan requiring treatment escalation from dimethyl fumarate. One participant 
withdrew consent for personal reasons at month 2. The remaining patients (31 at 
Cambridge and 18 at Edinburgh) attended all trial visits and completed the trial 
(Figure 2.2) and their baseline characteristics are included in Table 2.1. 
 
Safety 
In performing the safety analysis, I demonstrated that participants receiving 
bexarotene experienced a mean of 6.1 adverse events (compared to 1.6 on 
placebo). The study drug was discontinued in 5 (19%) and 2 (8%) participants in the 
bexarotene and placebo groups respectively due to adverse events (Table 2.2).  
 
All 26 (100%) bexarotene-treated participants developed central hypothyroidism 
(Figure 2.3). 24 of these required levothyroxine; two chose to withdraw from 
bexarotene because of a skin rash before levothyroxine could be started.  24 
bexarotene participants (92%) developed raised triglyceride levels; six of these 
reached ≥10 mmol/L and were commenced on fenofibrate. The median highest 
triglyceride level, per participant, was 4.85 (IQR 4.10, 10.02) mmol/L on bexarotene 
compared to 1.25 (IQR 0.98, 1.83) mmol/L on placebo. Neutropenia (<1.0 x109/L) 
occurred in 10 (38%) patients in the bexarotene group, requiring dose reductions in 
all, and treatment withdrawal in one. Skin reactions and headaches occurred more 
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commonly in the bexarotene group (18 (69%) vs 2 (8%) and 14 (54%) vs 8 (33%) 
respectively). One participant on bexarotene, without vascular risk factors and a 
peak triglyceride level of 4.2 mmol/L, had an asymptomatic cerebellar infarct noted 
on the month 6 scan. By month 9, at least three months after discontinuing 
bexarotene, all participants’ thyroid, lipid and neutrophil counts were normal. There 
were no pancreatitis or cardiovascular events. 
 
MRI outcomes 
All MRI scans were of sufficient quality to be included in the efficacy analyses, and 
3170 T2 hyperintense lesions were identified (1613 white matter (WM) lesions, 106 
grey matter (GM) lesions and 1451 mixed GM and WM lesions). There were too few 
enhancing lesions at baseline (single lesions in 3 patients, Table 2.1) or new T2 
hyperintense lesions at follow-up (7 lesions in 5 patients) to warrant further analysis. 
 
The primary efficacy endpoint of the intention to treat (ITT) population showed no 
evidence of treatment effect: the bexarotene – placebo adjusted difference in mean 
within-patient submedian lesion MTR change was 0.16 (95% CI -0.39, 0.71) pu, 
p=0.554; Table 2.3, Figure 2.4A. The upper limit of the confidence interval is well 
below the target 1.18 pu which the trial was powered to detect. In exploratory 
analyses, when the median MTR was defined for all lesions in the ITT population, 
bexarotene had no effect on supramedian lesions (-0.04 (95% CI -0.52, 0.43) pu, 
p=0.854) and a non-statistically significant increase in MTR for submedian lesions 
(0.30 (95% CI -0.18, 0.78) pu, p=0.223, Table 2.3, Figure 2.4B). However, an 
interaction term comparing the treatment group differences between submedian and 
supramedian lesions was highly statistically significant (p=0.007), suggesting a 
variation in treatment effect depending on the baseline lesional MTR.  
 
When lesions were subdivided by location (Table 2.3), statistically significant 
treatment effects were seen in the ITT population within cortical GM lesions 
(bexarotene-placebo adjusted mean difference 1.00 (95% CI 0.17, 1.83) pu, 
p=0.023), deep GM lesions (1.93 (95% CI 0.28, 3.59) pu, p=0.027) and brainstem 
lesions (1.75 (95% CI 0.86, 2.63) pu, p=0.0004), and the interaction test of variation 
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in treatment effects gave p<0.0001 (Figure 2.4C). A statistically significant treatment 
effect was seen in pure GM lesions (1.08 (95% CI 0.32, 1.83) pu, p=0.008) but not in 
pure WM lesions (0.10 (95% CI -0.38, 0.68) pu, p=0.568) (interaction test p=0.002). 
 
 Bexarotene  Placebo 
Total number of participants  
   Cambridge, number (%) 





15 (63)  
9 (37) 
Age, years; mean (SD) 40.4 (6.2) 38 (6.8) 
Sex 
   Female 







Disease duration, years; mean (SD) 11 (5.9) 8.4 (5.8) 
Number of relapses in last 2 years; 
mean (SD) 
0.4 (0.7) 0.9 (1.2) 
EDSS step; median (quartiles) 2.5 (1.5, 3.5) 2.0 (1.5, 3.0) 
Duration receiving dimethyl fumarate, 
years; median (quartiles) 
2.2 (1.1, 3.2) 1.6 (0.9, 2.3) 
MRI   
Within-patient number of T2 lesions; 
median (quartiles) 
63 (51, 111) 
 
43 (19.5, 66) 
 
Within-patient size of T2 lesions, mm2; 
median (quartiles) 
90.6 (67.7, 146.0) 83.96 (55.4, 119.3) 
 
Within-group total number of contrast-
enhancing lesions at baseline 
3 0 
Within-patient lesional MTR, pu; mean 
(SD) 
41.83 (2.03) 41.73 (2.08) 
Within-patient brain parenchymal 
fraction; mean (SD) 
0.74 (0.02) 0.75 (0.01) 
VEP   
Total number of VEP recordings with 
sufficient quality for inclusion; number 
of eyes (number of patients) 
42 (22) 44 (23) 
Participants with history of ON 
(number of eyes) 
11 (12) 14 (20) 
Time since ON, years; median 
(quartiles)  
12.2 (4.4, 15.5) 3.3 (1.6, 8.6) 
VEP P100 latency, ms; mean (SD) 126.2 (18.6) 119.3 (18.1) 
Table 2.1. Comparison of baseline variables between the two trial arms for all 
participants in the intention-to-treat analyses. One further participant randomised 
to bexarotene (who withdrew before month 2) and two further participants 
randomised to placebo (withdrawn before commencing the IMP) had no follow-up 
MRI or VEP so could not be included in the intention to treat analyses. EDSS: 
expanded disability status scale; MTR: magnetization transfer ratio; ON: optic 
neuritis; VEP: visual-evoked potential.  
  














































Figure 2.2. Trial design. EDSS: expanded disability status scale. 
 
56 assessed for eligibility 
4 excluded 
2 insufficient T2 lesions at MRI  
2 EDSS >6.0 
Efficacy analysis (n=25) 
Safety analysis (n=26) 
Per protocol sample (n=20) 
 
26 assigned to bexarotene 
52 randomly assigned 
26 assigned to placebo 
24 received placebo 26 received bexarotene 
2 withdrawn 
1 MRI not tolerated 
1 acute relapse 
1 consent withdrawn 
 
2 discontinued study drug 
1 lymphopenia 
1 cholecystitis 
5 discontinued study drug 
1 neutropenia 
1 hypertriglyceridaemia 
1 mood disturbance 
2 rash 
25 completed study 
20 completed treatment 
Efficacy analysis (n=24) 
Safety analysis (n=24) 
Per protocol sample (n=22) 
 
24 completed study 
22 completed treatment 
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 Bexarotene (n=26) Placebo (n=24) 
All adverse events 
Number of adverse events (mean per 
person) 
159 (6.12) 39 (1.63) 
Number of participants with ≥1 adverse 
event (%) 
26 (100%) 17 (71%) 
Number of participants who discontinued 
study drug because of adverse event (%) 
5 (19%) 2 (8%) 
Serious adverse events   
Hospitalisation 0 1 (4%) * 
 
Expected adverse events 
Metabolic and nutrition disorders 
Hypertriglyceridaemia 24 (92%) 0 
Secondary (central) hypothyroidism 26 (100%) 0 
Blood and lymphatic system disorders 
Neutropenia 10 (38%) 0 
Lymphopenia 1 (4%) 1 (4%) 
Nervous system disorders 
Headache 14 (54%) 8 (33%) 
Skin and subcutaneous tissue disorders 
Rash 13 (50%) 1 (4%) 
Pruritis 7 (27%) 0 
   
Unexpected adverse events 
Nervous system disorders 
MS Relapse 1 (4%) 0 
MS Pseudorelapse 1 (4%) 4 (17%) 
Lhermitte’s sign 1 (4%) 0 
Cerebellar infarction 1 (4%) 0 
Neuropathic pain 1 (4%) 1 (4%) 
Muscle spasticity aggravated 1 (4%) 0 
Dizziness 1 (4%) 0 
Low mood 1 (4%) 0 
Memory disturbance 0 1 (4%) 
Skin and subcutaneous tissue disorders 
Skin desquamation 5 (19%) 0 
Dry skin 4 (15%) 0 
Acne 1 (4%) 0 
Alopecia 1 (4%) 0 
Facial flushing 0 2 (8%) 
Dry eyes 1 (4%) 0 
Infections and infestations 
Upper respiratory tract infection 2 (8%) 1 (4%) 
Lower respiratory tract infection 1 (4%) 0 
Urinary tract infection 2 (8%) 1 (4%) 
Shingles 0 1 (4%) 
Ear infection 1 (4%) 0 
Coryzal symptoms 3 (12%) 4 (17%) 
Sinusitis 0 1 (4%) 
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Gastrointestinal and hepatobiliary disorders 
Nausea 5 (19%) 0 
Diarrhoea 4 (15%) 4 (17%) 
Constipation 2 (8%) 0 
Epigastric pain 1 (4%) 0 
Dry lips 2 (8%) 0 
Ulceration of mouth 2 (8%) 0 
Cholecystitis 0 1 (4%) 
Respiratory, thoracic and mediastinal disorders 
Cough 1 (4%) 1 (4%) 
Shortness of breath 0 1 (4%) 
Sore throat 1 (4%) 1 (4%) 
Musculoskeletal and connective tissue disorders 
Stiffness joints 1 (4%) 1 (4%) 
Myalgia 1 (4%) 0 
Renal and urinary disorders 
Nocturia 2 (8%) 0 
Urinary frequency  2 (8%) 0 
Vascular disorders 
Epistaxis 1 (4%) 0 
General disorders 
Fatigue 6 (23%) 4 (17%) 
Investigations 
Transaminitis 3 (12%) 0 
Weight loss 1 (4%) 0 
Table 2.2. Adverse events in each of the two trial arms for participants who 
received at least one IMP dose. Unless otherwise stated, values are numbers of 
participants (%) with at least one event of the stated type. *One patient, on placebo, 
was hospitalised overnight for treatment of cholecystitis. Expected adverse effects of 
bexarotene, identified from the Summary of Product Characteristics. 
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Figure 2.3. Variation in fasting blood levels of Free T3, Free T4 and thyroid 
stimulating hormone (TSH) in patients receiving placebo or bexarotene. Blood 
tests performed weekly (for the first month), then monthly until month 6 (when the 
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 Bexarotene Placebo Bexarotene-placebo change 










































1023 -0.31 (1.74) 562 -0.18 (1.51) -0.04 (-0.52, 
0.43) 
0.854 
Interaction test comparing treatment group differences between submedian and supramedian 
lesions 
0.007 
























Mixed DGM and WM 
lesions 




Brainstem lesions 64 0.24 (2.62) 24 -1.21 (1.59) 1.75 (0.86, 
2.63) 
0.0003 
Cerebellar lesions 82 0.04 (2.28) 41 -0.31 (1.54) -0.03 (-0.79, 
0.74) 
0.947 
Interaction test comparing treatment group differences between lesion locations <0.0001 
 
Table 2.3. Trial MRI outcomes for intention to treat analysis. p values and CIs 
are for the adjusted (for baseline value and prespecified covariates) bexarotene – 
placebo differences. MTR analyses are at the lesion level (for the same patient 
numbers given in the first table row) unless stated as being at patient level. MTR: 
magnetization transfer ratio; pu: percentage units; WM: white matter; CGM: cortical 
grey matter; DGM: deep grey matter. **primary efficacy outcome measure. 
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Figure 2.4. MRI outcomes. A: The change between month 6 and baseline in patient 
mean submedian lesional MTR by trial group. Bars are standard errors around the 
unadjusted group mean changes. B: The active-placebo adjusted differences in 
lesional MTR change, subdivided by lesion baseline MTR relative to the lesion 
sample median. Bars are 95% confidence intervals. C: The active-placebo adjusted 
differences in lesional MTR change, subdivided by lesion location. Bars are 95% 
confidence intervals. Pu: percentage unit; GM: grey matter; DGM: deep grey matter; 
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 - 95 - 
Electrophysiology outcomes 
86 out of 98 (88%) VEP recordings were of sufficient quality to be analysed. 27 of 
these eyes had previously been affected by an episode of clinical acute optic 
neuritis; six having occurred within 2 years of baseline, a further nine between 2 and 
5 years of baseline and twelve 5 years or more from baseline. One episode of acute 
optic neuritis occurred on the trial in a participant in the bexarotene group. We 
debated this diagnosis as it consisted of a painless reduction in visual acuity in an 
eye previously affected by ON, but as it lasted 3 weeks, in the absence of another 
illness, and was associated with a reduction in visual acuity, it was classified as a 
relapse; this participant was not, however, treated with steroids. 
 
In our prespecified analysis of eyes with baseline latency of >118 ms (29 
bexarotene, 22 placebo), the adjusted bexarotene-placebo difference was -4.06 ms 
(95% CI -7.68, -0.44) p=0.028; Table 2.4, Figure 2.5. This difference remained 
statistically significant after excluding eyes affected by clinical optic neuritis within 5 
years (adjusted latency difference was –4.75 ms (95% CI -8.80, -0.71), p=0.032 in 
an intention to treat (ITT) analysis, and -6.54 ms (95% CI, -10.62, -2.47), p=0.006 in 
the per protocol (PP) group). Excluding the eye that was likely affected by AON on 
trial made no material difference to these results. 
 
When all eyes were included (42 bexarotene and 44 placebo) there was a borderline 
statistically significant treatment effect in the ITT analysis (adjusted difference -2.85 
ms (95% CI -5.75, 0.05), p=0.054), but in the PP analysis a larger statistically 
significant adjusted difference (-4.02 ms (95% CI -7.27, -0.76), p=0.015)) was seen; 
Figure 2.5.  
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Eyes with P100 ≤118ms 
at baseline 




Eyes with P100 >118ms 
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previous 5 years 




Table 2.4. Trial electrophysiology outcomes for intention to treat analysis. p 
values and CIs are for the adjusted (for baseline value and prespecified covariates) 
bexarotene – placebo differences. One participant in the bexarotene group, and two 
in the placebo group, contributed one eye to each of the ≤118 ms and >118 ms 




Figure 2.5. Electrophysiological outcomes. A: the change in P100 latency 
between month 6 and baseline for all eyes subdivided by trial group. B: the change 
in P100 latency between month 6 and baseline for those eyes with a delayed (>118 
ms) latency at baseline subdivided by trial group. Bars are standard errors around 
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In additional analyses I conducted outside of the main trial outcomes, for N75-P100 
amplitude, the adjusted bexarotene-placebo difference was 0.16 µV, (95% CI -1.12, 
1.43) p=0.807, with a larger but still non-statistically significant improvement among 
those eyes that had evident optic neuropathy at baseline (adjusted difference 0.64 
µV (95% CI -1.09, 2.38) p=0.467). For N75 latency, there was a statistically 
significant adjusted bexarotene-placebo difference of -3.46 ms (95% CI -6.69, -0.23) 
p=0.036, which was more significant still in the optic neuropathy group (adjusted 
difference -5.92 ms (95% CI -10.20, -1.63) p=0.007). Finally, for N145 latency, the 
adjusted bexarotene-placebo difference was -3.18 ms (95% CI -7.04, 0.68) p=0.106, 
while there was a borderline statistically significant treatment effect in the optic 
neuropathy group (adjusted difference -5.11 ms (95% CI -10.23, 0.02) p=0.051).  
 
Overall evidence of a treatment effect on latencies was given by the joint test of the 
six latency measures. Five of the six outcomes showed a more negative bexarotene 
than placebo latency change; N145 right eye latency was non-statistically 
significantly higher in bexarotene than placebo. Jointly testing the six comparisons 
gave p=0.0012, providing with a single p-value evidence at the 1% level of a 
treatment effect in one or more of the six measures. This provides reassurance that 
statistically significant improvements on one part of the distribution are not just 
spurious false positives. 
 
Clinical efficacy 
This trial was not powered to detect a treatment effect on disability and none was 
seen on change in EDSS from baseline to 6 months (adjusted bexarotene-placebo 
difference 0.33 (-0.10, 0.76), p=0.134). In a retrospective analysis of the high-
contrast visual acuities performed during the EDSS assessments, there was also no 
treatment effect (adjusted bexarotene-placebo difference in logarithm of minimum 
angle of resolution (logMAR) 0.03 (-0.03, 0.08), p=0.339). 
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Discussion 
 
Bexarotene was poorly tolerated and the primary efficacy objective, using an MRI 
endpoint untested in previous trials, was not met. Nonetheless converging evidence 
from several other MRI and electrophysiological outcomes, in a trial not powered to 
detect a treatment difference with these outcomes, suggests that bexarotene has a 
small biological effect to promote remyelination in some demyelinated lesions in the 
brains of people with MS. This aligns with the preclinical finding that RXR-γ agonists 
enhance remyelination.291 
 
The electrophysiology data suggest that bexarotene has restored conduction in 
demyelinated pathways. These effects were numerically greater, and statistically 
significant, when excluding eyes with a normal baseline P100 latency (defined as 
≤118 ms). The results were clearer still in the per-protocol analyses; it is perhaps 
significant that 3 of the 5 participants that stopped taking bexarotene, received the 
drug for less than one month, which might explain the larger effect in the PP group 
despite the smaller sample size. I cannot exclude a direct action of bexarotene on 
demyelinated axons to promote conduction of the action potential, although none 
has been described previously, and submit that this most likely reflects 
remyelination. Hypothyroidism, experienced by most people on bexarotene would, if 
anything, prolong the P100 latency,405 and while other retinoids have not been 
reported to affect VEPs, they prolong latencies of the auditory evoked potential.406  
 
The MRI data suggests that multiple sclerosis lesions are heterogeneous in their 
response to retinoid X receptor agonists. Grey matter plaques showed greater 
remyelination than those in white matter, which is consistent with the pathology 
literature.270,271,407 The higher grey matter content of the brainstem may explain the 
greater treatment effect seen in lesions there, but segmentation of the brainstem into 
grey and white matter to confirm this was not possible technically. Additionally, there 
was a trend to an improvement in the MTR of submedian lesions (defined at the 
cohort level), while there was unsurprisingly no discernible treatment effect in 
supramedian lesions. The significant interaction term between these treatment 
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differences, however, suggests that remyelination is dependent on baseline MTR, 
and that there is a small biological effect of bexarotene.  
 
Despite these effects, we do not recommend the use of bexarotene in people with 
MS. It caused secondary (central) hypothyroidism in all patients, raised triglycerides 
in 92%, headache in 54%, rash in 50% and neutropenia in 38%. It is possible that 
the reason rates of hypothyroidism and raised triglycerides exceeded those seen 
when used in cutaneous T cell lymphoma (29% and 71% respectively)408 is an 
interaction with dimethyl fumarate, whose effects on nrf2 transcription may 
additionally have been suppressed by bexarotene.409 More selective RXR-γ 
agonists, which are not currently available, would reduce the adverse effects 
mediated by agonism of the RXR-α and RXR-ß pathways,292 although thyroid 
dysfunction would remain a potential adverse effect of RXR-γ agonists.410  
 
This is the first clinical trial that has shown remyelination on both MRI and 
electrophysiological measures (reviewed by Lubetzki400 and Cunniffe401). 
Mesenchymal stem cells led to improvements in VEP latency and visual acuity but 
not MTR.302 Clemastine reduced VEP latency in eyes with chronic stable optic 
neuropathy but had no impact on MRI outcomes.277 Opicinumab reduced VEP 
latency in acute optic neuritis in a per protocol analysis, but had no effect on MRI 
measures.285 MTR increases were reported with an H3 receptor antagonist (in 
gadolinium-enhancing lesions).290  
 
Perhaps one of the legacies of this trial will be the lessons learned for the design of 
future trials examining remyelination in MS. This study demonstrated that MS lesions 
are heterogeneous in their capacity for remyelination in response to RXR agonists 
with greatest remyelination in lesions that were more demyelinated at baseline and 
those located in grey matter. Enhanced remyelination of cortical grey matter neurons 
may also have contributed to the improved visual evoked potential, since less than 
half the variance of VEP latency can be attributed to MRI lesions within the visual 
tract.411 At 3T, FLAIR detects less than 7% of pure CGM lesions at post-mortem; it 
identifies no intracortical or purely subpial lesions.324 The cortical GM lesion results 
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may therefore not be generalisable to all cortical lesions. Future phase II 
remyelination trials should therefore use both VEP and MRI outcome measures 
sensitive to grey matter lesions.323 The advantage of MRI lesion-level analyses, 
enabling relatively powerful formal treatment effect comparisons in different lesion 
types, is offset by the fact that patients, not lesions, are randomised, the latter being 
potentially vulnerable to selection bias. The exploratory lesion level results here 
should therefore be considered hypothesis-generating. But this study does suggest 
that focusing patient-level analyses on certain lesion types may be promising. 
 
Limitations of this study are that it was not powered to detect a treatment difference 
with the exploratory outcomes. Also, although our trial was based on preclinical work 
showing RXR-γ agonists’ direct effect on OPCs,291 other mechanisms may be at 
play. Bexarotene may also have enhanced remyelination indirectly by increasing 
phagocytosis of myelin debris,412 which inhibits OPC differentiation,28 through the 
RXR-α pathway. We cannot exclude the possibility that thyroxine, used to treat 24 
patients’ hypothyroidism in the bexarotene arm, promoted remyelination,413 although 
patients’ T3 and T4 levels never rose above pre-treatment levels (Figure 2.3). 
Nevertheless, our data, together with other studies using therapies that target OPC 
differentiation,277,285,286 suggest this is a viable approach to promote remyelination in 
MS. 
 
Trials of remyelinating treatments mark the beginning of a new phase in the 
treatment of MS, following success in suppressing the inflammatory component of 
MS. Although bexarotene is unlikely to become a future treatment of MS because of 
its serious adverse effects, this trial identifies a potential new strategy, RXR-γ 
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Chapter 3: The impact of age on the remyelinating 
effect of bexarotene 




Remyelination becomes less efficient with advancing age in animal models, but the 
same has been more challenging to demonstrate in people with multiple sclerosis. 
While the histopathological literature indicates that extensive remyelination is 
achievable in elderly patients, remyelination appears to proceed more efficiently in 
younger people with MS. In phase II remyelination trials to date, few have 
interrogated the effect of age on treatment response. 
 
To that end, I conducted an exploratory analysis of the electrophysiological and 
magnetic resonance imaging markers of remyelination from the Cambridge Centre 
for Myelin Repair One (CCMR One) trial (ISRCTN14265371). In doing so I have 
shown an age-dependent treatment response amongst patients receiving the 
retinoid-X receptor agonist bexarotene. For eyes with chronic optic neuropathy 
(baseline latency >118 ms), bexarotene shortened the full-field visual evoked 
potential P100 latency maximally in younger patients, with the effect diminishing by 
0.45 ms per year of age. Similarly, age-dependent remyelination was seen in deep 
grey matter lesions. 
 
I conclude that interventions focussed on reversing hallmarks of ageing in OPCs – 
for example rejuvenating drugs, dietary interventions or gene editing – are likely to 
be needed to maximise the effects of drugs with a pro-differentiating mechanism of 
action, such as bexarotene and clemastine. 
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Contribution statement 
As described in the previous chapter, I was an evaluating physician and sub-
investigator on this trial, involved in all aspects of the data collection except for the 
analysis of the trial MRI brain scans. I conducted the analysis of these data, with 
technical support from Dr Christopher McMurran. I am grateful for advice from Dr 
Daniel Altmann, who reviewed our results and advised on the analysis plan. 
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Background 
 
As discussed in the introduction, in animal models remyelination becomes inefficient 
with advancing age, due to both an intrinsic decline in oligodendrocyte progenitor 
cells (OPCs)100 and adverse changes in their environment.268,414 As a result, much 
preclinical research is focused on interventions to reverse hallmarks of ageing in 
OPCs, by, for example, rejuvenating drugs, dietary interventions or gene editing and 
thereby reverse age-related decline in remyelination (reviewed by Neumann et 
al.415). 
 
Despite this, direct evidence for the same age-related decline in people with MS has 
been hindered by the challenges of measuring human remyelination in unbiased 
populations at meaningful timepoints. Pathological studies of remyelination have 
demonstrated that, whilst younger lesions are better remyelinated than chronic 
lesions,98 extensive remyelination can be observed in the brains of elderly 
patients.98,214,270 However, post-mortem studies can be confounded by survivorship 
bias, whereby patients that die in old-age are likely to be those with a more 
quiescent disease course, who accumulate remyelinated lesions throughout their 
lifespan: it is impossible to know when lesions that have undergone remyelination 
arose or how long they took to repair. Some of these drawbacks are overcome by 
longitudinal imaging studies, which hint at an age-dependent repair process. For 
example, older patients are more likely to develop large lesions with a persistent pro-
inflammatory rim, associated with minimal remyelination at post-mortem.97 Clinical 
studies of disability accumulation are also consistent with an age-dependent repair 
process: older onset of MS is associated with faster development of disability,416 
disability milestones tend to be reached at consistent ages regardless of prior 
disease course256 and less recovery is seen following relapses in older patients.417 
These are important outcomes for patients, but clearly the accumulation of disability 
in people with MS is attributable to many factors in addition to remyelination failure. 
 
I hypothesised that the response to bexarotene would decline with advancing age. I 
therefore investigated the effect of patient age on the electrophysiological and MRI 
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markers of remyelination in a post-hoc analysis of the CCMR One trial 




The full protocol and results from the CCMR One trial are discussed in Chapter 2. 
Briefly, patients with relapsing remitting MS were randomised to receive six months 
of either bexarotene (n=26) or placebo (n=26), with remyelination in the visual 
pathway assessed using full-field visual evoked potential (VEP) latencies,418 and 
lesion magnetisation transfer ratio (MTR) used to quantify remyelination in brain 
lesions.319 The age range of patients receiving bexarotene was 29 to 49 (mean 40.4) 
while those receiving placebo was 25 to 49 (mean 38.0). Data was analysed by 
intention to treat. 
 
Statistical analysis was performed in R. For VEP analysis, the effect of patient age 
was estimated using linear mixed models for eyes nested within patients, with patient 
random intercepts. The change in P100 latency was regressed on an interaction 
between age, treatment group and baseline value (≤ 118 / >118 ms), as well as 
three binary minimisation factors: EDSS (≤ 4.0 / > 4.0), gender and trial centre. 
Residuals were examined for departures from normality and homoscedasticity, and 
satisfied assumptions. For MRI analysis, lesions were nested within patients, with 
patient random intercepts. Change in whole lesion MTR was regressed on an 
interaction between age, treatment group and lesion location, as well as baseline 
MTR and the three minimisation factors. Residuals for the MTR models were non-
normal, so confidence intervals were verified using a bootstrap approach with 500 
replicates. Differences between treatment and control groups as a function of age 
were calculated using the Johnson-Neyman technique. 
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Results 
 
Previous work has identified the most robust effects of pro-remyelinating therapies 
on VEP amongst eyes with a prolonged baseline P100 latency (>118 ms). Analysing 
these eyes from participants of CCMR One, I found that bexarotene shortened the 
P100 latency maximally in younger patients (Figure 3.1A). With increasing age, the 
P100 improvement amongst patients on bexarotene diminished by 0.45 ms/year 
(95% CI 0.03, 0.88; p=0.044). Compared to patients on placebo, bexarotene 
significantly improved P100 latency only in patients below the age of 42 (α = 0.05, 
Figure 3.1B). The age-dependence of P100 improvement in the bexarotene group 
was magnified when eyes affected by optic neuritis during the trial or in the previous 
5 years were excluded (0.64 (95% CI 0.24, 1.04) ms/year, p=0.004). 
 
To investigate whether this age-dependence may instead represent an effect of 
disease duration, I replaced the age term in the model with disease duration (years 
since symptom onset). Unlike age, disease duration did not significantly modify the 
P100 improvement in the bexarotene group (0.18 (95% CI -0.26, 0.62) ms/year; 
p=0.43)). 
 
I next explored whether an age-dependent effect of bexarotene was also seen on 
MRI, by analysing change in lesion MTR as a marker of remyelination. In the CCMR 
One trial, bexarotene was found to have maximal remyelinating activity amongst 
lesions in the deep grey matter, cortical grey matter and brainstem (Chapter 2). 
Focusing on these areas, I identified a significant age-related attenuation in MTR 
improvement amongst deep grey matter lesions (-0.34 (95% CI -0.64, -0.04) pu/year, 
p = 0.028, Figure 3.2A-B). Compared to patients on placebo, bexarotene significantly 
improved deep grey matter lesion MTR only in patients younger than 43 (α = 0.05, 
Figure 3.2C). Lesion MTR improvements in cortical grey matter (0.08 (95% CI -0.01, 
0.18) pu/year, p=0.09) and brainstem (-0.01 (95% CI -0.10, 0.07) pu/year, p=0.73) 
did not significantly depend on age in the bexarotene group, and none of these 
regions showed significant age-dependent remyelination in the placebo group. 
 







Figure 3.1. A: Variation of P100 latency improvement (reduction) with patient age for 
eyes with a prolonged baseline latency (>118 ms). Each datapoint represents an 
eye, and the 95% confidence interval for the model is shown. B: Treatment effect 
(bexarotene versus placebo) from (A) as a function of age. 
 
  








Figure 3.2. A: Variation of MTR improvement (increase) with patient age for the 
three regions with greatest remyelination. The bexarotene group is shown in blue 
and placebo in red. Each datapoint represents a lesion, with superimposed 
horizontal jitter to better visualise lesions with the same patient age. The 95% 
confidence interval for the model is shown. B: Volcano plot showing the effect of age 
on lesion MTR improvement within the bexarotene group for the locations plotted in 
(A). Other brain regions are shown in grey for comparison. C: Treatment effect 
(bexarotene versus placebo) for deep grey matter lesions as a function of age. GM = 
grey matter, MTR = magnetization transfer ratio. 
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Discussion 
 
Here, I demonstrate – for the first time in humans – that the response to a 
remyelination-promoting drug decreases in older patients. Bexarotene, an RXR 
agonist, significantly improved VEP latency and deep grey matter MTR only in 
patients up to their early 40s. This is consistent with the comprehensive evidence-
base describing remyelination failure with age in rodent models,100,414,415 and clinical 
studies showing age-dependent accumulation of disability amongst people with 
MS.256,416,417 Indeed, the fifth decade of life is typically the age at which patients 
develop progressive disease, regardless of prior disease course,419 giving a possible 
indication of the timescale of age-related remyelination decline in humans. 
 
I observed heterogeneity in age-dependency amongst the brain regions that were 
most responsive to bexarotene: remyelination declined with age in the deep grey 
matter, but this effect was not seen in cortical grey matter or brainstem lesions. Deep 
grey matter volume loss can be seen very early in the course of MS,420 and 
histological assessment found premature accumulation of iron deposits and oxidised 
DNA in this region compared to white matter or cortex,421 suggesting that deep grey 
matter may be particularly sensitive to the effects of age. In contrast, we found 
cortical grey matter remyelination to be more resilient in older patients, mirroring 
pathological findings that these lesions can actively remyelinate in the brains of 
patients into their seventies.270 
 
This study is a post-hoc analysis of a trial that was not originally designed to assess 
the effect of age; as such, one limitation is the age range of participants, covering 
only young adulthood to middle-age (25-50). A more comprehensive picture of 
human remyelination and age will need recruitment of patients across the human 
lifespan. Additionally, our lesion numbers were relatively few in the deep grey matter 
(n = 16), and this finding will need to be replicated in a larger cohort. Nonetheless, 
this study advances the existing literature by measuring remyelination longitudinally 
in patients of different ages, using both structural and functional approaches. 
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This analysis contrasts somewhat with the RENEW trial, in which the best VEP 
latency response to opicinumab was seen in patients aged 33 and older.422 
Differences in the two study populations may underlie this disparity: the participants 
in CCMR One were older on average and with an established diagnosis of MS, 
whereas those in RENEW presented with a first episode of optic neuritis and no 
previous MS diagnosis. Additionally, we chose to focus on chronic optic neuropathy 
rather than acute optic neuritis. The intention of this was to avoid any confounding 
effects of active inflammation on the VEP; indeed, the age-related attenuation in 
VEP response in our study was strengthened when eyes with recent optic neuritis 
were excluded. One similarity between the studies was the poor response of older 
patients receiving placebo, suggesting little baseline remyelination in this group. 
 
Any approach to promoting remyelination in MS might be limited by the intrinsic 
capacity of the aged CNS to repair. Encouragingly, this capacity can be enhanced in 
rodent models through interventions that rejuvenate an older animal’s biological age, 
such as exposure to a youthful systemic environment,268 intermittent fasting100 or 
drugs including niacin423 and metformin.100 With the demographic of patients with MS 
getting older,424 such interventions are likely to play an important role in emerging 
strategies to promote remyelination and reduce disability. 
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Chapter 4: The durability of the remyelinating effect 
of bexarotene 




Remyelination has emerged as a critical therapeutic target in multiple sclerosis that 
has the potential to restore function and protect demyelinated axons. Successful 
trials of putative remyelination-promoting drugs depend on valid, non-invasive, and 
reliable outcome measures that are sufficiently responsive over short-duration trials. 
At this point, neuroimaging has not delivered sensitive and specific measures of 
remyelination; instead, electrophysiology is proving invaluable in phase II 
remyelination trials.  
 
The shortening of visual evoked potential (VEP) latency directly reflects 
remyelination in the visual pathway and has now shown positive treatment effects in 
clinical trials of clemastine, opicinumab and bexarotene. Meanwhile, the mounting 
recognition of the constraints of the full-field VEP has led to the increasing 
application of multifocal VEP, such as in studies of nanocrystalline gold, opicinumab 
and metformin. However, it is not known how soon after a bout of acute optic neuritis 
these measures can be reliably deployed. An additional unresolved question is 
centred on the durability of VEP latency reductions after trials of remyelination drugs 
– such as bexarotene. 
 
Unfortunately, the studies centred on these research questions were halted by the 
COVID-19 pandemic not long after I was granted ethical approval. However, I 
secured authorisation to proceed to recall the Cambridge CCMR One participants, 
successfully submitting that collecting these trial data fell within level 2 research of 
the NIHR recovery strategy. In so doing, I was able to demonstrate persistent 
improvements in full-field VEP latency in follow up assessments of 20 (of 31) 
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Cambridge-based participants from the CCMR One trial. I additionally evaluated 
multifocal VEP in these participants, allowing cross sectional comparisons of these 
measures with the full-field technique. 
 
Contribution statement 
In March 2020, I travelled to Sydney to visit Professor Sasha Klistorner and 
developed the skillset to independently conduct and analyse the multifocal visual 
evoked potentials. I conceptualised and designed this research study. I was granted 
ethical approval and commenced patient recruitment and assessment. I performed 
all of the assessments and undertook the statistical analyses of these data. 
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Background 
 
It has been extensively chronicled that remyelination of demyelinated axons in the 
spinal cord by newly formed oligodendrocytes results in recovery of nerve 
conduction velocities203,425 and is able to restore normal neurological function.426 The 
pressing need to capture and track remyelination in humans has led to a resurgence 
in the use of electrophysiology to document this biology. 
 
Full-field visual evoked potentials (FF-VEPs) have been used since the 1970s to 
detect occult visual pathology: increased latency with preserved waveform 
morphology being considered a sign of demyelination.427 Importantly, there is now 
direct evidence from feline models that shortening in VEP latencies corresponds 
directly with the degree of remyelination;418 strengthening the position that reductions 
in VEP latency reflect remyelination rather than ion channel redistribution or 
plasticity.428 This engenders more confidence in the results returned by trials 
including ReBUILD,277 RENEW,285 and CCMR One (Chapter 2). Of course, as 
described in my introductory chapter, FF-VEPs have to contend with the problems of 
phase cancellation, responses dominated by the inferior visual field, and potential 
insensitivity to small peripheral field abnormalities.429 This prompted the testing of 
discrete portions of the field through the technique of multifocal VEPs (MF-
VEPs),353,430 which seem more sensitive in the setting of remyelination trials.366 
 
In the course of my PhD, I recognised 2 important questions. First, that if VEPs are 
to be deployed as outcome measures, it is essential to understand the time course 
and extent of electrophysiological recovery in eyes after acute optic neuritis (AON) 
and in eyes with subclinically delayed VEPs. A combination of prospective357 and 
retrospective358 analyses of FF-VEP suggest that exclusion of patients within 2 years 
of the last clinical episode of AON is appropriate; the same stability has not yet been 
clearly demonstrated for MF-VEP.360 Second, it is unclear if the latency 
improvements observed following exposure to putative remyelinating drugs are 
durable. In ReBUILD, there was a signal that this is the case: latency reductions 
were still evident 2 months after clemastine cessation in one of the treatment 
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groups.277 However, in CCMR One (Chapter 2), the final FF-VEP was completed on 




I designed a research project entitled studying progressive remyelination in nerves 
by grading electrophysiological recovery (SPRINGER), with the intention of (a) 
quantifying how MF-VEP measures change over time in people living with multiple 
sclerosis, including after a recent episode of acute optic neuritis and (b) determining 
if latency changes seen in previous remyelination trials are durable, and potentially 
more significant, after the conclusion of the study. As part of the preparation for this, 
I wrote the study protocol and related documentation before navigating the ethical 
and local trials unit approval process; this study was authorised by the Wales REC 7 
committee (20/WA/0294). Unfortunately, due to the constraints of the pandemic, 
which closed the Cambridge clinical research centre to observational studies from 
March 2020, I have only been able to address the latter research question 
 
Subjects 
Participants were recruited with a diagnosis of multiple sclerosis who had previously 
been part of the CCMR One trial based in Cambridge (Chapter 2). All had a 
diagnosis of RRMS and had been treated with dimethyl fumarate during their trial 
participation. Data were collected on their relapse history, optic neuritis history, and 
any changes to disease modifying treatments. Meanwhile, healthy subjects were 
recruited as controls for the VEP assessments. All participants gave written informed 
consent. 
 
Equipment and protocols 
Both full-field and multifocal VEPs were assessed using a Vision-Search Plus 
system (VisionSearch, Sydney, NSW, Australia); the FF-VEPs undertaken during the 
CCMR One trial had been performed on a Synergy system (Optima Medical Ltd, 
UK). In both instances FF-VEPs were elicited by a 2 Hz reversing check pattern of 
size of 60-min of arc with signal recorded from a channel formed between gold-cup 
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electrodes positioned frontally in the midline and 2.5 cm above the inion (Fz-Oz). 
Between 3 and 5 averaged recordings were taken per eye, and the weighted 
average of these used to measure the N75, P100 and N145 latencies and the 
amplitude between the N75 and P100. Multifocal VEP testing instead recorded 
signal from four gold-cup electrodes (Grass Technologies): a vertical channel (using 
electrodes placed in the midline 2.5 cm above and 4.5 cm below the inion) and a 
horizontal channel (via electrodes placed 4 cm either side of the inion). VEP signals 
from each of the 56 segments were amplified (100,000 times) and band-pass filtered 
(1-20 Hz): amplitude was taken as the largest peak-trough signal from either the 
vertical or horizontal channel within an interval of 70-200 ms, latency was defined 
using the second peak of this maximum amplitude wave (Figure 4.1). Segments with 
no detectable amplitude (where the amplitude of the response was less than two 
times the noise level of the trace within the interval 400–1000 ms) were assigned an 
amplitude of 0 nV but not assigned a latency; the MF-VEP amplitudes and latencies 
were then averaged from each segment.  
 
All participants had a further expanded disability status scale (EDSS) assessment. 
Additionally, all participants had their Sloan low-contrast (1.25% and 2.5%) visual 
acuity recorded for each eye at 2m distance with a PrecisionVision wall chart. Acuity 
was recorded as the logarithm of the minimum angle of resolution (logMAR). 
 
Statistical analysis 
Statistical analysis was performed using R statistical software. To evaluate the 
pattern of FF-VEP amplitude and latency change, I tested the treatment effect using 
a mixed effects model applied with random effects for participant and eyes within 
participant, adjusting for fixed effects for baseline VEP latency and minimisation 
variables: age (≤ 40 /> 40 years), gender, and EDSS (≤ 4.0/> 4.0 score). For the 
EDSS analysis I used multiple regression of the change in EDSS on a group 
indicator with the same covariates as above. Cross sectional comparisons of MF-
VEP parameters and low contrast visual acuities were undertaken using either t-tests 
or Mann-Whitney U tests where any violation of distribution assumptions was 
evident. A p-value of ≤0.05 was considered statistically significant. 




Figure 4.1. The multifocal visual evoked potential (MF-VEP). Above: cortically 
scaled stimuli used in MF-VEP reverse in pseudorandom sequence. Below: example 
of recording performed by myself on the right eye of a patient with chronic optic 
neuropathy, with an expanded trace from one segment showing delayed latency in 
the vertical channel. The average amplitude and latency for this eye was 213 nV and 
155 ms respectively. 
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Results 
 
Between December 10th, 2020 and April 6th, 2021, 21 out of the 31 CCMR One 
participants from Cambridge consented to participate; one was unable to attend on 
account of sickness resulting in a sample of 20 people with MS (12 were from the 
bexarotene arm and 8 from the placebo arm of the trial, Table 4.1). Clinical relapses 
in two participants, radiological activity in one, and lymphopaenia in one further 
participant, had led to treatment escalation from dimethyl fumarate. Two participants 
had since been diagnosed with SPMS; both remained on dimethyl fumarate at the 
time of enrolment. No participants had had an episode of acute optic neuritis since 
their participation in CCMR One. 
 
 Bexarotene  Placebo Healthy Control 
Total number of participants  12 8 10 
Number converted to SPMS 1 1 NA 
Age, years; mean (SD) 44.3 (6.3) 42.8 (4.8) 32.8 (14.9) 
Sex 
   Female 










Disease duration, years; 
mean (SD) 
11 (5.9) 8.4 (5.8) NA 
Number of patients with 
clinical relapses since CCMR 
One 
1 1 NA 
Disease modifying drug 
   Dimethyl Fumarate 
   Cladribine 










Total number of VEP 
recordings with sufficient 
quality for inclusion (number 
of eyes) 
24 15* 20 
Baseline P100 latency, ms; 
mean (SD) 
132.3 (17.7) 126.1 (22.3) NA 
Table 4.1. Baseline variables of those who attended the CCMR One follow-up 
visit. Data are presented by trial group, alongside the information for the healthy 
controls who additionally undertook visual evoked potential (VEP) assessments. 
SPMS: secondary progressive multiple sclerosis.  *one eye included in this group 
had an unrecordable P100 latency at the baseline visit of CCMR One. 







Figure 4.2. The change in full-field P100 latency over time. A: the progression of 
the P100 latency for each eye over the course of the baseline and 6-month visits of 
CCMR One, and the follow up assessment, divided by treatment group. Red lines 
indicate eyes previously affected by a clinical episode of acute optic neuritis. B and 
C: the change in P100 latency for all eyes and for just those eyes with a baseline 
P100 latency >118 ms, respectively, over the 3 VEP assessments. 
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38 out of 40 full-field VEP recordings (95%) were of sufficient quality to be analysed 
at both the CCMR One baseline and the follow up visit recordings. With all eyes 
included (24 bexarotene and 14 placebo) there was a statistically significant 
difference between the follow-up and baseline P100 latencies of the two trial arms: 
the adjusted treatment difference was -7.79 (95% CI -14.76, -0.82) ms, p=0.044 
(Figure 4.2). However, when only eyes with a baseline P100 latency >118 ms were 
included (20 bexarotene and 7 placebo), the trend to improvement in P100 VEP 
latency remained but was not statistically significant: the adjusted treatment 
difference was -5.39 (95% CI -16.11, 5.32) ms, p=0.343.  
 
A similar pattern was observed for the adjusted change in N145 latency between the 
follow-up and baseline trial visits, which was -5.95 (95% CI -10.80, -1.10) ms 
(p=0.021) with all eyes included (23 bexarotene and 14 placebo), and -4.02 (95% CI 
-11.48, 3.43) ms (p=0.319) when the analysis was restricted those with a baseline 
P100 latency >118 ms (19 bexarotene and 7 placebo). Meanwhile, there were no 
differences in the adjusted changes of the N75 latency: for all eyes this was 1.85 
(95% CI -9.66, 13.37) ms (p=0.756) and for those eyes with delayed baseline P100 




Figure 4.3. The change in EDSS. The change in the EDSS over the course of the 
baseline and 6-month visits of CCMR One, and the follow up assessment, 
subdivided by treatment group. 
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3 participants – all from the bexarotene group – had had an improvement in disability 
between the CCMR One trial baseline and the follow-up visit (Figure 4.3). However, 
there was no treatment difference between the two groups: the EDSS difference, 
adjusted for age and gender, was -0.31 (95% CI -1.37, 0.74), p=0.569.  
 
I also performed multifocal VEP (MF-VEP) assessments on each of the 20 
participants at the follow-up visit, in addition to 10 healthy controls. There were 
statistically significant differences between the mean latencies of both the 
bexarotene (152.5 ms) and placebo (157.3 ms) groups, with the healthy controls 
(137 ms; p<0.001 in each instance, Figure 4.4A). There was, however, no difference 
between the mean MF-VEP latencies of the two CCMR One groups (p=0.413). MF-
VEP amplitudes did not differ between the 3 groups (Figure 4.4B). Linear regression 
analysis demonstrated a good correlation between the P100 latency of the full-field 
VEP and the averaged latency of the MF-VEP of those participants with MS: 
coefficient of correlation (r) was 0.81 (p<0.0001) (Figure 4.5A). The equivalent 
correlation of amplitudes between the two tests was less strong (Figure 4.5B). 
 
I additionally examined 2.5% Sloan low contrast letter acuity, and a statistically lower 
LogMAR was evident in the bexarotene-treated group (0.51), than those who had 
been treated with placebo (0.69), p=0.021, corresponding to an improvement of 9 
letters on the chart. There was, however, no between-group difference at the 1.25% 
contrast level (Figure 4.6). 
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Figure 4.4. Between group differences in multifocal VEP latency and 
amplitude. Plotted here is the MF-VEP latency (A) and amplitude (B) for each eye, 
performed at the follow-up visit, subdivided by CCMR One treatment group, or 
healthy control participants. Bars are standard errors around the group mean. *** 
p<0.01, **** p<0.001. 
  








Figure 4.5. Correlation between latencies (A) and amplitudes (B) of full-field 
and multifocal VEP. Values refer to the P100 component of the full-field VEP and 








Figure 4.6. Between group differences in low contrast visual acuity. Shown 
here is the logarithm of the minimum angle of resolution (logMAR) using a Sloan 
2.5% and 1.25% low contrast wall chart, performed at the follow-up visit, subdivided 





This follow-up study to CCMR One has shown that the full-field VEP latency 
improvements observed in the original trial are durable, with a larger treatment effect 
seen in the all eye analysis, which met the level of statistical significance despite a 
sample size less than half of that seen in CCMR One itself. That the change in those 
eyes with a baseline P100 latency of >118 ms was not statistically significant, 
despite a larger treatment effect size relative to the CCMR One trial, might be 
attributable to the very small numbers in the placebo group (just 7 eyes in this 
analysis) as well as the spread of their latencies. A further finding was that, between 
the baseline and the follow up visit, the 3 participants who displayed an improvement 
in disability were all in the bexarotene group from the trial; a point that should be 
interpreted with caution given there was, again, no treatment difference for EDSS 
between the two groups when all participants were included. Certainly, while these 
data support the finding that bexarotene has a biological effect in humans and 
additionally suggest that this might have a long-term benefit years after the treatment 
period has concluded, they should be interpreted in light of the adverse events we 
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observed that we feel precludes the use of bexarotene in the treatment of people 
with MS (Chapter 2). 
 
Durability of VEP latency changes after exposure to a putative remyelination drug 
has been shown before. In the ReBUILD study of clemastine, sustained VEP 
improvements were observed 2 months after clemastine discontinuation in one of the 
trial groups.277 Additionally, in the RENEW trial of opicinumab, the VEP was 
repeated 8 weeks after IMP discontinuation, at which point the treatment difference 
in the per-protocol sample had increased to -9.1 ms, from -7.6 ms at the end of the 
24 week treatment period, and then met the test of statistical significance.285 This 
sub study of CCMR One is the first conducted at a time years remote from 
participation in a remyelination trial. It additionally begins to address a potential 
criticism of CCMR One; that the end of trial VEP assessment occurred while the 
patients were still taking bexarotene (and, indeed, levothyroxine), which might 
potentially have affected VEP latency through mechanisms outside of structural 
changes in myelination.405 
 
There are, however, limitations to these findings. First is the relatively small number 
of participants, taken from only one of the trial sites, which introduces the possibility 
of selection bias. Second, a potential confounding factor is that the follow-up clinic 
used a VS+ device, in comparison to a synergy (Optima medical) set-up that had 
been used during the trial. Third, 2 participants in the bexarotene group had had their 
DMT treatment escalated to cladribine in the period between the end of trial 
participation and follow-up; this could be interpreted as being contributory to VEP 
improvements (through more effective control of inflammation), though the converse 
– that disease activity despite dimethyl fumarate was greater in these patients, thus 
the treatment escalation – could also be argued.  
 
The optimal biomarker to precisely capture and track demyelination, remyelination 
and neuroaxonal injury is not known. No imaging measure of remyelination has yet 
satisfied the 5 conditions for use in neuroprotective and reparative MS trials set forth 
by Barkhof et al.431: pathological specificity, reproducibility, sensitivity to change, 
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clinical relevance, and responsiveness to treatment. The latency of the VEP 
accurately reflects pathological quantification of myelin in animal models of optic 
neuritis,432 is sensitive to remyelination,418 correlates with disability in people with 
MS,350 and has now been shown to be responsive to treatment across 3 trials: 
CCMR One (Chapter 2), ReBUILD,277 and RENEW.285,366 The main limitation to the 
VEP in this context is the stringent requirements it places on participant selection 
criteria on account of the need for demyelination of the visual pathway and the high 
test-retest variability seen in the setting of acute optic neuritis.358 MF-VEPs are 
particularly appealing as they are more reproducible than FF-VEP,433 and are less 
subject to the ceiling effect (disappearance of the waveform) that can limit the 
usefulness of FF-VEP in patients with advanced disease.388  
 
In performing cross sectional analyses of the MF-VEP latency in these participants 
there was no significant difference between the bexarotene and placebo groups at 
the follow up visit; both were prolonged relative to the group of healthy volunteers. In 
line with previous work,434 there was a significant correlation between the FF-VEP 
and MF-VEP latencies at the follow-up visit (r=0.81, p<0.0001). This was less clear 
when it came to the equivalent comparisons of amplitude (r=0.42, p=0.008). A 
possible explanation is that the technique for quantification of amplitude is very 
different between the two tests; while the N75-P100 wave is used in full-field VEP, in 
MF-VEP the waveforms generated are of significantly different morphology. Another 
contributing factor is that the origins of the recorded signal in each instance is 
different: FF-VEPs mostly originate from a few central degrees of the visual field, 
while averaged MF-VEPs have a significant contribution from peripheral field.359,360 It 
is therefore easy to envisage a situation of a patient with a peripheral defect having a 
normal FF-VEP but an abnormal MF-VEP. The superior correlation seen for latency 
might be explained by the smaller inter-subject variability when compared to 
amplitude.434 In any case, the results of this study highlight the potential utility for 
MF-VEP testing in remyelination trials which, as described in the introduction, may 
allow for higher spatial resolution of remyelination of the visual pathway. 
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Chapter 5: The Cambridge Centre for Myelin Repair 
trial number Two (CCMR Two) 
 A phase IIa, randomised, double-blind, placebo-controlled 
clinical trial of the ability of the combination of metformin and 
clemastine to promote remyelination in people with relapsing-






Promotion of endogenous remyelination represents the most realistic prospect for a 
neuroprotective treatment in MS. Clinical trials have deployed drugs, such as 
bexarotene and clemastine, to target the rate limiting step in this process: 
differentiation of oligodendrocyte progenitor cells (OPCs). Now, preclinical research 
has shown that metformin can reverse an age-associated deficit in the 
responsiveness of OPCs to pro-differentiation factors. The purpose of the Cambridge 
Centre for Myelin Repair trial number Two (CCMR Two) is to evaluate the efficacy of 
the combination of metformin and clemastine to promote remyelination in people with 
MS. 
 
Patients with relapsing remitting MS (RRMS) will be randomised 1:1 to the 
combination of metformin and clemastine or matched placebos and followed for 24 
weeks of treatment. All participants must be stable on a disease modifying therapy 
and have evidence of chronic stable optic neuropathy in at least one eye (defined by 
a latency of the visual evoked potential (VEP) ≥118 ms, and the absence of acute 
optic neuritis in the preceding 2 years). The primary outcome measure will be the 
change in the P100 latency of the full-field VEP between baseline and week 26. 
Secondary outcome measures will examine the change in multifocal VEP latency, 
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and the change in lesional MTR for lesions stratified by location and the cohort 
baseline median lesional MTR. With a sample size of 25 participants per arm, this 
will afford 80% power to detect a 3 ms reduction in VEP P100 latency.  
 
In this chapter I set out the trial design, the rationale for participant and outcome 
measure selection, and all pre-specified analyses. In so doing, I expect to be able to 
detect the structural and functional consequences of remyelination within a sample 
size feasible for this single centre study. Following delays imposed by the COVID-19 
pandemic, the trial will commence patient enrolment in 2021. 
 
Contribution statement 
Over the course of my PhD, I have led the design of this trial, put together a 
successful funding application to the MS Society, and submitted this for ethical 
approval. As described in Chapter 4, I formed a collaboration with Professor Sasha 
Klistorner at Sydney University to learn to conduct and analyse multifocal visual 
evoked potentials. I have additionally been part of a successful grant application to 
build our own vision research laboratory in Cambridge, which allows our research 
group to independently perform evoked potentials, visual fields, colour vision, low-
contrast visual acuity, and saccadometry. I have written a protocol manuscript, which 
I intend to submit for publication once the trial has begun recruitment. 
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Background 
 
Treatments capable of enhancing endogenous remyelination are needed to protect 
vulnerable axons from degeneration.29 This can be achieved by promoting the 
differentiation of oligodendrocyte progenitor cells (OPCs) into mature, myelinating, 
oligodendrocytes.400 Bexarotene, as described in Chapter 2, and clemastine, as 
described in Chapter 1, have both been shown to promote remyelination in animals 
and in phase II trials of people with MS by targeting this rate-limiting step.246,277,291 
However, it has previously been shown that this response becomes inefficient with 
age (Chapter 3 and ref98). 
 
The scientific rationale for this trial has roots in the discovery that intrinsic changes 
take place within OPCs as they age that sees them become less responsive to the 
factors that normally enhance differentiation and remyelination.100 Ribonucleic acid 
(RNA) sequencing from young and aged OPCs highlighted a significant contribution 
from the mTOR nutrient signalling pathway. Therapeutic modulation of this was 
achieved by subjecting 12-month-old rats to a six-month regime of alternate day 
fasting – these aged animals were subsequently able to remyelinate ethidium 
bromide-induced demyelinated lesions as effectively as younger animals. This effect 
was phenocopied by deploying the AMP-activated protein kinase (AMPK) agonist 
metformin; in aged rats, 3 months of treatment with metformin 300 mg/kg/day 
enhanced remyelination (Figure 5.1).100  
 
In vitro differentiation assays on aged OPCs showed that metformin’s effect is 
mediated through increasing their responsiveness to pro-differentiation factors 
(examples include T3, 9-cis-retinoic acid, miconazole and anti-muscarinic agents 
such as benzatropine, Figure 5.1).100 Given that clemastine, which was identified to 
be pro-remyelinating in the same drug screens as benzatropine,246,275 has a superior 
blood-brain barrier penetrance compared to other anti-muscarinic compounds, we 
have elected to test the combination of metformin and clemastine in this trial. 
 
 - 128 - 
 
Figure 5.1. The scientific rationale for CCMR Two (reproduced from Neumann 
et al.)100 A: schematic of in vivo experiment. 12-month-old female rats were divided 
into three groups: control, alternate daily fasting (ADF) and metformin (MET); 
metformin animals had ad libitum access to food and additionally received metformin 
at dose of 300 mg/kg bodyweight in their drinking water from the age of 15 months. 
At 18 months of age, demyelinating lesions were induced. B: histological 
quantification of remyelination revealed increased proportions of remyelinated axons 
in metformin-treated animals. C: in vitro differentiation assays support the use of 
metformin in combination with pro-differentiation drugs. D: from aged OPCs, 
differentiated MBP+/Olig2+ oligodendrocytes were formed in greater quantities in 
response to metformin alone. The addition of growth factors, including agents with 
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In fact, an initial aim of my PhD was to develop a clinical trial with calorie restriction 
as the intervention. In preparatory work to establish the feasibility of such a trial, I 
collaborated with the MS Society’s research network (a group of people living with, 
or affected by, MS, who are trained to work with researchers to strengthen the 
quality and relevance of research by drawing on their personal experience of MS) in 
holding a focus group to better understand how a diet involving intermittent fasting 
might be tolerated and applied in a trial setting for people with MS. This was a 
productive exercise, revealing broad enthusiasm for participating in such a study, 
and valuable suggestions for how one might design a trial to additionally generate a 
reliable control population and monitor compliance (Appendix 1).  
 
A dietary-intervention trial was, however, put on hold after a unique funding 
opportunity allowed us to first test the remyelinating effect of metformin. Frequency 
therapeutics, a US-based clinical-stage biotechnology company, hold a licence to 
exploit the patent on the combination treatment of metformin and anti-muscarinic 
drugs. Their approach has been to use combinations of small molecule treatments to 
activate progenitor cells; their early therapeutic work has focussed on regenerative 
treatments for sensorineural hearing loss. They expressed a desire to support MS 
clinical research and so held several meetings with our group. They subsequently 
made a donation to the MS Society to support their direct funding of this trial. 
 
The outcome of this process has been the development of a phase IIa, randomised, 
double-blind, placebo-controlled clinical trial that will evaluate the ability of the 
combination of metformin and clemastine to promote remyelination in people with 
MS: the Cambridge Centre for Myelin Repair trial number Two (CCMR Two). 
Lessons drawn from CCMR One have featured strongly in our trial design. In 
particular, this trial tests the ability of this repurposed combination of drugs to reduce 
the latency of the VEP and to improve the MTR characteristics of chronic lesions 
stratified by their location and baseline tissue integrity. As previously described, the 
exploratory nature of outcome measures in phase II remyelination trials has been a 
particular obstacle. These need to be valid, reliable, and sufficiently responsive over 
a short-duration trial. Given that VEP latency strongly correlates with 
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myelination,354,355 is highly reproducible in individuals (in particular with larger check 
sizes),304 and has shown statistically significant effects in three trials (CCMR One, 
ReBUILD, and RENEW),277,285 we have chosen VEP latency as our primary outcome 
measure. However, the recognition of regional remyelination in demyelinated chronic 
lesions has additionally prompted us to select MRI analyses sensitive to these 
changes. 
 




The primary objective of CCMR Two is to test the ability of the combination of 
metformin and clemastine to promote remyelination in demyelinated lesions in 
people with relapsing remitting multiple sclerosis (RRMS). Secondary objectives are: 
(i) to assess the efficacy of the combination of metformin and clemastine to promote 
remyelination in those with evidence of demyelination in the visual pathway as 
measured by the multifocal VEP latency; (ii) to evaluate the ability of metformin and 
clemastine to improve the MTR characteristics of MS lesions, stratified by baseline 
lesion MTR and lesion location; and (iii) to survey the safety and tolerability of these 
drugs in people with RRMS. 
 
Exploratory objectives are to: (i) assess the clinical efficacy of this therapeutic 
combination by examining changes in Sloan low-contrast visual acuity, visual fields, 
colour vision and EDSS; and (ii) to evaluate the effects of metformin and clemastine 
on putative measures of neuroprotection including: optical coherence tomography, 
saccadic latency, amplitude of the full-field and multifocal VEP, brain atrophy, and 




CCMR Two is a phase IIa, single-centre, double-blind, randomised, placebo-
controlled, parallel groups add-on trial that compares the combination of metformin 
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and clemastine (maximally tolerated dose of metformin SR, up to 1 gram twice a 
day, alongside 5.36 mg clemastine twice daily) against matched placebos for 24 
weeks in people with RRMS and chronic stable optic neuropathy. The primary end 
point is the change in full-field VEP latency between baseline and 26 weeks. 50 
participants will be randomised in a 1:1 ratio, with an interim review by an 
independent data monitoring committee after 20 patients have completed their 
assessments to determine whether a sample size re-estimation should be 
considered. Participants will have a total of seven study visits with a final evaluation 
at week 28, all at the department of clinical neurosciences of Cambridge University 
(Figure 5.2).  
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Figure 5.2. The Cambridge Centre for Myelin Repair trial number Two (CCMR 
Two) participant timeline. 
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Participant characteristics 
 
Selection criteria for CCMR Two, alongside the rationale for each point, are shown in 
Table 5.1. Potential participants will be identified through specialist neurology clinics 
at the trial centre or referred to the trial team from other MS/neuroscience centres 
and hospitals. Candidate participants will then be seen in clinic or contacted via 
telephone to discuss the study directly with a member of the trial team and 
‘prescreen’ to ensure that the interested participant is likely to fulfil the general 
criteria to enter the trial and be able to comply with the trial assessments and 
interventions. The potential participant will be given a copy of the participant 
information sheet (PIS) and informed consent form (ICF) and asked to contact the 
study team at an interval of no less than 24 hours to confirm if they would like to 
proceed to screening. 
 
The screening visit will be divided into two sets of assessments. On the first, after 
signing of the informed consent form, the trial team will review the participant’s 
medical history, imaging and records, to confirm the diagnosis of RRMS115 and their 
eligibility for inclusion (Table 5.1). Participants will then have their screening VEP 
assessments to ensure there is detectable demyelination in the visual pathway. Data 
from CCMR One suggests that in the region of 36% of potential participants will not 
pass screening at this point; in the ReBUILD trial, it is noteworthy that 75 patients 
failed screening on this same criterion to yield 50 eligible participants.277 If these 
assessments are satisfied, the individual would then be invited to return for a second 
series of screening investigations including blood tests, EDSS assessment, and 
optical coherence tomography (OCT) to ensure the criteria outlined in Table 5.1 are 
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Inclusion criteria Rationale 
Age between 25 and 50 years 
(inclusive) at time of signing informed 
consent form* 
Upper limit selected to reduce chance that 
age-related changes at MRI not 
misidentified as MS lesions. Lower limit to 
align cohort with the preclinical data 
showing remyelination failure is age-
dependent 
Relapsing-remitting multiple sclerosis 
as per the McDonald 2017 criteria, 
including an MRI brain satisfying the 
2017 radiological criteria115 
The expectation is that selecting RRMS 
patients will maximise the number of 
demyelinated MS lesions with intact 
axons,28,401 thereby providing the 
substrate for remyelination 
Full-field visual evoked potential 
(VEP) P100 latency in at least one 
eye of ≥118 ms 
To ensure there is sufficient demyelination 
in the visual pathway to allow detection of 
remyelination. 118 ms is 2 SD greater 
than the mean of our control data, and the 
same threshold as that previously used in 
the ReBUILD trial277 
Kurtzke EDSS step 0.0 - 6.0* To maximise the number of intact axons; 
increased degrees of neurodegeneration 
would be anticipated at higher levels of 
baseline disability 
At the time of screening, being 
treated with a stable dose for at least 
6 months of a category 1 multiple 
sclerosis DMT or for at least 2 years 
with a category 2 DMT11* 
This allows the regeneration of myelin to 
be studied in some degree of isolation 
from active inflammation 
Exclusion criteria Rationale 
Female participants who are 
pregnant, lactating, planning 
pregnancy, or unwilling to use reliable 
contraception during the trial 
Metformin not recommended in pregnancy 
and is detectable in breast milk. 
Clemastine should not be given in 
pregnancy or when breastfeeding 
Retinal nerve fibre layer thickness on 
spectral-domain OCT <70 μm in the 
qualifying eye 
Below this threshold there are severe 
decrements in visual function;372 above 
this value implies there remain sufficient 
axons to remyelinate 
A clinical episode of optic neuritis in 
the qualifying eye within the 2 years 
preceding screening 
Following an attack of optic neuritis, VEP 
latencies are prolonged but a period of 
recovery follows for up to 2 years;137,357 
excluding these make improvements in 
latency more specific for drug-induced 
remyelination 
Any concomitant use of oxybutynin, 
monoamine oxidase inhibitors 
(MAOIs), hypnotics or high-dose 
opiates at screening 
These interact with clemastine. 
Oxybutynin additionally has potential 
remyelinating efficacy (though limited BBB 
penetrance) 
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Significant renal or liver impairment 
(eGFR <60 mL/min/1.73m2; alanine 
aminotransferase > 3 times the upper 
limit of normal) 
Metformin very rarely can cause liver 
dysfunction and the incidence of lactic 
acidosis rises with impaired renal function 
People taking medication for 
Diabetes Mellitus at screening 
Metformin would alter glycaemic control 
People with a diagnosis of epilepsy Clemastine contraindicated in epilepsy. 
VEP testing contraindicated in 
photosensitive epilepsy 
Concurrent use of 4-aminopyridine or 
fampridine 
These can improve VEP and saccadic 
latency390,435 
History of prostatic hypertrophy, 
cardiac conduction block, stenosing 
peptic ulcer, pyloroduodenal 
ulceration, ophthalmologic disease 
including glaucoma, macular 
degeneration, and severe myopia (>-
7 Diopters) 
Clemastine contraindicated in these 
conditions. Severe ophthalmic disease 
due to causes outside of demyelinating 
optic neuropathy might impact on VEP 
and OCT assessments 
Table 5.1. Selection criteria for the CCMR Two trial with corresponding 
justification. *age, disability, and disease modifying treatment category are 
additionally included alongside gender as stratification factors in the randomisation 
(main text) to ensure matching baseline characteristics between active and placebo 
groups. MS, multiple sclerosis; VEP, visual evoked potential; SD, standard deviation; 
BBB, blood-brain barrier; EDSS, expanded disability status scale; OCT, optical 




Following documented permission from the potential participant when signing the 
informed consent form, their usual treating neurologist and/or GP will be contacted to 
detail their involvement in the trial; if they are not able to be randomised after 
attending screening, reasons for this will be communicated to both the patient and 
referring clinician. We will also maintain an anonymised log of all patients who are 
ineligible for the trial and all eligible patients that will not be randomised because 
they declined participation. This process will enable generalisation of the trial results 
in accordance with the Consolidated Standards of Reporting Trials (CONSORT) 
guidelines of 2010.436 
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Details of the interventions 
 
Metformin 
Metformin is a biguanide licensed for human use in the management of type 2 
diabetes.437 The primary target of metformin is the respiratory chain complex I.438 
Towards this, the drug induces mild and transient inhibition, increasing the cellular 
adenosine monophosphate (AMP) to adenosine triphosphate (ATP) ratio, leading to 
activation of AMP-activated protein kinase (AMPK), which regulates various target 
genes. It also functions to inhibit the mammalian target of rapamycin (mTOR), 
through both AMPK-mediated and AMPK-independent mechanisms. Ultimately this 
leads to reduced hepatic glucose production (inhibits gluconeogenesis and 
glycogenolysis), increased insulin sensitivity in muscle (improves uptake and use of 
glucose), delayed intestinal glucose absorption and reduced total cholesterol, low 
density lipoprotein (LDL), and triglyceride levels.439 
 
Metformin, has previously been demonstrated to reduce inflammation in progressive 
and relapsing experimental autoimmune encephalomyelitis,440 and has been used in 
an open label trial of 20 people with MS and demonstrated a reduction in the number 
of new or enlarging T2 lesions compared with placebo.441 Now, the demonstration 
that it can also reverse an age-associated barrier to the ability of oligodendrocyte 
progenitor cells to respond to pro-differentiation factors and enhance 
remyelination,100 provides a compelling rationale for its use in this trial. 
 
Metformin has been used in clinical practice for over 60 years and its safety profile is 
well established. Metformin is contraindicated in those with an estimated glomerular 
filtration rate (eGFR) <30 mL/min/1.73m2 and the maximum dose is reduced in those 
with an eGFR between 30 and 60 mL/min/1.73m2. As a result, the selection criteria 
applied to the trial will ensure only those with an eGFR ≥60 mL/min/1.73m2 can be 
included. Helpfully, while metformin is an anti-diabetic agent, it never causes 
hypoglycaemia and requires no monitoring of blood glucose levels. Meanwhile, 
metformin is generally well-tolerated. Gastrointestinal (GI) upset occurs in up to 20%, 
leading to discontinuation in 5%, however this is often short lasting and can be 
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minimized by gradual up-titration of the dose.442 Prolonged-release forms, offering a 
slower absorption rate, additionally improve tolerability.443-445 
 
The oft-feared consequence of lactic acidosis with metformin use is usually 
predictable (in those with renal failure) and is a very rare event – between 3 and 9 
events per 100,000 patient years only.446 However, the summary of product 
characteristics for metformin highlight that it should be temporarily discontinued in 
circumstances that may precipitate renal injury (such as severe dehydration and 
vomiting) or with use of intravenous iodinated contrast.  
 
Clemastine 
Clemastine, is a first-generation (inverse agonist of histamine) anti-histamine that 
inhibits receptors of the H1 type. It has a number of licenced indications including 
allergic rhinitis, hay fever, allergic dermatoses, and urticaria. After preclinical work 
demonstrating the potential remyelinating effect of clemastine,246 it was tested in a 
phase II clinical trial.277 The ReBUILD study, discussed in detail in Chapter 1, 
showed a mean reduction in the VEP P100 full-field latency of 1.7 ms/eye (p = 
0.0048) in its crossover model, among those assigned to 5.36 mg clemastine twice 
daily. 
 
Clemastine is a safe medication with no serious adverse effects; in the 
aforementioned trial the drug was well tolerated, though was associated with fatigue. 
However, higher doses would be limited by its tendency to sedation, which seems 
likely to be problematic in a patient cohort in whom fatigue is a common complaint. 
The summary of product characteristics for clemastine suggests caution in those 
with narrow angle glaucoma, prostatic hypertrophy with urinary retention, a history of 
pyloroduodenal ulceration and cardiac conduction block; participants with these 
comorbidities will be excluded in the trial. 
 
Drug supply, packaging and dispensing 
In 2019, I worked with Cambridge University Hospital’s clinical trials pharmacy and 
the University procurement team to navigate the tendering procedures required to 
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secure the delivery and manufacture of the trial drugs and matched placebos. 
RenaClinical provided the most competitive quote relative to the other responding 
vendors (GSTT pharmaceuticals, and Royal Free) and so were awarded the 
contract. Labelling will be blinded in line with the requirements of EU Good 
Manufacturing Practice Annex 13. Blinding will be maintained by coding of bottles. 
All will be packaged in polyethylene bottles containing the same number of tablets. 
Bottles will be dispensed according to the standard operative procedures of the 
clinical trials pharmacy of Cambridge University Hospitals NHS Foundation Trust. A 
log will be kept recording each dose of IMP dispensed to each trial participant. 
 
Dosing regimen and modification 
Following randomisation, at the baseline visit study drug will be dispensed from the 
pharmacy. This will include tablets of clemastine 1.34 mg (or matched placebos), 
and metformin SR 500mg (or matched placebos). Participants will be instructed to 
commence 5.36 mg twice daily of clemastine on day 1 of the trial and continue this 
for the 24-week treatment period. This dose has been selected as it is the same 
dose has previously been deployed in the ReBUILD clinical trial (with no treatment 
discontinuation in a cohort of 50 patients with RRMS), while the study also reports 
only 50% saturation of the target muscarinic receptor (and so we have not opted for 
a lower dose).277 Participants will similarly be instructed to commence 500 mg twice 
daily of metformin SR on day 1. This will be up titrated to 500 mg mane, 1 gram 
nocte after 2 weeks, before a final dose increase to 1 gram twice daily at 4 weeks; 
this dose will continue for the remaining 20 weeks of the treatment period. This dose 
has been selected as, in the preclinical experiments, the rats consumed 250 
mg/kg/day (Neumann, personal communication); this translates to approximately 2.5 
grams per day for a human assuming a body surface area of 1.7 m2.447 With 2 
grams/day being the maximum dose recommended of a sustained release 
preparation of metformin, which is better tolerated compared to the standard release 
formulation, we have elected not to increase this any further. 
 
If adverse events occur that are attributable to metformin – most likely 
gastrointestinal side effects – the trial team may reduce the metformin dose. If 
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symptoms settle, then the dose may be increased again, at the discretion of the trial 
doctor. In the event of an unrelated illness, such as diarrhoea and vomiting requiring 
hospitalisation, then the metformin (or its placebo) should be temporarily 
discontinued.  
 
Evaluation of adherence to study drug  
Participants will be issued with a dosing diary at their baseline visit to record the 
number of tablets taken and to indicate any missed doses (and reasons for non-
adherence). However, participants will also be asked to return any unused study 
drug and a pill count conducted. A cumulative total of 28 missed doses over the 
entire treatment period will trigger a review by the CI/PI for consideration of 




Visual evoked potentials will be performed at screening, baseline, week 12 and week 
26; brain imaging will be performed at baseline and week 26; clinical efficacy will be 
measured by the EDSS at screening and week 26 and by Sloan visual acuity at 
baseline, week 12 and week 28 (Table 5.2). 
 
Primary outcome: full-field VEP 
The primary outcome measure of CCMR Two will be the change in the P100 latency 
of the full-field VEP between baseline and week 26 for each eye with a baseline 
latency of ≥118 ms. The latter timepoint, 2 weeks removed from the end of treatment 
(week 24), has been selected to ensure that more than five half-lives have passed 
prior to the final VEP assessment; in this way any change in latency cannot be 
attributed to a direct effect of the investigational medicinal product on conduction 
velocity (making any changes more specific to variation in myelination). An additional 
VEP will be performed at week 12 to facilitate exploratory analyses of the time 
course of remyelination; this period was sufficient to detect an effect in ReBUILD.277 
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Table 5.2. Schedule of assessments for CCMR Two. Study specific activity is 
shown for each visit, see text for additional information. 1Physical examination to 
include: height (screening only), weight, pulse, and blood pressure. 2Randomisation 
only to be undertaken once all screening assessments are complete and eligibility 
confirmed. 3The second MRI can be undertaken on a separate day to the week 26 
visit, if necessary, within a +7 day window. 4Stool samples will be collected by 
participants at home, approximately corresponding to the baseline visit and week 24. 
Samples should be collected up to 1 week prior to these time-points. MS, multiple 
sclerosis; EDSS, expanded disability status scale; IMP, investigational medicinal 
product; PBMC, peripheral blood mononuclear cells; ECG, electrocardiogram; VEP, 
visual evoked potential; OCT, optical coherence tomography; MRI, magnetic 
resonance imaging. 
 
Assessment  Screening 1 
Screening 
2 Baseline  Treatment phase 
Clinic visit number  1 2 3 No visit 4 5 
No 
visit 6 7 
Visit window Day -70 to -14 
Day -70 to 
-14 
Day -14 

























Eligibility assessments X X      
Medical and MS history X       
Physical examination1  X    X  
EDSS assessment  X    X  
Concomitant 
medication check X  X X X X  
Randomisation  X2      
Adverse event 
assessments   X X X X X X 
IMP dispensing   X X X   
IMP compliance check    X X X  
Safety bloods  X  X X X  
Optional research 
bloods (for storing 
serum and PBMCs) 
 X   X X  
12 lead ECG  X  X X X  
Pregnancy test (women 
of childbearing potential 
only) 
 X X X X X  
Full-field VEP X  X  X X  
Multifocal VEP X  X  X X  
OCT  X     X 
Visual acuity (Sloan 
1.25%, 2.5% and 
100%) 
  X  X  X 
Visual fields   X    X 
Cambridge colour test   X    X 
Saccadometry  X     X 
MRI imaging   X   X3  
Optional stool sample4   X   X   
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VEPs will be assessed by means of a Vision-Search Plus system (VisionSearch, 
Sydney, NSW, Australia). The stimulus protocol has been selected to comply with 
guidelines from the International Society for Clinical Electrophysiology of Vision.448 
The visual stimulus will be generated on a high-resolution liquid crystal display, with 
a 2 Hz reversing check pattern of size of 60-min of arc. The participant will be seated 
50 cm from the screen. All will be optimally refracted for near vision and pupil 
dilatation will not be required. Electrical signals will be recorded from a channel 
formed between gold-cup electrodes (Grass Technologies, West Warwick, RI, USA) 
positioned frontally in the midline and 2.5 cm above the inion (Fz-Oz); a ground 
electrode will be placed on the ear lobe and conductive gel (0.5ml) injected under 
each. Between 3 and 5 averaged recordings will be taken per eye, and the weighted 
average of these used to measure the N75, P100 and N145 latencies and the 
amplitude between the N75 and P100 (Figure 5.3). A blinded rater will be 
responsible for ensuring quality control of each VEP record, and for latency and 
amplitude determination.  
 
Figure 5.3. The full-field visual evoked potential. In response to a reversing 2 Hz 
60 minute of arc checkerboard patterned stimulus, the averaged recordable signal 
takes the form of an N75-P100-N145 waveform. This shows 2 repeated measures 
from the same eye of an individual with MS, performed by myself, 6 months apart. 
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Secondary outcomes: electrophysiology  
The first secondary outcome of the trial is to interrogate the change in multifocal VEP 
latency, between baseline and week 26, for those eyes with delayed latency at 
baseline. As detailed in the introductory chapter, multifocal VEPs overcome the 
problems of macular over-representation and phase cancellation,353,359-361 allowing a 
more precise analysis of latency and amplitude abnormalities in people with optic 
neuropathy.363-365 In this trial we will use the aforementioned equipment, this time to 
monocularly present a stimulus consisting of fifty-six cortically scaled segments, 
each containing a 4x4 checkerboard reversing in a pseudorandom sequence (Figure 
4.1). Four gold-cup electrodes (Grass Technologies) will be used for bipolar 
recording: a vertical channel (using electrodes placed in the midline 2.5 cm above 
and 4.5 cm below the inion) and a horizontal channel (via electrodes placed 4 cm 
either side of the inion). The resultant VEP signals from each of the 56 segments are 
amplified 100,000 times and band-pass filtered (1-20 Hz). Amplitude is defined as 
the largest peak-trough signal from either the vertical or horizontal channel, within an 
interval of 70-200 ms, while latency is taken as the second peak of this maximum 
amplitude wave. Segments with no detectable amplitude are assigned an amplitude 
of 0 nV but are not assigned a latency. The software then averages the amplitudes 
from each segment and averages the latencies from only those segments with 
recordable signal. In order to be included in the analysis, the baseline recording must 
have recordable signal in at least 28 of the 56 segments, and a prolonged baseline 
latency is defined as being ≥151 ms. Progression analysis will then be performed 
across each of the 56 segments from each of the study visits by a blinded rater, to 
determine the change in multifocal VEP latency and amplitude for each affected eye. 
 
Secondary outcomes: MRI  
There are two secondary outcomes using MRI. First, is the change in lesional MTR, 
between baseline and week 26, for MS lesions stratified by location (e.g. cortical 
grey matter, brainstem etc.). Second is the change in lesional MTR, between 
baseline and week 26, for the lesions stratified by the cohort baseline median 
lesional MTR (especially those lesions with submedian MTR). MTR correlates with 
histopathological demonstration of myelin in MS lesions319 and these analyses have 
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been selected to account for evidence presented in Chapter 2 that the degree of 
remyelination in an MS lesion is dependent both on its location, being greatest in the 
grey matter,270,271,407 and the extent of its demyelination at baseline. We have 
prioritised chronic lesions in our analysis as remyelination trials centred on acute 
lesions require frequent MRI scans and large numbers of patients.290  
 
In CCMR Two, MRI scans will be performed at baseline and at 26 weeks, using a 
Siemens 3T Prismafit scanner (Siemens, Erlangen, Germany) with 20-channel head-
neck coils. Lesion identification, contouring and checking will be performed by 
blinded observers, with lesion location classified by using the brain parcellation from 
the volumetric T1 scan. Sequences sensitive to grey matter lesions will also be 




CCMR-Two will additionally assess exploratory outcome measures to include the 
change in the Sloan low-contrast visual acuity (which will be measured as the 
logarithm of the minimum angle of resolution (LogMAR) for each corrected eye at 
1.25% and 2.5% contrast levels), the change in colour vision (as measured by the 
Cambridge colour test), the change in Humphrey visual fields (as measured by the 
mean deviation in the Swedish Interactive Thresholding Algorithm (SITA)-Standard 
24-2 protocol), and the change in disability (measured by the EDSS step). 
 
The trial will also evaluate the effects of metformin and clemastine on putative 
measures of neuroprotection measured both before and after the treatment period: 
(i) optical coherence tomography (OCT), which visualises the proximal effects of 
demyelination that is often seen in the retrobulbar portion of the optic nerve;367 (ii) 
saccadic latency parameters, which depend on a network of diffuse pathways and a 
lengthening in latency is likely to represent neurodegeneration;391 (iii) the amplitude 
of the full-field and multifocal VEP; (iv) brain atrophy; and (vi) serum neurofilament 
light.  
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Safety and tolerability outcomes 
Each study visit after the point of informed consent will capture data on adverse 
events (AEs), which will be evaluated by the investigator to establish its seriousness 
and any relationship with the AE (causality). Participants will have renal and liver 
function checked at screening and weeks 4, 12 and 26. They will also have 12-lead 




50 patients will be randomised equally (1:1) between the active arm (the combination 
of metformin and clemastine) and the placebo arm. The primary analysis will be on 
an intention-to-treat on the whole study cohort. 
 
In developing this trial, I worked with Dr Wendi Qian, now the trial statistician, to 
perform the sample size calculations. We powered CCMR-Two to detect an average 
reduction of 3.0 ms/eye in full-field VEP latency at week 26 between metformin + 
clemastine (research arm) and placebo (control arm). The common standard 
deviation in our power calculation was 5, based on the ReBUILD study,277 which was 
approximately 4.1; we have added 20% (4.1x1.20 = 4.92) more variation. With a 5% 
significance level (two-sided), 80% power, and a common standard deviation of 5, 45 
eyes in each arm are required to detect a difference of 3.0 ms/eye in the mean 
change of VEP at week 26 from baseline between two treatment groups (nQuery). 
Allowing for 5-10% of non-compliance,442,443 that is 50 eyes per arm, it is therefore 
planned to recruit 50 patients. 
 
These estimates are limited by their using a common standard deviation derived 
from another group’s dataset. With a more heterogenous group of patients in CCMR 
One, the common standard deviation was 5.75. This trial, however, returned a 
statistically significant result as the effect size was an improvement of 4.06 ms. We 
have therefore decided to test the aforementioned assumptions in this sample size 
estimation: when 20 patients have had their primary endpoint data assessed, the 
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trial’s Independent Data Monitoring Committee (IDMC) will review the data and 
advise whether a sample size re-estimation should be considered.   
 
Assignment of interventions 
 
Eligible participants will be randomly assigned to metformin + clemastine (active 
arm) or placebo (control arm) in a 1:1 ratio using a minimisation with random 
element method. The stratification factors used in the randomisation will be: age 
(≤40 vs >40 years), baseline MS DMT treatment category (1 vs 2), gender (male vs 
female) and disability (an EDSS step ≤4.0 vs >4.0). We have chosen these criteria to 
promote matching of baseline characteristics between the active and placebo arms. 
In contrast to CCMR One – in which all participants were on dimethyl fumarate – we 
have instead introduced DMT category as a stratification factor. This decision 
reflects the realisation of the recruitment challenge afforded by only including those 
on a single DMT, but a corresponding desire to ensure comparable proportions of 
participants on high-efficacy DMTs between the two groups; such a mismatch might 
affect the interpretation of the trial result. Additionally, in the knowledge that disability 
correlates with axonal loss,449 while intact axons are the substrate of remyelination,28 
we have similarly introduced EDSS into our stratification. 
 
A web-based central randomisation system will allocate the participant a trial ID and 
treatment code which will relate uniquely to a supply of IMP. Access to the web-
based randomisation system will be via individual user accounts provided to the 
Principal Investigator (PI) and suitably trained and delegated members of the 
research team. Immediate allocation of treatment will be performed, with 
documentation of the decision sent in a confirmatory email.  
 
Throughout the trial investigators and participants will be blinded to the treatment 
allocation. The blind will be protected by means of: identical appearance of tablets 
for active and placebo drugs, equal numbers of tablets prescribed to participants in 
each arm, coded drug supplies being provided to the clinical trials pharmacy, and the 
randomisation list being held securely from the investigator’s team (with provision for 
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unblinding in emergencies if required). An additional layer of blinding is added by the 
anonymisation of VEPs and MRIs, such that they are analysed without reference to 
any participant information. 
 
Statistical analyses  
 
Descriptive statistics 
The pathway of participants through the trial will be summarised in a CONSORT flow 
diagram. Baseline characteristics will be summarised by treatment group, using 
summary statistics (mean, SD, median, IQR, maximum and minimum) for continuous 
variables and frequencies and percentages for categorical variables. Proportions of 
patients with missing and non-missing follow up data will also be reported in each 
treatment group. 
 
Primary VEP outcome measure 
The primary outcome, the mean change in the P100 latency of the full-field VEP 
between baseline and week 26 for eyes with a baseline latency of ≥118 ms, will be 
compared between the active and placebo arms using a mixed effects model applied 
with random effects for participant and eyes within participant, adjusting for fixed 
effects for baseline VEP latency and minimisation variables: age, gender, DMT 
category and baseline EDSS. The primary analysis will be on complete cases of 
patients with baseline and week 26 data.  
 
Secondary outcome measures 
Using the same method as for the primary VEP analysis, the mean difference in 
multifocal VEP latency from baseline to 26 weeks will be compared between the 
active and placebo groups. The lesion-level MTR analyses will use linear mixed 
models for lesions nested within patients, with patient random intercepts; these 
models regress lesion MTR on the same prespecified covariates but with lesion-
subgroup interaction terms to estimate lesion-subgroup specific treatment 
differences and test for variation between these differences.  
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Exploratory outcome measures 
If the changes in EDSS, colour vision and Sloan LCLA are found to be normally 
distributed, comparisons will be made between active and placebo arms using linear 
models, adjusting for baseline values and minimisation variables. The change in 
EDSS, colour vision or LCLA will be entered into the model as a continuous variable, 
as will age and baseline value; gender and DMT category will be included as a 
categorical variable. If normality cannot be assumed, unadjusted non-parametric 
Mann-Whitney U tests can be used to compare active treatment to placebo. 
 
Safety analyses  
The safety analyses will be based on all participants who received at least one IMP 
dose. Summary tables will be presented for incidence rates (number of patients with 
at least one event) of AEs and serious adverse events (SAEs), categorised 
according to the Medical Dictionary for Regulatory Activities (MedDRA) classification. 
The AEs that caused treatment modifications will be listed. 
 
Ethics and dissemination  
 
Before the start of the trial we obtained ethical approval from the Nottingham NRES 
Committee (21/EM/0120), which included endorsement of the trial protocol, 
participant information sheet (PIS), informed consent form (ICF), advertisements, 
and GP information letter. We will additionally seek approval before implementation 
of any substantial amendment. The trial will be performed in accordance with the 
spirit and the letter of the declaration of Helsinki, the conditions and principles of 




All participants of CCMR Two will be required to provide written informed consent 
prior to any trial-specific procedures are carried out. Participants will agree to their 
records being inspected by the trial team, regulatory authorities and representatives 
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of the sponsors. They will also agree that their GP be informed of their participation 
in the trial and be informed of any abnormal investigations during the trial.  
 
Confidentiality 
All investigators and trial site staff involved in CCMR Two will comply with the 
requirements of the General Data Protection Regulation (GDPR) 2018, Data 
Protection Act 2018 and trust policy with regards to the collection, storage, 
processing, transfer and disclosure of personal information and will uphold the Act’s 
core principles. The trial staff will ensure that the participants’ anonymity is 
maintained. The participants will be identified only by initials and a participant ID 
number on the case report form and any electronic database. All documents will be 
stored securely and only accessible by trial staff and authorised personnel.  
 
Copies of the raw data from the full-field VEP, MF-VEP and saccadometry testing 
will be stored on internal University of Cambridge Secure Data Hosting Service 
(SDHS). The SDHS provides a dedicated network provides a dedicated network for 
storing sensitive personal data. Access to this data will be restricted to authorised 
members of the trial team via a two-factor authentication system. 
 
Data access 
The chief investigator will have full access to the final data set following completion 
of the analysis by the trial statistician. The datasets generated during the study will 





The results of the trial will be released either at oral presentation or study publication, 
after a dissemination plan is agreed with the trial steering committee. Summaries of 
results will also be made available to participants by means of a newsletter 
(communicated by email) and by means of an informal meeting with the trial team 
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(virtual or in person). Authorship decisions will be guided by uniform requirements for 
manuscripts submitted to medical journals (www.icmje.org). 
 
Patient and public involvement 
 
Patient and public involvement (PPI) has been valuable the development of this 
research and will continue to be involved in the management of the trial. As part of 
the design and preparation for the study we have shared our protocol and participant 
information sheet with ten people with MS who have provided constructive feedback. 
People living with MS from the MS Society’s Research Network were also involved 
as part of the peer review process undertaken during the funding application. All 
have been in agreement with the trial design and thought that both documents 
outlined what would be expected of its participants and would be acceptable to 
people living with MS. Contributions from our PPI group have specifically led to: (i) a 
change to the visit schedule so that not more than one electrophysiological 
investigation (VEP or saccadometry) occurred on the same date; (ii) changes to the 
phraseology of the PIS to more clearly explain the overall aim of the trial, and the 
rationale for its selection criteria; and (iii) the consideration that the burden of the trial 
assessments were acceptable in view of the information they would provide both for 
this trial and those that might follow it. In the management of the trial, two people 
with MS from the MS Society's research network will serve as members on the trial 
steering committee, ensuring the views of people living with MS remain linked to our 
research throughout the study. 
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Discussion 
 
While several clinical trials have deployed drugs capable of enhancing differentiation 
of the OPC,277,285,290 the demonstration that metformin can reverse age-related 
changes in OPCs that prevent them from responding to such factors is an important 
development.100 Consequently, there is a compelling rationale to test metformin, 
alongside pro-differentiation agents such as clemastine, in clinical trials of people 
with MS.  
 
CCMR Two will test the hypothesis that metformin and clemastine can enhance 
remyelination in people with MS using both visual evoked potentials and 
magnetization transfer ratio imaging; it is anticipated that in this way we will be able 
to detect the functional and structural consequences of remyelination with a sample 
size feasible for a single centre study. We have applied our experience from the 
CCMR One trial – which showed that lesion remyelination in response to RXR 
agonism was dependent on its location and baseline tissue integrity – and optimised 
our analyses to be sensitive to remyelination in those lesions that are more 
demyelinated at baseline and those that are located in the grey matter. We have 
additionally introduced selection criteria to yield a cohort that we expect is most likely 
to have a measurable between-group response in this trial setting.  
 
There are, however, limitations to our chosen trial design. A particular challenge to 
translating promising preclinical research into remyelination trials is uncertainty about 
the optimum outcome measures to employ.450 Our approach for CCMR Two has 
been to prioritise the visual evoked potential, given it has been directly confirmed to 
reflect myelin status in chronically demyelinated optic nerves418 and has shown 
significant effects in three previous clinical trials,277,285 but to also include the MTR 
analyses that we think will be most sensitive to remyelination; in CCMR One, 
perhaps the most compelling evidence of a biological effect of bexarotene was the 
alignment between the imaging and electrophysiological results. We have also 
included several techniques that might be more sensitive to, or represent the 
downstream consequences of, remyelination: multifocal VEP,360 OCT,372 
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saccadometry,391 colour vision,357 and LCLA.384 However, all outcome measures in 
this field are essentially exploratory and several of this trial’s limitations stem from 
this point. First, in selecting only relapsing remitting patients with visual pathway 
demyelination and focussing on remyelination of this particular tract, there follows 
uncertainties about the generalisability of results to the wider MS population. 
Therefore, if CCMR Two did return a positive result, a further trial with a definitive 
disability outcome would be needed. Second, the sample size calculation is 
confounded by doubts in what constitutes a clinically important effect size and 
uncertainty in the variation in effects we might observe; we hope to mitigate against 
the latter point through the IDMC mid-point review of the sample size calculation.  
 
An additional limitation is the interpretation of a positive result. Would the primary 
effect be primarily attributable to the action of metformin, clemastine, or is there 
evidence of synergy between the two? There are pro-differentiation factors already 
present in demyelinated lesions210 and metformin alone might be sufficient to 
achieve remyelination. Meanwhile, the modest effect of clemastine on the VEP in 
ReBUILD, yet no MRI improvement,277 might indicate a mild pro-differentiation effect 
that can be better ‘unlocked’ by co-administration of metformin. CCMR Two is not 
designed to test these questions; the objective is to see if the remyelinating effect 
seen in animals translates into humans. Dissecting the different contributions of each 
drug and interrogating the possibility of synergy would require a much larger study, 
which would then demand a multi-centre design, which then poses a particular 
challenge to using electrophysiological outcome measures.358,450 Questions would 
also remain as to how to deploy a remyelination treatment, such as whether it should 
be given continuously or in short pulses. 
 
Finally, it should also be acknowledged that remyelination failure may not be entirely 
due to a block to OPC differentiation; recent evidence has suggested that pre-
existing oligodendrocytes can contribute to remyelination in humans237,238. 
Therefore, the effect of metformin and clemastine, which would only target the 
abovementioned endogenous OPC differentiation step, may not address 
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remyelination failure across a population of lesions, which may have heterogenous 
reasons for failing to repair. 
 
In spite of this, CCMR Two represents an important step towards identifying a 
treatment capable of directly protecting neurons from degeneration, outside of the 
indirect effects of immunomodulatory disease modifying treatments. Further, as 
these drugs are widely used and known to be safe, this approach could then be 
readily deployed in confirmatory and phase III trials. And, if no treatment effects are 
shown, we are confident that the trial will have legacies that will lead to 
improvements in trial design and outcome measures.  
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Chapter 6: Neuroprotective treatments for 
progressive MS 
 A systematic approach to selecting licensed drugs for 




Although substantial progress has been made in the development of effective 
treatments for relapsing-remitting MS, these disease modifying treatments do not 
address the multifaceted pathophysiological mechanisms of progression. The lack of 
success in therapeutic development for progressive MS has led to interest in novel 
approaches such as drug rescue and repurposing. Techniques are therefore 
required to enable rational selection from a wide range of candidates, in order to 
maximise the chance of successful clinical development. 
 
In this body of work, we sought to establish a rigorous, expert-led, evidence-based 
approach to the evaluation of licensed drugs for repurposing and testing in clinical 
trials of people with progressive multiple sclerosis. We long-listed licensed drugs with 
evidence of human safety, blood-brain barrier penetrance, and demonstrable 
efficacy in at least one animal model, or mechanistic target, agreed by a panel of 
experts and people with MS to be relevant to the pathogenesis of progression. I 
systematically reviewed the preclinical and clinical literature for each compound, 
condensed this into a database of summary documents, which were presented to the 
rest of the treatment selection panel for short-listing by scoring each one of them. 
Drugs were then evaluated for immediate use in a clinical trial, following which our 
selection was sent to be scrutinised by a final independent expert review.  
 
From a short list of 55 treatments, we recommended four treatments for immediate 
testing in progressive MS: R-α-lipoic acid, metformin, the combination treatment of 
 - 154 - 
R-α-lipoic acid and metformin, and niacin. We also prioritised clemastine, 
lamotrigine, oxcarbazepine, nimodipine and flunarizine.  
 
Contribution statement 
I was a member of the treatment selection group and worked alongside the rest of 
the panel in designing a process for shortlisting treatments. After the pilot stage of 
this process, I volunteered to take on a more active role, in particular addressing the 
heterogeneity in the levels of detail in the drug CVs, alongside the MS Society’s 
Kayla Vuong. I worked to create our prioritised list with the rest of the group and 
attended the meetings to ultimately formulate our final list. I was asked by the group 
to document our methodology: I wrote the first draft of the manuscript, compiled all of 
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Background 
 
The expanding repertoire of anti-inflammatory disease modifying treatments (DMTs) 
contrasts with a paucity of effective therapies for the 15% of people that present with 
progressive disability (primary progressive MS; PPMS), and indeed the 80% of 
RRMS patients who subsequently develop progression (secondary progressive MS; 
SPMS).191 While ocrelizumab and siponimod have shown modest benefits in phase 
III trials,24,25 most immunotherapies have failed in non-active progressive disease. 
Finding drugs to treat progression remains the greatest unmet need for people with 
MS. 
 
The reasons for the lack of an effective therapy for progressive MS are multifaceted. 
The pathophysiology of progressive MS is poorly understood (reviewed in 26), and 
there is no animal model that accurately mimics the entirety of the disease. So, new 
target and drug discovery are challenging. Drug repurposing is attractive, with fewer 
hurdles before reaching clinical trials, but the rationale behind drug selection needs 
to be carefully considered.451,452 
 
In 2011 the MS Society sponsored an initiative to choose licensed drugs to be 
trialled in secondary progressive MS.453 Only oral treatments with a putative action 
against neurodegeneration were considered. Highest priority was given to drugs that 
had been tested in MS, Alzheimer’s disease, motor neuron disease / amyotrophic-
lateral sclerosis, Parkinson’s disease and/or Huntington’s disease. Clinical and 
laboratory data from each drug were brought, in a standard template, to a panel 
composed of people with MS, and experts in animal models, disease biology, clinical 
trial design and systematic review. The final panel treatment selection was: riluzole, 
amiloride, fluoxetine, ibudilast, oxcarbazepine, pirfenidone and agents of the 
polyunsaturated fatty acid (PUFA) class (including lipoic acid). Of these, both 
ibudilast and lipoic acid have since shown efficacy in progressive MS in phase II 
trials.201,454 Meanwhile, the MS-secondary progressive multi-arm randomisation trial 
(MS SMART) tested riluzole, amiloride and fluoxetine versus placebo in 445 people 
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with SPMS.346 Unfortunately, no treatment effect on brain atrophy (percentage brain 
volume change) was seen over 2 years.119 
 
In 2018, the MS Society set up an expert consortium (Figure 6.1) to select 
treatments and design a new phase of drug trials in progressive MS utilising a novel 
adaptive methodology. I joined the treatment selection component of this consortium, 
with the objective of augmenting the previous strategy with an expert and 
mechanism-led approach. I worked with the rest of the panel to design a process for 
shortlisting treatments, which required our compiling a list of drugs of seminal 
interest, my preparing a database of summary documents for each, before we 




Pilot stage of treatment selection 
The original treatment selection group included 10 scientific members (specialist 
multiple sclerosis clinicians, laboratory scientists, people with experience of the 
pharmaceutical industry) and two people with MS. The latter were selected from the 
MS Society’s Research Network (RN): a group of people living with, or caring for, 
someone with MS.  
 
At the first meeting of the treatment selection group in January 2018 we agreed the 
following principles of treatment selection: the highest priority would be given to safe 
licensed drugs acting on pathological mechanisms thought to be relevant to 
progression in multiple sclerosis, including remyelination; to drugs which cross the 
blood-brain barrier; and those that had demonstrable efficacy in at least one relevant 
animal model. Experience of the drug’s use in MS or any other neurological illnesses 
was considered but did not weight treatment choice. Immunotherapies, such as B-
cell depleting drugs, were excluded, given the considerable industrial investment in 
this area. The agreed mechanistic areas were: (i) energy, blood flow and 
mitochondria; (ii) the neuron and axon; (iii) sodium channels; (iv) microglia and 
astroglia; (v) intrathecal B cells and plasma cells; (vi) demyelination and myelin 
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repair; and (vii) antioxidants. It was also agreed that the process of drug selection 
should be iterative, using a modified Delphi method, led by expert opinion within 
treatment selection group, while at each stage independent expert input would be 
sought. 
 
We then convened an international treatment selection workshop, held in London in 
April 2018. Leading experts from the research community gave a series of talks in 
each mechanistic area and were asked to suggest drugs for consideration. We also 
invited representatives of the Cure Parkinson’s Trust, the Alzheimer’s Society, Motor 
Neuron Disease Association, Parkinson’s UK, and Medicine Discovery Catapult 
(MDC), who had undertaken drug repurposing programmes within their own disease 
area.455,456 We resolved to draw up a template (a “drug CV”) for each compound 
based on the Cure Parkinson’s Trust linked clinical trials initiative dossier model. 
These documents included information on pharmacodynamics, pharmacokinetics, 
mechanism of action, and evidence-base in vitro, in vivo, and in clinical trials (Table 
6.1). This CV condensed and systematised the literature on each drug into an 
accessible summary manuscript; a drug CV for each potential treatment would be 
completed by at least 2 members of the treatment selection group.  
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Figure 6.1. Above Summary of the UK MS Society’s expert consortium for 
progressive MS clinical trials, which has been set up to test treatments in an 
adaptive platform trial, termed the efficient clinical trials platform. The treatment 
selection group and treatment advisory committee were responsible for formulating 
the prioritised list of drugs to enter the clinical trial. Below Flow chart of the 
procedures undertaken during the final round of treatment selection by the treatment 
selection element. *Drug CVs were completed by 4 members of the treatment 
selection group – 2 with a scientific background and 2 MS specialist clinicians. 
**Drugs failing to reach the short list of drugs on account of a low score, could be 
added back for consideration at the panel meeting if reasons were proposed by a 
member of the treatment selection group and its rescue approved by majority vote. 
MDC: medicines discovery catapult; PPI: patient and public involvement. 
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Table 6.1: Information recorded in the drug CV 
Summary information 
• Drug name 
• Regulatory status 
• Mechanistic target 
• Dose for human use (and appropriateness for MS) 
• Key safety concerns 
• Intellectual property 
• Outstanding critical issues 
• Overall evaluation  
Absorption, distribution, metabolism, excretion, pharmacokinetics and 
pharmacodynamics 
• Chemical structure 
• Molecular target 
• Pathway affected 
• Human pharmacodynamics 
• Human pharmacokinetics 
• Blood-brain barrier penetrance 
• Route of administration 
• Licenced indication 
• Dose for licenced indication 
• Dose suitability for MS 
• Known, or anticipated, drug-drug interactions 
Scientific rationale 
• Efficacy in in vitro models 
• Efficacy in in vivo models 
• Efficacy for primary indication 
• Efficacy in people with MS (if applicable) 
• Particular subgroups of people with MS likely to benefit (if applicable) 
Safety 
• Animal safety issues 
• Therapeutic ratio (if known) 
• Safety record in humans 
• Safety record in people with MS 
• Monitoring requirements 
• Any particular drug-drug interaction that would limit use in MS 
Landscape review 
• Is there active pre-clinical research on the use of this drug in MS? Where? 
• Has the Progressive MS Alliance prioritized this drug? 
• Are there any relevant trials listed on clinical trials databases? 
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There was then a call for suggestions for repurposed drugs to members of the 
committee, clinicians, experts from the wider MS research community, people with 
MS, and the public, via a web-based system that was advertised to the MS Society’s 
mailing lists. Contributors were prompted to describe the scientific rationale for their 
proposed intervention. After four months, the call was closed, a long list of drugs was 
compiled, and drug CVs completed for each. 
 
The scientific members of the committee scored each drug CV according to an 
agreed system prioritising safety and efficacy (Table 6.2A). Members of the MS 
Society’s research network also scored each drug, for ease of administration, 
tolerability, safety and monitoring requirements based on the drug CV and the 
European Medicines Agency’s (EMA) patient information leaflets (Table 6.2B). The 
scores were collated before a second face-to-face meeting. 
 
At this meeting, in September 2018, the treatment selection group (voting) members 
were joined by new members of the research community and research network 
(invited attendees), to provide a fresh perspective on the drug list. Each drug was 
presented, discussed, and given an overall score (between 0 lowest and 5 highest). 
The results were further reviewed and discussed, before all attendees ranked their 
top 5 drugs, which resulted in a list of seven prioritised drugs. 
 
In parallel to the pilot stage of treatment selection, the MS Society commissioned 
Medicines Discovery Catapult (MDC) to independently identify licensed drugs that 
might impact progressive MS. This was undertaken to scrutinise our long list of drugs 
which had been compiled through the aforementioned mechanism of drug proposals. 
MDC searched for all ongoing, or completed, trials in people with MS to identify 
drugs being tested for any type of MS. They then characterised their molecular 
targets and sought other compounds that were predicted to impact these targets. We 
pruned the list of immunotherapies and symptomatic drugs, as well as those that did 
not cross the blood-brain barrier, and any not on the original long list were added for 
consideration during the final stage of treatment selection. 
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Table 6.2: scoring system for shortlisting drug CVs 
A) For scientific members of the panel 
 
Safety – Are the safety data for the treatment satisfactory? To include any 
regulatory warnings, adverse events, drug-drug interactions, therapeutic index, 
and safety profile. (Score 0-2) 
Efficacy – Do we have sufficient evidence that the treatment is likely to be 
effective in slowing progression? To include in vitro and in vivo experimental 
models, blood-brain barrier penetration, along with human data where available. 
(Score 0-2) 
Overall evaluation - Priority level for the treatment (select one) 
a. Licensed drug, ready for a phase 2 trial in MS, high priority 
b. Licensed drug, ready for a phase 2 trial in MS, low priority 
c. Licensed drug, with critical issues to be resolved before a phase 2 trial in MS 
d. Interesting drug, with considerable pre-clinical work to be done 
e. Poor scientific rationale: not to be prioritised 
B) For research network members (people with MS) 
 
Administration – is the method of taking the drug acceptable? To consider 
whether it is a tablet, injection or infusion as well as how often it needs to be taken. 
(Score 0-2) 
Side effects and risks – is the safety of the drug acceptable? To consider both 
the immediate side effects and risks as well as the long term. (Score 0-2) 
Overall evaluation - Priority level (select one) 
a. I would take this drug even if it only moderately slowed the progression of my 
MS. 
b. I would take this drug if it stopped the progression of my MS. 
c. I would not take this drug even if it stopped the progression of my MS. 
 
 
Final stage of treatment selection 
The treatment selection group appointed new members, and some original members 
left, leaving 13 scientific and 6 research network members. A renewed call for drug 
proposals was opened, and the newly formed group reviewed any new suggested 
compounds, the original long list of drugs considered during the pilot stage, and 
those generated by Medicines Discovery Catapult, resulting in a new long list of 29 
drugs. Each of these had a drug CV compiled or updated by myself and another with 
a scientific or clinical background. Myself and the other 12 scientific members of the 
treatment selection group then scored each drug CV according to our simplified 
scoring system based on safety, efficacy and an overall assessment of priority 
(Table 6.2). Similarly, 6 research network (RN) members of the treatment selection 
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group and an additional 10 invited RN members scored between 5 and 10 of the 
drug CVs, with additional access to the EMA-approved patient information leaflet, 
such that at least 5 scores were recorded for each drug. The highest ranked 12 
drugs from the collated scores formed the shortlist for a third face-to-face meeting in 
September 2019 of the treatment selection group, alongside a new group of invited 
experts and people with MS.  
 
Members of the treatment selection group had the option to rescue a low scoring 
drug in advance of the meeting by presenting a case for its inclusion and it being 
accepted by majority vote. For the meeting, each drug was presented by one 
scientific and one research network member, who focussed on the scientific case 
and attractiveness to people with MS, respectively. Drugs were then scored out of 5 
and the resulting ranking discussed before each attendee individually ranked up to 5 
drugs that they felt ready for use in a clinical trial.  
 
External scrutiny of treatment selection 
The drug CVs of the treatments recommended by this meeting, and the two highest 
scoring drugs in the sodium channel antagonist class, were sent to 4 independent 
international MS experts outside the UK to achieve a further layer of scrutiny of the 
decisions and to elicit any information on the drugs that was not publicly available. 
Their comments were collated and considered alongside the outcome of the final 
treatment selection meeting by the Treatment Advisory Committee (Figure 6.1). This 
committee advised on the final drug selection for the MS Society’s Efficient Clinical 
Trials Platform, which is intended to evaluate repurposed treatments quickly and 
affordably. This committee comprised 6 scientific members and 3 people affected by 
MS. They assessed the prioritised list on the basis of scientific evidence, but also in 
the context of other trials known to be going ahead elsewhere. They also scrutinised 
drug mechanisms and whether the chosen trial design and outcome measures would 
allow detection of treatment effects.  This facilitated a final decision to be made for 
the drugs to be tested in a platform trial (Figure 6.1). 
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Results 
 
Pilot stage of treatment selection 
44 treatments were proposed during the 2018 call for drug suggestions, with at least 
one believed to act on each of the target mechanisms. 35 were deemed by the 
treatment selection group to have sufficient scientific rationale for consideration, and 
drug CVs were completed by myself and other scientific members. Each was then 
scored, prioritising considerations of efficacy and safety as detailed in Table 6.2, 
leading to a shortlist of 19 compounds to be discussed face-to-face in September 
2018. At that meeting, each drug was presented and discussed before being scored 
again, collated separately for the members of the treatment selection group (voting 
members) and the invited attendees (experts and people affected by MS) (Figure 
6.2).  After open discussion of these scores, the treatment selection group members 
ranked their preferred 7 drugs. 
 
During this pilot stage we learned that the drug CVs were effective, but needed more 
consistency in authorship to promote comparable levels of detail in each CV, with 
multiple contributors from different backgrounds to each to encourage impartiality in 
the presentation of the literature for each compound. We also reflected on the 
valuable contributions from people affected by MS, who were in a unique position to 
weigh the safety and tolerability of each drug and consider the level of benefit they 
would require to take the proposed treatment for their MS. The group resolved that 
more research network members should be invited onto the treatment selection 
group to maximise representation of different viewpoints from within the MS 
community and to share the burden of scoring CVs and presenting drugs at 
meetings beyond the 2 original members. 
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Figure 6.2. Outcome of the pilot screen of candidate interventions. Mean scores 
(out of 5) of each drug by voting members of the treatment selection group and 
invited attendees are displayed in descending order. Inset: the provisional list for 
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Final stage of treatment selection 
MDC identified 320 licensed drugs which had a mechanism similar to a drug that had 
been tried in multiple sclerosis.457 Once immunotherapies, drugs which did not cross 
the blood brain barrier and duplicates were removed, guanabenz and trazodone 
remained from this list. These were added to the 44 treatments that had emerged 
from the pilot phase. During the renewed call for proposals in 2019, new members of 
the treatment selection committee and outside experts contributed these new 
suggestions: domperidone, benztropine, prednisolone, ibudilast, spironolactone, 
oxcarbazepine, hydroxychloroquine, niacin and the combination of metformin and R- 
α-lipoic acid. This long list of 55 treatments was screened by the new treatment 
selection group, and 28 drugs and one combination therapy were chosen to have 
comprehensive drug CVs completed by myself and at least one other.  
 
12 scientific members of the group scored all 29 drug CVs and 16 research network 
(RN) members (6 of which were members of the treatment selection group) scored 
up to 10 of the drug CVs, with additional access to the EMA-approved patient 
information leaflet, such that 5 research network scores were recorded for each 
drug. The scientific scores were ranked and 13 drugs and 1 combination treatment 
(metformin and R-α-lipoic acid) were short-listed. If a scientific member disagreed 
with a drug excluded at this stage, they were able to make a case for its inclusion to 
the group and add to the shortlist by majority vote. Flunarizine and lamotrigine, which 
had initially been excluded from the list of 12 at the CV scoring stage, were re-added 
to the list in this way. 
 
The 14 shortlisted treatments were discussed and scored, one by one, at a face-to-
face meeting of the treatment selection group and invited attendees. The collated 
scores (Figure 6.3) were then discussed and debated before the treatment selection 
group ranked up to 5 drugs, which were ready for immediate use in a phase II clinical 
trial.  The final shortlist list of drugs were, in order of preference: R-α-lipoic acid, 
metformin, the combination treatment of R-α-lipoic acid and metformin, and 
clemastine. We considered that niacin, flunarizine, and nimodipine were particularly 
promising, but the treatment selection group felt they needed more pre-clinical work. 
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Figure 6.3. Outcome of the final meeting of the treatment selection group 
during the final stage of candidate screening. The mean scores (out of 5) for the 
14 shortlisted compounds presented at the meeting are divided into those awarded 
by voting members of the panel and invited attendees. 
 
This selection, in addition to the 2 highest scoring sodium channel antagonist drugs 
(lamotrigine and oxcarbazepine), were sent to 4 independent expert reviewers. They 
scored each compound on safety and efficacy and ranked the drugs by priority level. 
They were also asked to provide information on any of these drugs that was not 
publicly accessible. The results of this procedure were considered by the Treatment 
Advisory Committee of the MS Society’s Efficient Clinical Trials Platform (Figure 6.1), 
and a final order of prioritisation was made (Table 6.3). The top 4 were 
recommended as the most promising for clinical evaluation. The pathway of each 
drug through these procedures is summarised in Figure 6.4. 
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Final list of drugs for 
prioritisation 
Mechanism of action 
1. R-α-lipoic acida  Dietary supplement, approved in Germany for 
diabetic neuropathy; anti-oxidant, anti-inflammatory, 
and neuroprotective454,458,459 
2. Metforminb Anti-hyperglycaemic agent used for type 2 diabetes 
mellitus; anti-inflammatory440 and promotes 
remyelination100 and neuroprotection460 
3. R-α-lipoic acid 
and metformin 
combination 
Mechanisms as above; complimentary mechanistic 
targets and neuroprotective in combination461 
4. Niacinc Anti-hypercholesterolaemic drug; promotes 
oligodendrocyte proliferation,462 remyelination,423 and 
neuroprotection463 
5. Clemastine Antihistamine used for allergic rhinitis; off-target 
anti-muscarinic (M1) action which promotes 
oligodendrocyte progenitor differentiation and 
remyelination246,277 
6. Lamotrigine Sodium channel antagonist widely used as an 
anticonvulsant; neuroprotective effects464 
7. Oxcarbazepine Sodium channel antagonist widely used as an 
anticonvulsant;; neuroprotective effects465 
8. Nimodipine Calcium channel antagonist used to treat 
vasospasm in subarachnoid haemorrhage; promotes 
remyelination, neuroprotection,466 and restores CNS 
perfusion and oxygenation467 
9. Flunarizine Migraine prophylactic; neuroprotective effects468 
 
Table 6.3. Final recommendations of repurposed interventions for clinical 
testing in progressive MS. The top 4 were determined to be the most promising for 
clinical evaluation. a1200 mg/day, b1 gram twice daily, starting at 500mg twice daily, 
c750mg twice daily of slow release formulation of Niaspan. 
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Figure 6.4. Summary of the pathway of each drug through the treatment 
selection process to yield a final prioritised list of drugs.  
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Discussion 
 
The pathogenesis of progressive MS is complex, multifaceted and poorly 
understood. As with many other neurodegenerative diseases, there are no licensed 
treatments. This remains the greatest unmet need for the more than 2.3 million 
people affected by MS globally.469 Placed in context of the high cost, long time, and 
high attrition rate from target selection to regulatory approval via conventional 
pathways, there are compelling reasons to explore opportunities provided by drug 
repurposing. This nevertheless presents a substantial challenge. The myriad 
reasons for the prior failure to find an effective treatment remain,26 and the optimum 
process for selection of drugs to progress to repurposing clinical trials are not 
standardised. Procedures for synthesising experimental and clinical trial data to 
enable rational drug selection are required to maximise the chance of successful 
clinical development. 
 
The UK MS Society Clinical Trials Network was initiated in 2007 and commissioned 
key underpinning work including a review of animal and human data on promising 
drugs. Given the mechanistic overlap between SPMS and other neurodegenerative 
disorders (namely Alzheimer’s disease, Parkinson’s disease, Huntington’s disease 
and amyotrophic lateral sclerosis), their strategy centred on a systematic review and 
meta-analysis of clinical and preclinical data for agents previously tested in these 
illnesses.453 The ensuing list prioritised ibudilast, riluzole, amiloride, fluoxetine, 
pirfenidone, oxcarbazepine and agents of the polyunsaturated fatty-acid (PUFA) 
class. Ibudilast and lipoic acid proved successful at phase II,201,454 but unfortunately 
riluzole, amiloride and fluoxetine did not reduce brain atrophy in the MS-SMART 
study compared to placebo.119  
 
The MS Society’s ambition in setting up its expert consortium (Figure 6.1) is 
ultimately to deliver a platform trial capable of testing multiple drugs at the same time 
(as with MS-SMART), across thousands of people with MS (as with MS-STAT2), 
with an adaptive method allowing switching participants between drugs if efficacy is 
not demonstrated. The treatment selection group, to which I contributed as outlined 
 - 170 - 
here, was tasked with identifying the most promising treatments to go into the trial 
first. In parallel the trial design and delivery component have been independently 
designing the trial and setting up its infrastructure. All of these contributions will 
ultimately converge on the multi-arm adaptive trial, which will be led by Professor 
Jeremy Chataway; the MS Society recently announced the Optimal Clinical Trials 
Platform for Progressive Multiple Sclerosis (OCTOPUS). 
 
Here I describe the rigorous, expert-led, evidence-based approach we took to the 
selection of licensed compounds for repurposing in clinical trials of people with 
progressive forms of MS, led by scientific and clinical experts as well as people with 
MS, involving repeated rounds of assessment, scoring, and independent peer 
review. We identified key biological mechanisms, performed an exhaustive literature 
search on identified drugs, and went through two cycles of shortlisting and 
prioritisation. We selected this strategy to retain the evidence-based approach of 
previous mechanisms of drug selection, but with added emphasis on expert opinion 
and independent expert review which, in our view, would enable our selection to be 
based on current scientific opinion and more readily identify barriers and knowledge 
gaps that might affect trials of the proposed compounds. A particular contrast 
between our strategy and that previously used was that we did not prioritise agents 
that had previously been subject of clinical trials of people with neurodegenerative 
illnesses and we required all candidates to have evidence of blood-brain barrier 
permeability. Other differences are summarised in Table 6.4.  
 
It is noteworthy that our first ranked drug, lipoic acid, was also prioritised in the 2011 
drug selection initiative, despite the contrasting methodologies. Three interventions – 
R-α-lipoic acid (R-ALA), metformin and niacin – and one combination preparation – 
of metformin and R-α-lipoic acid – were identified as being priorities for clinical 
evaluation in cohorts of people with progressive MS, and as having sufficient data to 
permit immediate entry into a phase II trial. Clemastine, lamotrigine, oxcarbazepine, 
nimodipine and flunarizine were also felt to be promising and ranked in order of 
priority. 
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R-α-lipoic acid is the R-enantiomer that makes up 50% of the racemic mixture (R 
and S) of lipoic acid, a dietary supplement approved in Germany for the treatment of 
diabetic neuropathies. It has previously been shown to be a potent antioxidant, have 
anti-inflammatory properties,470,471 and reduce excitotoxic damage;472 while the R 
enantiomer has superior pharmacokinetic, antioxidant and neuroprotective properties 
than the S enantiomer.473 When given to 51 people with SPMS, it was shown to have 
a small benefit to brain atrophy.454,474  
 
Metformin, a biguanide licensed for human use in type 2 diabetes, has previously 
been demonstrated to reduce inflammation in progressive and relapsing 
experimental autoimmune encephalomyelitis models,440 is neuroprotective in models 
of glucose deprivation/reoxygenation460 and, more recently, has been shown to 
reverse an age-associated barrier to the ability of oligodendrocyte progenitor cells to 
respond to differentiation factors and facilitate subsequent remyelination.100 
Additionally, it has previously been used in 20 people with MS, and demonstrated a 
reduction in the number of new or enlarging T2 lesions compared to placebo.441 The 
complimentary mechanistic targets of metformin and R-ALA, as well as the potential 
for synergy,461 led to the combination of the two featuring on our prioritised list. 
 
Niacin, a nicotinamide adenine dinucleotide (NAD) precursor in use for the treatment 
of hypercholesterolaemia, has previously been shown to be protective against 
activated microglial-induced neurotoxicity463 and to promote oligodendrocyte 
proliferation in vitro.462 In line with these observations, it reduces axonal 
degeneration, delays progression, and increases oligodendrocyte proliferation in 
extrinsic allergic encephalomyelitis.462,463 While ranked below clemastine by the 
treatment selection group, data that was unpublished at the time came to light during 
the treatment advisory committee review: niacin also enhances myelin phagocytosis 
by microglia, leading to increases in oligodendrocyte progenitor cell numbers and 
improved remyelination in mice.423 Niacin has not yet been trialled in people with 
multiple sclerosis. 
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A particular strength of this methodology was the multiple layers of revision and 
review. By undertaking a pilot of treatment selection, we refined the procedures by 
which we evaluated the literature and assessed each compound to facilitate robust 
comparisons of agents with disparate mechanistic targets and safety profiles. We 
also ratified our procedures for drug identification by the work of Medicines 
Discovery Catapult, which generated a list of drugs of which only 2 had not 
previously been identified. Finally, by sending our list of prioritised treatments for 
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 2011 2019 
Method of drug 
identification 
Thorough and systematic search 
of online databases (PubMed, ISI 
Web of Knowledge, Embase, 
Clinicaltrials.gov, Cochrane MS 
group)  
Calls for recommendations from 
academics, clinicians, and people 
with MS. 
Systematic search of online 
databases by medicines discovery 
catapult 
Previous clinical trial 
use 
Previously used in a 
neurodegenerative disease 
including progressive MS, PD, 
HD, AD, and ALS. 
Human safety data required only 
Mechanistic targets Excluded immunosuppressant 
mechanism of action. 
Combination treatments 
excluded. 
Priority given to candidates 
targeting several mechanistic 
targets. 
Excluded those with solely 
immunosuppressant mechanism. 
Combination treatments accepted 
Method of 
administration 
Oral Any method of administration 
CNS penetration Reviewed at selection meeting Evidence of BBB permeability 
required at study entry 
Safety Excluded those with significant 
adverse effects associated with 
treatment. 
Excluded those with significant 
adverse effects associated with 
treatment. 
Method of selection Systematic evaluation of 
publications pertaining to each 
candidate. 
Systematic review of 
experimental autoimmune 
encephalomyelitis (EAE) 
preclinical data for each 
candidate. 
Scrutiny of each drug by an 
international multi-disciplinary 
committee 
Systematic evaluation of preclinical 
and clinical publications pertaining 
to each candidate. 
Formation of a database of drug 
CVs. 
Rating of these by scientific panel. 
Presentation and decision at 
international multi-disciplinary 
meeting 
Input from people 
affected by MS 
Patient representatives acting as 
external advisors 
6 members of MS research 
network on voting panel. 
Scoring of drug CVs by at least 5 
people with, or affected by, MS. 
Members of MS research network 
at treatment selection meeting. 
Peer review External advisors with a range of 
expertise including animal 
models, disease biology, clinical 
trial design, systematic review 
and patient representation. 
Methodology and final treatment 
selection sent for external peer 
review 
Table 6.4. Comparison between the current methodology and that previously 
used in 2011;453 MS, multiple sclerosis; AD, Alzheimer’s disease; ALS, amyotrophic-
lateral sclerosis; PD, Parkinson’s disease; HD, Huntington’s disease; BBB, blood-
brain barrier. 
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Chapter 7: The factors affecting interventional trial 
recruitment during the first wave of the SARS-CoV-2 




During the first wave of the coronavirus 2019 (COVID-19) pandemic, I volunteered to 
join a multidisciplinary group from the University of Cambridge to rapidly set up, and 
subsequently recruit participants to, interventional trials (particularly the RECOVERY 
trial). During this time, I led a research project to analyse enrolment to treatment 
trials, to describe the barriers to and implications of, low recruitment rates ahead of 
further waves.  
 
I led a prospective observational study of hospitalised patients with COVID-19 who 
were being assessed for eligibility to one of the RECOVERY, C19-ACS or SIMPLE 
trials across 5 centres in a respiratory NIHR network. In parallel, I analysed 
registered interventional COVID-19 trial data from the clinicaltrials.gov and ISRCTN 
databases on July 12, 2020 and combined these with population and modelling data 
taken from published reports from the UK government and MRC biostatistics unit. 
 
2,082 consecutive admitted patients with laboratory-confirmed SARS-CoV-2 
infection from March 27, 2020 were included in the cohort study. 430 (20.7%) 
proceeded to randomisation in one of the aforementioned trials. 82 (3.9%) declined 
participation, 699 (33.6%) were excluded on clinical grounds, 363 (17.4%) were 
medically fit for discharge, 153 (7.3%) were receiving palliative care and 153 (6.6%) 
lacked capacity. Analysis of trial registration data for COVID-19 treatment studies 
enrolling in England showed that by July 12, 2020, 29,142 participants were needed. 
With 111,037 people hospitalised with COVID-19 in England by that date, we 
determined that 22,985 people were potentially suitable for trial enrolment. We 
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estimated a UK hospitalisation rate of 2.38%, and that another 1.25 million infections 
would be required to meet recruitment targets of trials on going at that time. 
 
We concluded that recruitment rates, study design, and proliferation of trials can limit 
the number, and size, that will successfully complete recruitment. We considered 
that fewer, more appropriately designed trials, prioritising cooperation between 
centres would maximise productivity in a further wave. 
 
Contribution statement 
While working for the Cambridge COVID-19 clinical research team, I led this study of 
trial recruitment across the five centres; I collected the data from Addenbrooke’s and 
collated it with that from the others. I additionally analysed the trial registry data and 
built a collaboration with Dr Villar of Medical Research Council (MRC) Biostatistics 
Unit to strengthen our assessment of the gaps between the trial community’s 
aspirations and delivery. I wrote the first draft of the trial manuscript, marshalled all of 
the comments/edits from the authorship, and submitted this for publication. 
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Background 
 
One of the greatest needs for coronavirus disease 2019 (COVID-19), outside of a 
successful vaccination programme, is effective treatments. Ostensibly, the early 
response from the experimental medicine community to the first wave was robust, 
with more than 1,970 clinical trials planned, recruiting, or completed, at the time of 
undertaking this project in July 2020;475 this has risen to 2478 at the time of writing in 
January 2021. This enabled enrolment of patients to trials of drugs with known safety 
profiles – including lopinavir,476 remdesivir,477-479 hydroxychloroquine480,481 and 
tocilizumab482,483. The Randomised Evaluation of COVID-19 Therapy (RECOVERY) 
trial has been particularly effective in the UK, having demonstrated a 12.1% absolute 
risk reduction in mortality among ventilated patients treated with dexamethasone,484 
and a further reduction in mortality afforded by treatment with tocilizumab (preprint 
result at 485). It has additionally provided conclusive negative results, with no clinical 
benefits of lopinavir,486 hydroxychloroquine487 and azithromycin.488  
 
However, while many of these trials have been pragmatic in terms of selection 
criteria, the proportion of hospitalised COVID-19 patients being recruited to clinical 
trials is lower than might have been anticipated; the authors of the RECOVERY trial 
estimated a 10% recruitment rate in the UK in April 2020.489 Meanwhile, in areas 
where public health measures limited viral transmission, trials terminated early on 
account of under recruitment.490,491 With mounting concern about an ensuing second 
wave of infection in the summer of 2020,492,493 it was increasingly important to learn 
lessons from the first, and consider the number, size, and design of clinical trials that 
could feasibly be completed. 
 
We hypothesised that the proliferation of SARS-CoV-2 interventional studies during 
the pandemic and under recognised barriers to recruitment of COVID-19 patients led 
to unachievable recruitment targets in England. I used data from clinical trial registry 
databases to quantify recruitment targets and concurrently studied recruitment rates, 
including reasons for exclusion, across 5 centres enrolling patients at the peak of the 
first wave of the pandemic. In conjunction with publicly available data from the UK 
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government, I considered the differences between the trials community’s aspirations 




Establishing recruitment targets for registered trials during first wave 
COVID-19 clinical studies registered on clinicaltrials.gov or the International 
Standard Randomized Controlled Trial Number (ISRCTN) databases were identified, 
and study data downloaded on July 12, 2020. Data for trials based in England, 
multinational trials with centres in England, and global trials were extracted in turn. 
Cross-registered studies were identified and accounted for once in the analysis. A 
manual review determined whether sponsors were academic, non-academic or 
mixed. Trials were excluded if they were labelled as terminated, withdrawn or 
suspended. Data for interventional trials examining treatment and prevention were 
documented, but only trials of COVID-19 treatments were used in the analysis. 
Analyses were performed using RStudio Version 1.2.5042. 
 
Observational study of recruitment of hospitalised patients 
We performed a prospective observational study of 2,082 consecutive patients with 
SARS-CoV-2 infection at 5 hospitals affiliated to the NIHR-Translational Research 
Collaboration with representation from secondary and tertiary centres: Cambridge 
University Hospitals NHS Foundation Trust (CUHFT), Cambridge; Imperial College 
Healthcare, University College Hospital and King’s College Hospitals, London; and 
University Hospital of North Tees, Middlesbrough. Subjects were admitted and 
eligibility assessed for: RECOVERY (ISRCTN50189673), C19-ACS (NCT04333407) 
or SIMPLE (NCT04292730/NCT04292899). CUHFT local R&D approval was 
undertaken. 
 
Demographic and clinical data were collected by contemporaneous review of 
potential participants’ case notes. A categorical approach subdivided primary 
reasons subjects were not enrolled into: (a) clinical grounds (the screening or 
treating physician judgement that comorbidity or other reason for admission was 
 - 178 - 
more critical to patient outcome than COVID-19), (b) being medically fit for 
discharge, (c) receiving end of life care, (d) lack of capacity, (e) patient refusal, (f) 
interactions between pre-existing medications and trial drugs, or (g) being on 
mechanical ventilation. Though already being on mechanical intervention was not an 
exclusion criterion for RECOVERY, patients categorised as excluded on these 
grounds were ineligible on account of competing, intensive care-based, studies. 
 
Establishing feasible recruitment for registered trials during first wave 
Using publicly available UK government data of the numbers of patients with COVID-
19 admitted to English hospitals during the first wave between March 17 and August 
5, 2020,494 and the recruitment rate (with 95% confidence interval (CI) for one 
sample proportion with continuity correction) from the aforementioned observational 
study, we estimated a maximum bound for the accumulated feasible recruitment 
during that time. Simultaneously, we used the estimated cumulative number of 
infected cases in England by 12 July provided by MRC Biostatistics Unit at the 
University of Cambridge495 to calculate an approximate hospitalisation rate in 
England among COVID-19 infections. We based our estimates on data from centres 
in England as the infection rate estimates were more reliable, hospitalisation criteria 





Establishing recruitment targets to registered trials during first wave 
Clinical trial registry data were downloaded on July 12, 2020; 28 interventional 
studies were included in our analysis of those registered in England. 22 (78%) were 
academically sponsored, 5 (18%) were non-academically sponsored and 1 (4%) was 
mixed. The first registration date of a COVID-19 treatment trial in England was 
March 22; the earliest registered start date was March 12. Analysis of recruitment 
targets for each trial revealed that 46,154 participants would have been required to 
complete recruitment to all studies in England: 17,012 people required for trials of 
prophylactic drugs to prevent COVID-19, while 29,142 were needed for those 
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treating established COVID-19 (Table 7.1). The median (IQR) treatment trial 
recruitment target was 195 (50-793). 
 
 




Global Trials   
Prevention 172 260,446 
Treatment 935 306,426 
Total 1,107 566,872 
UK Multi-National and 
National Trials  
  
Prevention 11 97,272 
Treatment 38 44,362 
Total 49 141,634 
England Trials    
Prevention 8 17,012 
Treatment 20 29,142 
Total 28 46,154 
Table 7.1. Summary of number of trials and required numbers of participants 
by July 12, 2020. 
 
By contrast, the global situation was such that 1,107 registered interventional trials 
were ongoing or completed, requiring 566,872 patients to be randomised to allow 
their completion; 306,426 of these were needed for trials of COVID-19 treatments 
(Figure 7.1A and 7.1B). These trials were geographically clustered in China, North 
America and Europe (Figure 7.1C).  
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Figure 7.1. The proliferation of global clinical trials in response to COVID-19. A: 
cumulative number of enrolling studies registered with clinicaltrials.gov or ISRCTN 
until Jul 12, 2020, subdivided by those testing drugs for COVID-19 treatment and 
prevention. B: cumulative number of participants required to meet recruitment targets 
for registered clinical trials. C: geographical distribution of COVID-19 clinical trials. 
 
Observational study of recruitment of hospitalised patients 
From March 27 to May 22, 2020 a total of 2,082 consecutive patients were included 
across the 5 sites (Table 7.2). Age and sex data were available for 1,971 patients: 
the median (IQR) age was 71 (58-82) and 56.2% were male. Across the four trials, 
430 (20.7%; 95% CI 18.95%, 22.47%) proceeded to randomisation.  
 
Of the remaining 1,652 patients, 82 (3.9%) declined participation, 363 (17.4%) were 
medically fit for discharge, 153 (7.3%) were receiving end of life care and 106 (5.1%) 
were mechanically ventilated at the time of screening. In 699 (33.6%) patients, the 
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screening or treating physician determined that the potential participant should not 








Total screened per 
centre  
281 83 415 Total 
(779) 
445 784 74 2,082 
Number recruited 
(%) 














10 (3.6) 19 
(22.9) 




83 (29.5) 15 
(18.1) 










Lacked capacity (%) 22 (7.8) 0 (0.0) 1 (0.2) 23 (3.0) 16 (3.6) 98 
(12.5) 




37 (13.2) 7 (8.4) 0 (0.0) 44 (5.6) 7 (1.6) 48 (6.1) 7 (9.5) 106 
(5.1) 
Drug interactions (%) 12 (4.3) 2 (2.4) 0 (0.0) 14 (1.8) 2 (0.4) 1 (0.1) 0 (0.0) 17 
(0.8) 
Medically fit for 
discharge (%) 


















8 (1.8) 51 (6.5) 7 (9.5) 153 
(7.3) 
Not approached or 
considered (%) 
8 (2.8) 3 (3.6) 35 (8.4) 46 (5.9) 48 
(10.8) 
0 (0.0) 1 (1.4) 95 
(4.6) 


















Table 7.2. Screening data for 2,082 consecutive patients with laboratory-
confirmed SARS-CoV-2 admitted to one of 5 centres. *centre screened 
concurrently to both RECOVERY and SIMPLE: moderate and severe trials 
 
 
Establishing feasible recruitment for registered trials during first wave 
By combining these observed recruitment rates with publicly reported hospitalisation 
data (between March 17, and July 12, 2020), we estimated a maximum upper bound 
for the accumulated feasible recruitment for registered trials of COVID-19 treatments 
in England during the first wave (Figure 7.2).  
 
The estimated number of cumulative infected cases by 12 July reported by MRC 
Biostatistics Unit was 4.67 million with a 95% credible interval (3.76, 6.04). 
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Combined with the number of cumulative admitted patients in England by 12 July 
from government data (i.e. 111,037 hospital admissions), this gave an approximate 




Figure 7.2. Feasibility of achieving target recruitment in England for COVID-19 
interventional studies. A: cumulative number of enrolling studies in England 
registered with clinicaltrials.gov or ISRCTN until July 12, 2020, subdivided by those 
testing drugs for COVID-19 treatment and prevention. B: cumulative number of 
participants required to meet recruitment targets for registered COVID-19 treatment 
trials until July 12, 2020, and predicted number of patients whom would have been 
eligible for randomisation (grey shaded area represents point-wise 95% confidence 
band for the predictive cumulative number of eligible patients using the lower and 
upper value of 95% confidence interval for the recruitment rate estimate with 
continuity correction). The reduction in the infection rate in England meant that the 
recruitment target at July 12 was unlikely to be reached without a second wave; 
further illustrated by extending hospitalisation data to August 5, 2020. 
 
This analysis indicated that by July 12th, 6,158 patients might still be needed to meet 
the total recruitment targets for currently recruiting clinical trials. If considering 
uncertainty in recruitment rate estimate reflected by 95% CI (18.95%, 22.47%), 
4,192-8,100 patients might be required to meet recruitment target. Assuming the 
recruitment rate 20.7%, this implies that 29,749 hospitalised patients would need to 
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be screened for these trials to complete recruitment. With the approximate 
hospitalisation rate 2.38% in England as observed in the first wave, this would 
require a further 1.249 million patients to be infected.  
 
With the daily infection rate for UK estimated to be 3,310 (95% credible interval  of 
2440, 4460) on 12 July,495 it was highly unlikely such a large number of 
hospitalisations would occur without an increase in the infection numbers as seen in 
the second wave. Indeed, incorporating hospitalisation data to August 5, 2020, 
showed minimal progress toward the recruitment target, even assuming no new trials 




This study found that the proliferation of clinical trials475 in response to the first wave 
of the COVID-19 pandemic in England required 29,142 participants to complete 
enrolment to those registered with a trials database. Globally, 306,426 participants 
were required to meet recruitment targets for trials of treatments of COVID-19. 
Meanwhile, in this multicentre prospective observational cohort study of patients 
admitted to hospital with laboratory-confirmed COVID-19, 79.3% of potential 
participants were not recruited to a clinical trial; the reasons for excluding patients 
were varied and clarify the challenges faced in both general hospitals and well-
resourced centres experienced in experimental medicine. This experience was 
consistent with the general literature on clinical trial recruitment where many factors 
have been posited to contribute to heterogeneity of recruitment.496 With 111,037 
people hospitalised in England between March 17 and July 12, 2020, the net 
recruitment rate suggested that 22,985 (21,042-24,950 if taking into account 
uncertainty in recruitment rate estimate by random errors) would have been 
potentially suitable for selection in the first wave.  However, this is clearly an 
overestimate, given that it would require each of these individuals to be hospitalised 
in geographical locations where medical centres were undertaking these trials. We 
concluded that unless there were a second wave it would be highly unlikely that the 
total recruitment target will be met in any reasonable timeframe. 
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Strengths of my study were that the analyses of registry and population databases 
utilised the largest and most robust data available. Meanwhile, my observational 
study applied a large cohort size, prospective data acquisition, and recorded detailed 
reasons for excluding patients. By using both secondary and tertiary care centres, 
we concluded our results were generalisable to other hospitals in the UK. Also, by 
following studies with minimal selection criteria, particularly in the RECOVERY trial, 
we reduced the chance of underestimating trial recruitment. 
 
The study did have limitations, however. First, the predictions were based on registry 
data for studies based in England alone; we did not include the numbers of 
participants required to be recruited into multinational trials in which the English 
centres were involved. The result is that we likely underestimated the trial 
recruitment target for England and, by extension, the gap between this and the 
number of participants available. Second, although we used hospitalisation data from 
17 March 2020, as this was the time the UK government commenced public 
reporting of COVID-19 admissions, all trials included in the registry analysis were not 
recruiting at that stage; the earliest start date for a trial registered in England was 
March 12, 2020, but the last trial start date was not until July 7, 2020. In this sense, 
using cumulative number of admitted patients in our prediction was optimistic. Third, 
we only included the two registry datasets in most widespread use, and so may have 
further underestimated the number of studies and participants required.  Fourth, the 
95% CI for recruitment rate estimate only reflects the uncertainty due to random 
errors in the data, it does not consider the uncertainty due to unrepresentativeness 
of data from the 5 hospital centres in our study. Finally, although I illustrated the 
scale of trial recruitment required globally, the populations tested may not be 
representative of, or translatable to, international cohorts. 
 
This study was the first to characterise the suitability and barriers for trial enrolment 
for a complete cohort of hospitalised patients with COVID-19. Results of trials 
published to the point of publication had conveyed a different message: 
interventional studies of lopinavir and remdesivir, for example, had recruitment rates 
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ranging from 55.7%-96.0%.476-478 This difference is most likely explained by the 
different denominators used in our calculations: the CONSORT diagrams in clinical 
trials are unlikely to include every single patient hospitalised with a positive test. 
Instead, our results align with or exceed other centres, such as the 10% recruitment 
rate to RECOVERY.489 During the 2013-16 Ebola Virus Disease (EVD) epidemic in 
west Africa, most clinical trials during that crisis either started too late to enrol 
sufficient case numbers or were simply unable to reach their recruitment targets.497 
This study showed that trials in England started recruiting relatively quickly, however 
many were highly unlikely to recruit on time; we concluded that starting early is 
important but not enough to ensure recruitment targets are met. Finally, it is notable 
that our calculated hospitalisation rate of 2.38% is lower than that observed in 
Wuhan,498 which if applied to the UK age structure,499 is equivalent to approximately 
5.8%. 
 
The disparity between the realistic recruitment rates and high requirements we 
reported led us to conclude that the scientific community should be increasingly 
selective in the number, size and design of clinical trials deployed in the COVID-19 
pandemic; our findings had meaning for those planning single trials, and those 
strategizing the national response. Potential solutions include practical changes to 
trial design, for instance capturing patients earlier in their disease path, and adopting 
dynamic and adaptive trial designs.500 Yet, such measures seemed unlikely to bridge 
the estimated large recruitment gap. Instead, we concluded it may be necessary for 
healthcare authorities and policy makers to foster more academic cooperation to 
prioritise compounds, prevent duplication and, perhaps more radically, perform real-
time meta-analyses of ongoing trials of the same therapies and provide stop/go 
recommendations across trials to rationalise treatment and prevent multiple studies 
delaying reporting.501 Indeed, proposals had been forthcoming for mechanisms by 
which data from different trials might be shared and analysed in a robust and 
scientifically meaningful way.502 These conclusions are not dissimilar to reflections 
from the Ebola pandemic, when there was a strong call for strengthening and 
coordinating research efforts in response to outbreaks of emerging infectious 
diseases.503,504 For planning future trials and deriving realistic recruitment targets, 
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real-time tracking of the pandemic, as data accumulate over time, is essential to plan 
research in response of an emerging epidemics outbreak. The Medical Research 
Council (MRC) Biostatistics Unit regularly report and forecast COVID-19 infections 
and deaths.495 This information feeds directly to SAGE sub-group, Scientific 
Pandemic Influenza sub-group on Modelling (SPI-M) and to regional PHE teams. 
This same data could be used to establish realistic recruitment trends to inform, 
monitor and coordinate research efforts both for treatment and prevention trials.  
 
Our primary conclusion was that clinical trialists and healthcare authorities must 
consider the recruitment challenges when determining the feasibility of clinical trials 
in a second wave, while urgently rationalising those currently active. At the time of 
publishing this study, it remained unclear how relaxing of non-pharmacological 
interventions would affect transmission rates, and therefore the achievability of 
remaining recruitment to these trials. Of course, the ensuing waves of COVID-19 led 
to markedly increased hospitalisation rates. Applying the same methodology with 
hospitalisation and trial registry data up to Feb 01, 2021 (Figure 7.3), it is possible to 
see how the magnitude of the subsequent waves in England led to large numbers of 
potential participants, perhaps sufficient to meet recruitment demands. However, it 
remains noteworthy that the most successful studies in this pandemic have been 
those undertaken by collaborative initiatives. Special attention must be given to 
these successful studies, so that trial policies can be developed to prepare for future 
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Figure 7.3. How subsequent waves of COVID-19 have affected the gap between 
target and predicted clinical trial recruitment in England. A: cumulative number 
of enrolling studies in England registered with clinicaltrials.gov or ISRCTN until Feb 
01, 2021, subdivided by those testing drugs for COVID-19 treatment and prevention. 
B: cumulative number of participants required to meet recruitment targets for 
registered COVID-19 treatment trials until Feb 01, 2021, and predicted number of 
patients who would have been eligible for randomisation. 
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Chapter 8: Conclusions and future plans 
 
Currently available disease modifying treatments for multiple sclerosis are, 
predominantly, immune modulatory and do not directly promote repair. However, the 
treatment of MS has arrived at a new and exciting juncture in which a myriad of 
medications, both novel and repurposed, are being evaluated on their ability to elicit 
repair of myelin, and thereby reduce disability accrual. Our work with bexarotene 
has, for the first time with converging evidence from electrophysiology and MRI, 
shown that a small-molecule drug can therapeutically enhance remyelination in 
people with relapsing remitting multiple sclerosis. While the side effect profile of 
bexarotene will preclude its further testing in people with MS, CCMR One has 
highlighted a druggable pathway that might be more selectively targeted to achieve 
its therapeutic effect without the breadth of adverse effects we observed. It has also 
emphasised the sensitivity of electrophysiological assessments of the visual pathway 
to detect remyelination, and it has highlighted regional variations in the 
responsiveness of MS lesions to a putative remyelinating drug. An additional 
learning, elaborated in this thesis, has been the reduced responsiveness of older 
individuals to bexarotene. This final point is particularly pertinent given recent 
research has identified interventions with the potential to reverse the hallmarks of 
ageing in oligodendrocyte progenitor cells, by, for example, rejuvenating drugs like 
metformin and niacin. These lessons have featured strongly in our approach to 
CCMR Two, in which our therapeutic strategy is to combine a pro-differentiation drug 
(clemastine) alongside a rejuvenating drug (metformin), with the implementation of a 
trial design that we believe will be able to detect the structural and functional 
consequences of remyelination in a, comparatively small, single-centre study. 
 
Of course, there exist several unresolved questions and potential limitations with 
such a therapeutic strategy. In particular, it remains unclear whether remyelination 
failure can be adequately resolved in humans by reversing the block to OPC 
differentiation, and there is uncertainty around what amount of remyelination would 
be clinically meaningful. Inevitably, clarification will also be needed on how a clinician 
should deploy a remyelinating drug, once a safe and efficacious one is identified. But 
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ultimately, the pathological processes that drive the accrual of disability in 
progressive forms of MS are multifaceted, and an approach outside of exclusively 
enhancing remyelination – for example one that targets remyelination alongside 
other mechanisms – may emerge. Optimism about such a method was exemplified 
during my work with the treatment selection group in which 2 of the 3 repurposed 
drugs chosen by the panel (metformin and niacin) were primarily remyelinating, but 
had additional effects on other targets thought relevant to the pathobiology of 
progression. Seeing these drugs evaluated in the MS Society’s new phase of drug 
trials in progressive MS, with a range of outcome measures sensitive to both 
remyelination and neurodegeneration, will be one of the most exciting events in MS 
clinical research over the coming years. 
 
It has been a disappointment that the COVID-19 pandemic significantly limited my 
clinical research, in particular by preventing any recruitment of patients to 
observational clinical studies (which, being within level 3 of the NIHR recovery 
strategy, have not been permitted to recruit participants in Cambridge since March 
2020). I am, however, pleased to have been able to work to contribute to the 
successes of the RECOVERY trial, and to have been able to lead an important 
research project to document the barriers to trial recruitment during the first wave of 
the pandemic. I am additionally thankful to have been still able to conduct my CCMR 
One recall study, which, even with the limited time available, highlighted the 
reproducibility, sensitivity to change, and responsiveness to treatment of the VEP, 
with durable improvements evident more than 2 years after treatment with 
bexarotene.  
 
Electrophysiology will undoubtedly continue to play an important role in phase II 
remyelination trials and should support the realisation of the therapeutic promise of a 
remyelinating drug. The full-field visual evoked potential has, as elaborated in this 
thesis, emerged as the most sensitive outcome measure across the remyelination 
trials to date. The additional sensitivity and specificity of multifocal VEP to capture 
changes in small regions of optic nerve demyelination, has promoted its inclusion as 
an outcome for both acute and chronic remyelination trials. Meanwhile, an alternative 
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technique, that has already proven useful in quantifying pathology in other 
neurological diseases, is the measurement of saccadic reaction times. While 
prolonged saccadic latencies can arise from multiple pathologies, and so lack the 
pathological specificity of the VEP, they remain stable over time for individuals so 
that sequential changes can provide a sensitive method for quantifying influences on 
neural mechanisms, including neuroprotection. The constraints of the COVID-19 
pandemic have prevented me from conducting the complete assessment of these 
saccadic parameters in people with MS that I had intended, but I was able to gain 
pilot data between November 2019 and March 2020 from healthy controls and 
people living with MS (Appendix 2).  
 
Given the frequent involvement of the visual pathway in MS, and the histopathologic 
similarities between optic nerve damage and MS lesions within the brain and spinal 
cord, I plan to continue to embrace visual pathway outcomes for remyelination in 
post-doctoral research. This aligns with recent investment in the development of an 
academic vision laboratory in the department of clinical neurosciences at Cambridge; 
a collaboration between Professors Alasdair Coles and Patrick Yu-Wai-Man. This 
resource, coupled with the skillset I have acquired over the duration of the PhD, 
allows me to apply the aforementioned electrophysiological tests, as well as 
measures of visual function including acuity, colour vision, optical coherence 
tomography and Humphrey visual fields.  
 
My future plans are the following research projects: 
 
The Cambridge Centre for Myelin Repair trial number Two. Having led the 
development of this trial, secured ethical approval (21/EM/0120) and established the 
skillset required for measuring the endpoints, I plan to see this study through to its 
completion, while also building experience in running clinical trials, under the 
supervision of an experienced chief investigator. Additionally, I will recruit 
participants to the study of progressive remyelination in nerves by grading 
electrophysiological recovery (SPRINGER); allowing me to test whether long term 
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changes occur in response to metformin and clemastine, in the same way I showed 
with bexarotene (Chapter 4). 
 
Clinical study of saccadometry in MS. Assessments of saccadic latency have 
been advocated as a way to monitor response to neuroprotective therapies in the 
field of MS;391 just as they previously have in Parkinson’s disease505 and 
Huntington’s disease,506,507 among others.508 There remains a significant amount of 
work to be done before this possibility might be realised: they would need to be 
shown – in a large cohort of people with MS – to be reliable, reproducible, and be 
responsive to change. I have a research protocol authorised by the London-
Hampstead committee (19/LO/1284) to test this; I will recruit 30 participants from the 
progressive MS clinic, while saccadic parameters will additionally be tested in the 50 
RRMS participants of the CCMR Two trial. Three protocols will be tested: a 
(“reflexive”) step task, an antisaccade task, and the Wheeless task.509 The rationale 
is to evaluate the different neuronal populations that contribute to both reflex and 
voluntary eye movements that can become disordered in multiple sclerosis (and 
might improve with remyelination and axonal protection). 
 
Submission of a research proposal to measure full-field, and multi-focal, VEP 
in a sub study of the OCTOPUS trial. As documented in this thesis, VEP has 
emerged as the most sensitive way to measure remyelination. Given that two from 
the top three drugs recommended by the treatment selection group have a primarily 
remyelinating mechanism of action, OCTOPUS offers an unrivalled chance to test 
the remyelinating effect of these drugs using the infrastructure we have put in place 
in the Cambridge academic vision laboratory. We propose to recruit trial participants 
from centres in London and the East of England to travel to Cambridge for visits at 
baseline, and if delayed VEP latencies are demonstrated, they will return at month 
12 and month 24. 
 
To bring measurements of remyelination and axonal health to routine clinical 
practice. My conclusions in this thesis support previous research that has described 
high inter-subject and inter-lesional variability in remyelination capacity. One of the 
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new research aims of the Cambridge Centre for Myelin Repair, now in its fourth 
phase, is to elucidate the deterministic factors for remyelination failure in people with 
MS, in particular to assess the contribution of age, so that we might better 
understand how and when to deploy a remyelination strategy. We plan to achieve 
this by becoming the first MS centre to bring measures of remyelination and 
neuronal health to routine clinical practice. I will first collaborate with MRI physicists 
and radiologists in Cambridge to develop an MTR sequence on our NHS 3T GE 
scanner, before building and testing the analysis and processing pipeline, including 
registration and segmentation methods. This will allow automated lesion counting 
and quantification of cerebral volume, either in-house or through a third party such 
as Icometrix. 40 patients will then be recruited to a pilot trial from the Addenbrooke’s 
DMT, paediatric (n=5) and progressive MS clinics. Participants will attend at 
baseline, month 6, and month 12; with the option for extra visits in the circumstance 
of an acute relapse. At each visit, participants will have an MRI, a full-field and 
multifocal VEP, LCLA and OCT performed. These pilot data will determine which 
assessments of myelination and axonal health will be taken into clinical practice as 
part of a well-powered study, and set the foundation of a research platform that will 
allow future researchers to assess the influence of lifestyle, age, stage of disease 
and treatments on remyelination, and to optimise therapeutic strategies to enhance 
neuroprotection. 
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Appendix 1: Intermittent fasting as a way of 
promoting remyelination in patients living with 
multiple sclerosis:  
A focus group to inform the design of a study of intermittent 
fasting in MS 
 
In order to develop a dietary intervention involving fasting, that takes into account the 
needs of patients with MS, we held a focus group at the Addenbrooke’s brain repair 
centre on Wednesday 25th July 2018. The intention was to engage with the public at 
an early stage of our trial’s development through opening a dialogue with a body of 
people living with MS. The MS Society, which has a research network comprised of 
approximately 250 people with MS, supported us in this endeavour by recruiting a 




Healthcare professionals: Alasdair Coles (Professor of Neuroimmunology), Nick 
Cunniffe (Neurology Registrar), Katie Carr (Academic nutritionist) 
MS Society public engagement officer: Jenny Robertson 
Participants: 6 people with RRMS, 1 person with PPMS, 2 people with SPMS, and 3 
carers/friends. All were members of the MS Society research network.  
 
Statement of objectives 
 
In planning the afternoon, there were a few aims we had for our discussions: 
1. To better understand how a diet involving intermittent fasting might positively and 
negatively impact on someone living with MS. 
2. To gauge what sort of diet might be feasible and tolerable for the duration of a 
clinical trial.   
3. To discuss the different ways in which we could encourage compliance. 
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4. To appreciate how significant a positive effect would have to be for someone to 
follow an intermittent fasting diet. 
5. To discuss how one might pragmatically design a clinical trial of a dietary 
intervention in people with MS. 
 
Outline of programme 
 
Following a welcome and introduction from both the MS Society’s representative and 
Prof Coles, a short presentation was given to outline the latest research which had 
led to the hypothesis that fasting in humans would enhance remyelination. The 
conversation was then opened to the group, with the following questions used to 
structure the discussions: 
1. Has anyone tried any similar diets before? What were the positive and 
negative effects? 
2. Do you think you could undertake a diet involving fasting?  
3. For how long do you think you could sustain an intermittent fasting diet? 
4. In the design of a trial, how would you encourage compliance?   
5. What would be the magnitude of therapeutic effect would you want to gain to 
undertake such a diet?  
6. In the design of the trial, how would you monitor participants? 




The group started by detailing their own experiences of dieting while living with MS. 
One patient explained she had undertaken a diet limiting herself to 600 calories a 
day for a period of 5 weeks, with the intention of losing weight. She reported that she 
lost 20lbs with no adverse effects and that a particular help with compliance had 
been use of low calorie sachets, soups for example, which gave her defined 
amounts that she could eat. Another patient explained that she had trialled an 
intermittent fasting diet (5:2), but had to stop on account of developing headaches 
that limited her ability to work. However, she subsequently tried gradually increasing 
the degree of fasting over several weeks, which counteracted the problem. Both 
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explained that they had noted an improvement in their well-being and strength, 
though others in the group did raise the possibility that this might be the effect of 
their weight loss rather than an effect on their MS.  
 
There followed a conversation about the literature and other diets that have 
previously been trialled. One patient volunteered to having tried the “fasting 
mimicking diet” reported by Choi et al. in 2016.510 This involved one pre-fast day of 
800kcal in brown rice, followed by 7 consecutive days of 200 calories a day, which 
was taken as a vegetable broth. He had initially tolerated this well, but became 
gradually more weak and fatigued towards the end of the fast. He explained that he 
lost weight but noticed no convincing improvement in his MS symptoms. He did 
however find he had much more free time without the daily need to prepare food. 
 
Subsequently, there was a discussion around some of the barriers to fasting. Firstly, 
a couple of patients raised a concern that some disease modifying treatments have 
side effects that might make a complete fast for a whole day rather more difficult. For 
example, one patient emphasised the importance of taking her Tecfidera with food, 
which negated GI side effects. Also discussed were the social implications of fasting, 
and some expressed a wish that fasting days be flexible so that they could plan them 
into their week. Despite this, all in the group believed that a diet incorporating fasting 
was achievable. However, very few believed that a diet akin to that used in Franklin’s 
experiments (absolute fasting Monday, Wednesday and Friday) would be possible 
for a prolonged period. Far more preferable would be 2-3 non-consecutive days of a 
calorie-restricted diet (such as 500 calories on these days). 
 
Such considerations fed into a discussion about the length of time such a diet could 
be trialled. All agreed that, for a diet with limited calories, 3 to 6 months would be 
very achievable. However, if it were a matter of fasting MWF, then 3 months was felt 
to be a limit. When the suggested time period approached 6 months, some explained 
that their compliance would be more likely to stray and that they would be happier if 
they were seeing an improvement, either in their physical health or in some objective 
marker of disease activity, their MRI for instance. However, all said that, if there were 
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an effect on the natural history of their MS, even years into the future, proven in a 
study such as the one proposed, they would be motivated to maintain a diet that 
involved intermittent fasting indefinitely.  
 
There was less of a consensus when it came to the dialogue about how best to 
encourage compliance. Some of the group were confident that they would need no 
contact from the trial team in order to keep up a fasting diet. Similarly, some also felt 
no contact would be needed, but that they would benefit from having aids such as 
the defined amounts in sachets. A few participants thought that it would be a good 
idea for the trial team to keep in touch with patients, particularly towards the start of 
the trial period, by email or telephone calls. One idea that was mooted was to have 
an app where they could record their meals, which might be linked to investigators of 
the trial. The most agreement came from wanting to know that someone would be 
available to speak to if they needed while on the trial.  
 
Katie, the research nutritionist, explained that an alternative to sachets would be for 
her to provide a series of low calorie meal recipes and low calorie snack ideas, which 
was well accepted by the group. Most agreed that this would allow more choice for 
the patients and so appeared to be the best option. She also explained how she, and 
a dietician, would monitor people on the diet. 
 
One of the questions put to the group was, if we could quantify the positive effect of 
the diet, how large a benefit would they want before they would consider such a diet. 
All agreed that they would do this if there was a reduction in the rate of progression 
and wouldn’t need to be told that this would stop or even reverse disability. 
 
In terms of trial design, there were some very helpful suggestions from the group. It 
was put to the participants that, if you were allocated to a “control” diet in a study, 
would you continue with your normal diet or would you try fasting yourself? Several 
agreed that it would be hard to carry on as normal in such a scenario, knowing that 
others in the study might derive a positive effect. In meeting the need for a control 
population, some in the group thought that there would be patients from MS clinics 
 - 230 - 
who would be willing to have the baseline and follow up investigations and opt out of 
the diet. Another suggestion was a crossover design, in which participants were 
enrolled, had a control diet for 6 months, and then underwent the diet for 6 months, 
with investigations at 0, 6, and 12 months. A final idea was to have a dose ranging 
study, with some on a fasting diet, some on a low calorie, and some on a control 
diet. 
 
The next consideration was blinding and it was recognised that it would be very hard 
for patients and doctors to be blinded to whether the patient is on the trial diet or not; 
ideas such as high calorie sachets were quickly dismissed by the group. However, it 
was agreed that an objective measure, with blinded raters, such as with MRI or VEP, 
would be a sensible option and acceptable to those that might participate. 
 
As we came to a conclusion, we discussed the bias that might be involved in the 
information gathered from this focus group. All had responded to an advert from the 
MS Society to take part in a “discussion regarding intermittent fasting to promote 
remyelination”. The group therefore described themselves as fairly self-selecting: 
they were all interested in the topic of diet in MS, as well as already being actively 
involved with research through the MS Society research network. The group did say 
they thought their outcomes were valid to the MS community at large, but noted that 
there may be some challenges, especially with compliance, with a more diverse 
cohort. 
 
Results of questionnaire 
 
In order to gain some more quantitative information from our participants we also 
asked the attendees to complete a short questionnaire. Of our group of 12, 11 
completed the form, though 1 of these did so only partially. The mean age of 
respondents was 51 years and, in those living with MS, the mean length of time with 
this was 13 years. Average levels of alcohol intake were low with a mean of 6 units a 
week and only one person reported to an intake greater than their recommended 
weekly amount (42 units for one gentleman). 
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All respondents said that they would be willing to undertake a diet involving 
intermittent fasting. When asked how long they would be willing to try this, 100% 
reported they would be happy with at least 6 months. Questions on how might be 
best to monitor compliance showed no clear consensus: 70% preferred email 
contact with the trial team, while 30% preferred telephone calls. Only 2 respondents 
were happy to complete food diaries.  
 
Finally, the hypothetical question, “if we could quantify the positive effect of 
intermittent fasting on the course of MS, how large would this need to be for you to 
follow the diet”, was asked. Of the 9 respondents that completed this question, all 





• The majority of participants had already trialled diets involving fasting, 
motivated by weight loss or improvement in MS symptoms. 
• Generally, these were well tolerated and patients felt better for doing so, 
though some noticed headaches and, in cases of more extreme fasting, 
increased fatigue. 
• Everyone in the group thought they could change their diet to one involving 
intermittent fasting. However, while a couple thought 3 non-consecutive days 
of fasting was possible, most did not, and all agreed that any more than 3 
months on such a diet would be problematic. 
• All were open to 2-3 days of fasting with low calorie (<500) meal options on 
the fasting days for a period of at least 6 months. 
• In order to encourage compliance, it was suggested the fasting days be 
flexible to allow for social occasions and, while some would find low calorie 
meal sachets a help, most preferred the option of low calorie meal and snack 
recipes from a nutrition or dietician. 
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• In the trial design, there was concern that a control population would not 
observe their normal diet, and so a crossover design or recruiting MS patients 
whom do not want to undertake a diet were suggested as potential options. 
• Blinding of patients was felt to be impractical, but participants would be 
comfortable if there were an objective measure such as MRI with a blinded 
rater.  
• The conclusions of the focus group were believed to be translatable to the 
wider MS population, but there was agreement that the assembled group 
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Appendix 2: Oculometry in multiple sclerosis 




Each saccade is the result of a decision on where to look, and the time needed to 
make these decisions can provide precise information about the underlying neural 
mechanisms of decision, distributed amongst many structures in the brain, both 
cortical and sub-cortical.511,512 Saccadic latencies are typically delayed by around 
100-130 ms more than would be predicted from considering the shortest pathway for 
a visually evoked saccade (from the retina through the brainstem, to the extraocular 
muscles). This is known as oculomotor procrastination: the cortex tonically inhibits 
the collicular mechanisms via the basal ganglia, only releasing this inhibition briefly 
and locally after the decision process is complete.513  
 
Although distributions of saccadic latency have much inter-subject variability, they 
remain relatively stable over time for the individual so that sequential changes can 
provide a sensitive method for quantifying influences on neural mechanisms 
responsible for their generation, such as disease or therapeutic intervention. 
Saccadic reaction times are known to be abnormal in a very wide variety of 
neurological disorders,506,514-519 they correlate with grey matter volumes in 
Parkinson’s disease,520 and saccadic paradigms are being increasingly used to help 
give insight into disordered neural processes. Meanwhile, in the field of MS, one 
group has published several studies from the same cohort of 25 people with multiple 
sclerosis (MS).392-395 They reported deficits in complex decision making, such as 
prolonged latency and increased proportion of errors (prosaccades) in the 
antisaccade task.394 Because these measurements are so easy to make, they hold 
promise for being useful biomarkers of disease progression and treatment, 
particularly as outcome measures in clinical trials.391 I therefore additionally sought to 
study saccadic latency distributions in people with MS, and describe how they vary 
with disability and disease duration.  
  
 - 234 - 
Methods 
 
In this project, I sought to compare distributions of reaction times in saccadic tasks of 
varying complexity between MS patients with both cross sectional, and longitudinal 
analyses. A research ethics application was authorised by the London-Hampstead 
committee in August 2019 (19/LO/1284).  
 
Equipment and protocols 
I used a head-mounted saccadometer plus (Ober consulting), which uses binocular 
infrared scleral reflectance to measure eye movements in response to the 
presentation of high contrast horizontal targets from three low-power lasers that 
project red 13 cd m-2 dots subtending 10° on a flat background. This device has FDA 
approval for use in the clinical setting, is non-invasive, and does not require restraint. 
Two protocols were tested (Figure A2.1): a (“reflexive”) step task and an antisaccade 
task.521 The rationale for this was to evaluate the different neuronal populations that 
contribute to both reflex and voluntary eye movements that can become disordered 
in multiple sclerosis (and might improve with remyelination).513 Further, as seen 
below, the sending of a “stop” signal to cancel a movement is more rapid process 
than required for the step task; I hypothesised that this might be more sensitive to 
changes with remyelination. 
 
Analysis 
Latency data were downloaded onto a computer running LatencyMeter®. This 
software automatically removes abnormal eye movements. These include saccades 
in the wrong direction (in the step task), those with an abnormal profiles, those falling 
outside the amplitude range 5–15°, or saccades outside the latency range 50–600 
ms (arbitrary limits chosen to include express or other early saccades but exclude 
saccades with prolonged latency due to inattention). Each is also checked manually.  
 
 - 235 - 
 
Figure A2.1. The step and antisaccade tasks. In the step task paradigm, after a 
random period of between 0.5 - 1.0 seconds, the central target is extinguished and, 
simultaneously, either the left or right target presented. The device measures the 
latency of the resulting saccade (time between presentation of the target and eyes 
starting to move). The antisaccade paradigm involves the same sequence, but the 
subject is instructed to look in the opposite direction to the stimulus; thus one can 
respond with either an antisaccade or make an error (a prosaccade).  
 
 
The resultant saccadic latency distributions are skewed with a tail towards longer 
latencies. However, if instead of latency, one plots the reciprocal of this reaction time 
(a measure of the rate of decision), a normal distribution is formed. This reflects the 
underlying biology of the decision making process, which is generally agreed to 
involve a rise-to-threshold decision signal; the brain accumulates sensory 
information toward a threshold level, at which point a certain action is selected.509,522 
If reciprocal latencies are plotted cumulatively on a probit scale (forming a reciprobit 
plot), then a straight line is obtained and the results can be explained using an 
established model of neural decision: the LATER model (linear approach to 
threshold with ergodic rate; Figure A2.2).509,522 
 
The LATER model is particularly powerful as it provides a more sophisticated 
measure of the neural decision-making process than basic behavioural measures, 
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like the mean latency of response, or proportion of errors made. It is also supported 
by neurophysiological measurements from movement cells in the frontal eye fields in 
monkeys,523 and neuronal responses in the parietal cortex.524 As a result, this 
approach has greater potential to support clinical trials than simply recording crude 
metrics like reaction time in isolation.509 
 
Using the SPIC programme, I generated reciprobit plots for each participant and, 
using a Kolmogorov-Smirnov statistical test, obtained the best fit for the data and 
defined the distribution in terms of LATER parameters: the inverse median latency 
(μ)-essentially a measure of “promptness”, and the variance (σ²).  
 
 
Figure A2.2. The LATER model. Left: The decision signal rises from a starting 
level, So, until it reaches a threshold criterion, ST, at which a response is initiated. 
The rate of rise (arrow) varies randomly from trial to trial around a mean, μ. In the 
real world, competing LATER units race against each other, and the first to reach 
threshold initiates the response. Right: the reciprobit plot. When cumulative 
probability, on a probit scale, is plotted against inverse latency a straight line is 
formed, representing the normal distribution. This can be quantified in terms of its 
median, μ, its intercept with infinity, σ, and, if present, a population of “early” 
saccades can be described by the term σE. 
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Results 
 
While the constraints of the COVID-19 pandemic have prevented me from 
conducting a complete assessment of these saccadic parameters in people with MS, 
I have been able to use the saccadometer to gain pilot data from seven healthy 
controls and seven people living with MS, between November 28, 2019 and 
February 27, 2020, administering the protocols specified in the methods. Saccadic 
distributions in each instance were used to generate reciprobit plots and obtain the 
best fit in terms of LATER parameters: inverse median latency (μ), variance (σ²) and, 
if present, σE of the early distribution. Representative data for a single subject are 




Figure A2.3. Representative results from one MS subject. A cumulative 
histogram, using a probit scale, is plotted against inverse latency – a normal 
distribution forms a straight line, which is quantified by median latency (μ) and its 
variance (σ²). In this case distributions from the step task (median latency 190 ms, μ 
= 5.24; blue), and the antisaccade task (latency 267 ms, purple, with 45% 
prosaccadic error rate, green) are shown; an additional population of early saccades 
were present in this subject (σE). 
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As expected, in the step task, there was a statistically significant difference (p = 
0.015) between the means of the median latencies of saccadic reaction times of 
people with MS (188.0 ms) versus the healthy controls (151.3 ms). Similarly, when 
these saccadic distributions were modelled using LATER, μ (inverse median latency 
or “promptness”) was smaller in those with MS, compared to healthy controls 
(between group difference -1.39, p = 0.024, Figure A2.4A and B). σ, a measure of 
variability, was no different between the two groups (1.2 vs 1.3, p = 0.473), though 3 
people with MS had a significant early population of saccades versus none of the 
healthy controls. 
 
Antisaccades were assessed for the same participants and the results summarised 
in Figure A2.4C and D. Visually, this appears to demonstrate a trend for 
antisaccades to occur at greater latency in people with RRMS than those of healthy 
controls, but the means of these were not statistically significant from one another 
(311.6 versus 271 ms for MS participants and healthy controls, respectively, p = 
0.261). While 2 people with MS had a large proportion of prosaccadic errors (Figure 




The main step I have been able to take has been to become familiar with the 
equipment, and to learn how to administer and analyse saccadic paradigms using 
the LATER model. The pilot data presented in this appendix, while only a small 
sample due to the study being halted at the start of the COVID-19 pandemic, does 
highlight prolonged saccadic latencies in people living with MS in both the step and 
antisaccade task, which is broadly in line with the only other study in this patient 
group to date.391-395 A significant difference with previous work has been that I have 
not replicated the observation that people with MS have an increased proportion of 
errors (prosaccades) in the antisaccade task.394  
 
Assessments of saccadic latency have been advocated as a way to monitor the 
response to neuroprotective therapies in the field of MS,391 Parkinson’s disease,505 
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Huntington’s disease,506,507 and others.508 The hope behind this continuing line of 
research, is that changes in saccadic latency will vary with remyelination in a clinical 
trial, and potentially be more sensitive than established measures such as VEP. With 
tests of saccadic latency being introduced into the CCMR Two trial, there will be 






Figure A2.4. Between group differences in performance at the step and 
antisaccade tasks. A: the median latencies (in ms) for healthy controls and 
participants with relapsing remitting MS (RRMS) performing the step task. B: the 
inverse median latency, μ, of the LATER unit fitted to the latency distribution (μ is a 
measure of promptness, and higher values infer faster reaction times). C: the median 
latencies (in ms) for antisaccades in the same groups of participants. D: the 
proportion of correct responses (expressed as a percentage) during the antisaccade 
task (higher values mean fewer prosaccadic errors). Bars are standard errors around 
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